Agonistic antibodies that bind to human CD137 and uses thereof
Novel anti-CD137 antibodies with specific epitope binding and affinity address hepatotoxicity issues, effectively inducing tumor regression and immune activation in the tumor microenvironment.
Patent Information
- Application Number
- JP2022180410
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-10-26
- Filing Date
- 2022-11-10
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2038-07-11
AI Technical Summary
Existing CD137 agonists, such as antibodies, often cause severe hepatotoxicity and other adverse events, limiting their effectiveness and safety as cancer immunotherapeutics.
Development of novel agonistic anti-CD137 antibodies with specific epitope binding and affinity in the range of 30-100 nM, which minimize liver toxicity and enhance anti-tumor immunity by inducing immune cell infiltration and cytokine production without inhibiting CD137:CD137L interaction.
The antibodies achieve complete regression of large tumors with minimal liver toxicity, enhancing immune cell activation and cytokine production in the tumor microenvironment while reducing adverse effects.
Smart Images

Figure 0007587858000017 
Figure 0007587858000018 
Figure 0007587858000019
Abstract
Description
[Technical Field]
[0001] Related Applications This application claims the benefit of U.S. Provisional Patent Application No. 62 / 531,259, filed July 11, 2017; U.S. Provisional Patent Application No. 62 / 531,190, filed July 11, 2017; U.S. Provisional Patent Application No. 62 / 568,231, filed October 4, 2017; U.S. Provisional Patent Application No. 62 / 577,257, filed October 26, 2017; and U.S. Provisional Patent Application No. 62 / 577,259, filed October 26, 2017. The entire contents of these referenced applications are incorporated herein by reference. [Background technology]
[0002] In recent years, increasing evidence has suggested that the immune system acts as an important barrier against tumor formation and progression. The existence of naturally occurring T cells with antitumor potential or activity in cancer patients provides rationale for the development of immunotherapeutic approaches in the oncology field. Immune cells, such as T cells, macrophages, and natural killer cells, can exhibit antitumor activity and effectively control the development and growth of malignant tumors. Tumor-specific or tumor-associated antigens can induce immune cells to recognize and eliminate malignant tumors (Chen & Mellman, (2013) Immunity 39(1):1-10). Despite the existence of tumor-specific immune responses, malignant tumors often evade or avoid immune attack through various immunoregulatory mechanisms, resulting in failure to control tumor development and progression (Motz & Coukos, (2013) Immunity 39(1):61-730). Indeed, a hallmark of cancer emergence is the exploitation of these immune regulatory mechanisms and the neutralization of antitumor immune responses, allowing tumors to evade and escape immune killing (Hanahan and Weinberg (2011) Cell 144(5):646-674).
[0003] Novel approaches to cancer immunotherapy involve countering these immune evasion and escape mechanisms and inducing the endogenous immune system to reject tumors. CD137 (also known as "tumor necrosis factor receptor superfamily member 9" (TNFRSF9), 4-1BB, and "induced by lymphocyte activation" (ILA)) is a transmembrane costimulatory receptor protein belonging to the tumor necrosis factor superfamily. CD137 is a T cell costimulatory receptor induced by TCR activation (Nam et al., (2005) Curr Cancer Drug Targets 5:357-363; Watts et al., (2005) Annu Rev Immunol 23:23-68). In addition to its expression on activated CD4+ and CD8+ T cells, CD137 is also expressed on CD4+CD25+ regulatory T cells, activated natural killer (NK) T cells and NK-T cells, monocytes, neutrophils, and dendritic cells.
[0004] Under physiological conditions, CD137 is ligated to CD137 ligand (CD137L), an agonistic membrane molecule present on antigen-presenting cells, including B cells, monocytes, macrophages, and dendritic cells (Watts et al., (2005) Annu Rev Immunol 23:23-68). Upon interaction with the ligand, CD137 leads to increased TCR-induced T cell proliferation, cytokine production, functional maturation, and prolonged CD8+ T cell survival. The potential of CD137 costimulation using various agonists (e.g., agonistic antibodies, recombinant CD137L protein, and CD137-specific aptamers) in directing the immune system to attack tumors has been reported in many models (Dharmadhikari et al., (2016) Oncoimmunology 5(4):e1113367 and references therein). A recent report on the clinical evaluation of an agonistic CD137 antibody (urelumab, BMS-663513; Bristol-Myers Squibb) reported that treatment-related adverse events were observed in human subjects, including signs of severe hepatotoxicity (hypertransaminasemia) that correlated with antibody dose (Segal et al., (2016) Clin Cancer Res 23(8):1929-1936). In contrast, another agonistic CD137 antibody (utomilumab, PF-05082566; Pfizer) was tested in combination with an anti-PD-1 antibody (pembrolizumab) without any dose-limiting toxicities and demonstrated results comparable to anti-PD-1 monotherapy (Tolcher, A. et al., (2017) Clin Cancer Res 23(18): 5349-5357). These results highlight the ongoing unmet need for novel agonistic antibodies that bind to human CD137 and are well characterized for the development of safe and effective therapeutics for patients with a variety of diseases and conditions, including cancers, that are amenable to treatment with CD137 agonists. [Prior art documents]
Non-Patent Literature
[0005]
Non-Patent Literature 1
Non-Patent Literature 2
Non-Patent Literature 3
Non-Patent Literature 4
Non-Patent Literature 5
Non-Patent Literature 6
Non-Patent Literature 7
Non-Patent Literature 8
Summary of the Invention
Means for Solving the Problems
[0006] The present disclosure is based, at least in part, on the development of novel agonistic anti-CD137 antibodies that confer protective anti-tumor immunity in animals. In particular, the antibodies described herein are effective against a variety of tumor types and across a broad dose range. Furthermore, as illustrated in the Examples, the antibodies described herein are therapeutically effective against very large tumors. For example, treatment of tumor-bearing mice with the agonistic anti-CD137 antibodies described herein resulted in tumors of 1,800 mm 3 Treatment of these mice resulted in complete regression of tumors of up to 100% tumor size. As shown in Figure 15, treatment of these mice also resulted in protective immunity. Consistent with the observed efficacy, there were positive immunophenotypic changes in the tumor microenvironment, such as increased immune cell infiltration accompanied by a decrease in regulatory T cell and exhausted T cell populations (see, e.g., Figures 22A-22D).
[0007] As mentioned above, CD137 agonism is associated with certain adverse events in humans, including hepatotoxicity-related death (e.g., Segal et al. (2017) Clin Cancer Res 23(8) : 1929-1935). Similar toxicities resulting from treatment with agonistic anti-CD137 antibodies (e.g., 3H3 antibody) have also been observed in animal models (see, e.g., Bartkowiak et al. (2018) Clin Cancer Res 24(5) (See, e.g., J. Immunol. 1999, 1138-1151). However, the agonistic anti-CD137 antibodies described herein have minimal effects on the liver, as determined, for example, by plasma levels of liver enzymes (e.g., alanine aminotransferase (ALT)) and immune cell infiltration. For example, there is no evidence of increased immune cell infiltration in the liver or spleen in mice treated with the antibodies. Thus, the antibodies described herein are not only highly effective, but also reduce certain toxicities associated with CD137 agonism.
[0008] Although the present disclosure is not limited to any particular theory or mechanism of action, it is believed that the superior therapeutic and toxicity-reducing properties of the antibodies described herein are derived in part from one or both of the antibody's affinity and the novel epitope to which it binds. That is, the antibodies described herein share a common novel epitope that is distinct from other agonistic anti-CD137 antibodies. As illustrated in the Examples, the association of the antibodies described herein with the epitope results in enhanced, for example, regulatory T cell proliferation, CD8 + Different in vitro activities occur, such as effects on cytokine production by T cells and macrophages and intracellular signaling. Furthermore, the affinity range (sweet spot) of antibodies has been shown to be particularly optimal for antitumor activity. For example, antibodies with intermediate affinity have been shown to be more effective against large tumors than antibodies with higher or lower affinity.
[0009] In view of the foregoing, in some aspects, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion has an affinity (K D In some aspects, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion binds to human CD137 with an affinity (K) of about 30 nM to 100 nM (e.g., about 30 nM to about 110 nM). D) binds to human CD137. In some embodiments, the affinity of the anti-CD137 antibody for human CD137 is at least 2-fold (e.g., at least 3, 4, 5, 6, 7, 8, 9, or 10-fold) greater than the affinity of mAb10 for mouse CD137. In some embodiments, the affinity of the anti-CD137 antibody is 500, 450, 400, 350, 300, 250, 200, 250, 200, 175, 150, 125, 110, or 100 nM or less. In some embodiments, the affinity of the anti-CD137 antibody for human CD137 is at least 2-fold (e.g., at least 3, 4, 5, 6, 7, 8, 9, or 10-fold) higher than the affinity of mAb10 for mouse CD137, but is 500, 450, 400, 350, 300, 250, 200, 250, 200, 175, 150, 125, 110, or 100 nM or less.
[0010] In some aspects, the disclosure provides an isolated monoclonal antibody, or antigen-binding portion thereof, that specifically binds to human CD137, wherein the antibody or antigen-binding portion binds to an epitope on human CD137 that includes one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or all 25) amino acids 111-132 of SEQ ID NO: 3. In some aspects, the disclosure provides an isolated monoclonal antibody, or antigen-binding portion thereof, that specifically binds to human CD137, wherein the antibody or antigen-binding portion binds to an epitope within amino acids 111-132 of SEQ ID NO: 3. In some aspects, the disclosure provides an isolated monoclonal antibody, or antigen-binding portion thereof, that specifically binds to human CD137, wherein the antibody or antigen-binding portion binds to all or a portion of amino acids 111-132 of SEQ ID NO: 3. In some embodiments, the epitope binds to K114 of SEQ ID NO: 3. In some embodiments, the epitope includes residues E111, T113, and K114 of SEQ ID NO: 3. In some embodiments, the epitope includes residues E111, T113, K114, N126, and I132 of SEQ ID NO: 3. In some embodiments, the epitope includes residues E111, T113, K114, and P135 of SEQ ID NO: 3. In some embodiments, the epitope includes residues E111, T113, K114, N126, I132, and P135 of SEQ ID NO: 3. In some embodiments, the antibody or antigen-binding portion thereof binds to human CD137 with an affinity of about 30 nM to about 100 nM (e.g., about 30 nM to about 110 nM).
[0011] In some aspects, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion has an affinity (K D) and binds to an epitope on human CD137 that includes K114 of SEQ ID NO: 3. In some embodiments, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion binds to human CD137 with an affinity (K) of about 30 nM to 100 nM (e.g., about 30 nM to about 100 nM). D ) and binds to an epitope on human CD137 comprising K114 of SEQ ID NO:3. In some embodiments, the epitope comprises residues E111, T113, and K114 of SEQ ID NO:3. In some embodiments, the epitope comprises residues E111, T113, K114, N126, and I132 of SEQ ID NO:3. In some embodiments, the epitope comprises residues E111, T113, K114, and P135 of SEQ ID NO:3. In some embodiments, the epitope comprises residues E111, T113, K114, N126, I132, and P135 of SEQ ID NO:3.
[0012] In some aspects, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion has an affinity (K D ) and binds to an epitope on human CD137 comprising a sequence of one or more amino acid residues corresponding to amino acids 111 to 135 of SEQ ID NO: 3. In some embodiments, the epitope comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acid residues corresponding to amino acids 111 to 135 of SEQ ID NO: 3.
[0013] In some aspects, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion has an affinity (K D) and binds to an epitope on human CD137 located within amino acid residues 111 to 135 of SEQ ID NO: 3. In some embodiments, the epitope is at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids. In some embodiments, the epitope is fewer than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, or 5 amino acids.
[0014] In some aspects, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion has an affinity (K D ) and binds to an epitope on human CD137 comprising ELTK (corresponding to amino acid residues 111-114 of SEQ ID NO: 3). In some embodiments, the epitope further comprises one or more of residues N126, I132, and P135 of SEQ ID NO: 3.
[0015] In any of the foregoing embodiments, the epitope is a non-linear epitope. In any of the foregoing embodiments, mutation of residue K114 of SEQ ID NO: 3 abolishes binding of the antibody, or antigen-binding portion thereof, to human CD137.
[0016] In any of the foregoing embodiments, the antibodies or antigen-binding portions thereof described herein have an affinity (K D) binds to human CD137. In some embodiments, the antibody or antigen-binding portion thereof binds to a non-ligand binding region of the extracellular domain of human CD137. In some embodiments, the antibody or antigen-binding portion thereof does not inhibit the interaction of CD137 with CD137L. In some embodiments, the non-ligand binding region spans cysteine-rich domain (CRD) III and CRD IV. In any of the foregoing embodiments, the antibody or antigen-binding portion thereof does not inhibit trimer formation of CD137:CD137L monomers.
[0017] In some aspects, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion is: (i) an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); D ) binds to human CD137; (ii) binds to a non-ligand binding region of the extracellular domain of human CD137; and (iii) binds to an epitope on human CD137 that includes K114 of SEQ ID NO:3. In some aspects, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion is: (i) an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); D ) binds to human CD137; (ii) does not inhibit the interaction between human CD137 and human CD137 ligand; and (iii) binds to an epitope on human CD137 that includes K114 of SEQ ID NO:3. In some aspects, the disclosure features an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion has (i) an affinity (K) of between about 30 nM and 100 nM (e.g., between about 30 nM and about 100 nM). D) and (ii) does not inhibit the formation of CD137:CD137L monomer trimers (i.e., CD137:CD137L trimer:trimer complexes). In some aspects, the disclosure features an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion (i) binds to human CD137 with an affinity (K) of about 30 nM to 100 nM (e.g., about 30 nM to about 100 nM). D ) binds to human CD137, and (ii) binds to a non-ligand binding region of the extracellular domain of human CD137. In some aspects, the disclosure features an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, the antibody or antigen-binding portion thereof having (i) an affinity (K) of about 30 nM to 100 nM (e.g., about 30 nM to about 100 nM). D ) binds to human CD137, and (ii) does not inhibit the interaction between human CD137 and CD137 ligand.
[0018] In any of the foregoing embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain CDR3 comprising the amino acid sequence DXXXXLXXXXYXYYX (SEQ ID NO: 126), where X is any amino acid. In some embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain CDR3 comprising the amino acid sequence DXPFXLDXXYYYYYX (SEQ ID NO: 127), where X is any amino acid. In any of the foregoing embodiments, mutation of residues D95, L100, Y100E, Y100G, Y100H, or combinations thereof, of the heavy chain CDR3 to alanine results in abolished binding to human CD137. In any of the foregoing embodiments, mutation of residues P97, F98, D100A, Y100D, Y100F, or combinations thereof, to alanine results in reduced binding to human CD137. In any of the foregoing embodiments, the antibody or antigen-binding portion thereof comprises a heavy chain CDR and a light chain CDR, wherein the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO:68.
[0019] In another aspect, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein: (i) The antibody or antigen-binding portion thereof has an affinity (K D and (ii) the antibody, or antigen-binding portion thereof, comprises a heavy chain CDR3 comprising the amino acid sequence DXXXXLXXXXYXYYX (SEQ ID NO: 126), where X is any amino acid. In some embodiments, X is any amino acid except alanine.
[0020] In another aspect, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein: (i) The antibody or antigen-binding portion thereof has an affinity (K D ) binds to human CD137; and (ii) an antibody, or antigen-binding portion thereof, having the amino acid sequence DX1X2X3X4LX5X6X7X8YX9YYX 10 (SEQ ID NO: 128), wherein X1 is any amino acid, wherein X2 is a nonpolar amino acid, wherein X3 is a nonpolar amino acid, wherein X4 is any amino acid, wherein X5 is a polar amino acid, wherein X6 is any amino acid, wherein X7 is any amino acid, wherein X8 is a polar amino acid, wherein X9 is a polar amino acid, and wherein X 10 is any amino acid. In some embodiments, X2 is proline, X3 is phenylalanine or tryptophan, X5 is aspartic acid or glutamic acid, X8 is tyrosine, and X9 is tyrosine.
[0021] In another aspect, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein: (i) The antibody or antigen-binding portion thereof has an affinity (K D ) binds to human CD137; and (ii) the antibody, or antigen-binding portion thereof, specifically binds to an epitope on human CD137 that includes one or more of residues E111, T113, K114, N126, I132, and P135 of SEQ ID NO:3;
[0022] In another aspect, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein: (i) The antibody or antigen-binding portion thereof has an affinity (K D ) binds to human CD137; (ii) the antibody, or antigen-binding portion thereof, specifically binds to an epitope on human CD137 that includes one or more of residues E111, T113, K114, N126, I132, and P135 of SEQ ID NO:3; (iii) the antibody, or antigen-binding portion thereof, has the amino acid sequence DXXXXLXXXXYXYYX (SEQ ID NO: 126). wherein X is any amino acid; or (iv) combinations thereof. In some embodiments, X is any amino acid except alanine.
[0023] In another aspect, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein: (i) The antibody or antigen-binding portion thereof has an affinity (K D ) binds to human CD137; (ii) the antibody, or antigen-binding portion thereof, specifically binds to an epitope on human CD137 that includes one or more of residues E111, T113, K114, N126, I132, and P135 of SEQ ID NO:3; (iii) an antibody, or antigen-binding portion thereof, having the amino acid sequence DX1X2X3X4LX5X6X7X8YX9YYX 10 (SEQ ID NO: 128), wherein X1 is any amino acid, wherein X2 is a nonpolar amino acid, wherein X3 is a nonpolar amino acid, wherein X4 is any amino acid, wherein X5 is a polar amino acid, wherein X6 is any amino acid, wherein X7 is any amino acid, wherein X8 is a polar amino acid, wherein X9 is a polar amino acid, and wherein X 10 is any amino acid; or (iv) Combinations thereof. In some embodiments, X2 is proline, X3 is phenylalanine or tryptophan, X5 is aspartic acid or glutamic acid, X8 is tyrosine, and X9 is tyrosine.
[0024] In another aspect, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein: (i) The antibody or antigen-binding portion thereof has an affinity (K D ) binds to human CD137; (ii) the antibody, or antigen-binding portion thereof, specifically binds to an epitope on human CD137 that includes one or more of residues E111, T113, K114, N126, I132, and P135 of SEQ ID NO: 3; and (iii) the antibody, or antigen-binding portion thereof, has the amino acid sequence DXXXXLXXXXYXYYX (SEQ ID NO: 126). wherein X is any amino acid. In some embodiments, X is any amino acid except alanine.
[0025] In another aspect, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein: (i) The antibody or antigen-binding portion thereof has an affinity (K D ) binds to human CD137; (ii) the antibody, or antigen-binding portion thereof, specifically binds to an epitope on human CD137 that includes one or more of residues E111, T113, K114, N126, I132, and P135 of SEQ ID NO: 3; and (iii) an antibody, or antigen-binding portion thereof, having the amino acid sequence DX1X2X3X4LX5X6X7X8YX9YYX 10 (SEQ ID NO: 128), wherein X1 is any amino acid, wherein X2 is a nonpolar amino acid, wherein X3 is a nonpolar amino acid, wherein X4 is any amino acid, wherein X5 is a polar amino acid, wherein X6 is any amino acid, wherein X7 is any amino acid, wherein X8 is a polar amino acid, wherein X9 is a polar amino acid, and wherein X 10 is any amino acid. In some embodiments, X2 is proline, X3 is phenylalanine or tryptophan, X5 is aspartic acid or glutamic acid, X8 is tyrosine, and X9 is tyrosine.
[0026] In any of the foregoing embodiments, the epitope comprises K114. In any of the foregoing embodiments, the epitope comprises E111, T113, and K114. In any of the foregoing embodiments, the epitope comprises E111, T113, K114, N126, and I132. In any of the foregoing embodiments, the epitope comprises residues E111, T113, K114, N126, I132, and P135 of SEQ ID NO:3.
[0027] In another aspect, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein: (i) The antibody or antigen-binding portion thereof has an affinity (K D ) binds to human CD137; and (ii) The antibody or antigen-binding portion thereof specifically binds to an epitope comprising a sequence of one or more amino acid residues corresponding to amino acids 111 to 135 of SEQ ID NO:3.
[0028] In another aspect, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein: (i) The antibody or antigen-binding portion thereof has an affinity (K D ) binds to human CD137; (ii) The antibody or antigen-binding portion thereof specifically binds to an epitope comprising a sequence of one or more amino acid residues corresponding to amino acids 111 to 135 of SEQ ID NO:3. (iii) the antibody, or antigen-binding portion thereof, has the amino acid sequence DXXXXLXXXXYXYYX (SEQ ID NO: 126). wherein X is any amino acid; or (iv) combinations thereof. In some embodiments, X is any amino acid except alanine.
[0029] In another aspect, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein: (i) The antibody or antigen-binding portion thereof has an affinity (K D ) binds to human CD137; (ii) The antibody or antigen-binding portion thereof specifically binds to an epitope comprising a sequence of one or more amino acid residues corresponding to amino acids 111 to 135 of SEQ ID NO:3. (iii) an antibody, or antigen-binding portion thereof, having the amino acid sequence DX1X2X3X4LX5X6X7X8YX9YYX 10(SEQ ID NO: 128), wherein X1 is any amino acid, wherein X2 is a nonpolar amino acid, wherein X3 is a nonpolar amino acid, wherein X4 is any amino acid, wherein X5 is a polar amino acid, wherein X6 is any amino acid, wherein X7 is any amino acid, wherein X8 is a polar amino acid, wherein X9 is a polar amino acid, and wherein X 10 is any amino acid; or (iv) Combinations thereof. In some embodiments, X2 is proline, X3 is phenylalanine or tryptophan, X5 is aspartic acid or glutamic acid, X8 is tyrosine, and X9 is tyrosine.
[0030] In another aspect, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein: (i) The antibody or antigen-binding portion thereof has an affinity (K D ) binds to human CD137; (ii) the antibody, or antigen-binding portion thereof, specifically binds to an epitope comprising a sequence of one or more amino acid residues corresponding to amino acids 111 to 135 of SEQ ID NO:3; and (iii) the antibody, or antigen-binding portion thereof, has the amino acid sequence DXXXXLXXXXYXYYX (SEQ ID NO: 126). wherein X is any amino acid. In some embodiments, X is any amino acid except alanine.
[0031] In another aspect, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein: (i) The antibody or antigen-binding portion thereof has an affinity (K D ) binds to human CD137; (ii) the antibody, or antigen-binding portion thereof, specifically binds to an epitope comprising a sequence of one or more amino acid residues corresponding to amino acids 111 to 135 of SEQ ID NO:3; and (iii) an antibody, or antigen-binding portion thereof, having the amino acid sequence DX1X2X3X4LX5X6X7X8YX9YYX 10 (SEQ ID NO: 128), wherein X1 is any amino acid, wherein X2 is a nonpolar amino acid, wherein X3 is a nonpolar amino acid, wherein X4 is any amino acid, wherein X5 is a polar amino acid, wherein X6 is any amino acid, wherein X7 is any amino acid, wherein X8 is a polar amino acid, wherein X9 is a polar amino acid, and wherein X 10 is any amino acid. In some embodiments, X2 is proline, X3 is phenylalanine or tryptophan, X5 is aspartic acid or glutamic acid, X8 is tyrosine, and X9 is tyrosine.
[0032] In any of the foregoing embodiments, the epitope comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acid residues corresponding to amino acids 111 to 135 of SEQ ID NO:3.
[0033] In some aspects, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein: (i) the antibody, or antigen-binding portion thereof, binds to human CD137 with an affinity of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); and (ii) The antibody or antigen-binding portion thereof specifically binds to an epitope comprising ELTK (corresponding to amino acid residues 111 to 114 of SEQ ID NO: 3).
[0034] In some aspects, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein: (i) The antibody or antigen-binding portion thereof has an affinity (K D ) binds to human CD137; (ii) the antibody, or antigen-binding portion thereof, specifically binds to an epitope comprising ELTK (corresponding to amino acid residues 111 to 114 of SEQ ID NO: 3); (iii) the antibody, or antigen-binding portion thereof, has the amino acid sequence DXXXXLXXXXYXYYX (SEQ ID NO: 126). wherein X is any amino acid; or (iv) combinations thereof. In some embodiments, X is any amino acid except alanine.
[0035] In some aspects, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein: (i) The antibody or antigen-binding portion thereof has an affinity (K D ) binds to human CD137; (ii) the antibody, or antigen-binding portion thereof, specifically binds to an epitope comprising ELTK (corresponding to amino acid residues 111 to 114 of SEQ ID NO: 3); (iii) an antibody, or antigen-binding portion thereof, having the amino acid sequence DX1X2X3X4LX5X6X7X8YX9YYX 10 (SEQ ID NO: 128), wherein X1 is any amino acid, wherein X2 is a nonpolar amino acid, wherein X3 is a nonpolar amino acid, wherein X4 is any amino acid, wherein X5 is a polar amino acid, wherein X6 is any amino acid, wherein X7 is any amino acid, wherein X8 is a polar amino acid, wherein X9 is a polar amino acid, and wherein X 10 is any amino acid; or (iv) Combinations thereof. In some embodiments, X2 is proline, X3 is phenylalanine or tryptophan, X5 is aspartic acid or glutamic acid, X8 is tyrosine, and X9 is tyrosine.
[0036] In some aspects, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein: (i) The antibody or antigen-binding portion thereof has an affinity (K D ) binds to human CD137; (ii) the antibody, or antigen-binding portion thereof, specifically binds to an epitope comprising ELTK (corresponding to amino acid residues 111 to 114 of SEQ ID NO: 3); and (iii) the antibody, or antigen-binding portion thereof, has the amino acid sequence DXXXXLXXXXYXYYX (SEQ ID NO: 126). wherein X is any amino acid. In some embodiments, X is any amino acid except alanine.
[0037] In some aspects, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein: (i) The antibody or antigen-binding portion thereof has an affinity (K D ) binds to human CD137; (ii) the antibody, or antigen-binding portion thereof, specifically binds to an epitope comprising ELTK (corresponding to amino acid residues 111 to 114 of SEQ ID NO: 3); and (iii) an antibody, or antigen-binding portion thereof, having the amino acid sequence DX1X2X3X4LX5X6X7X8YX9YYX 10(SEQ ID NO: 128), wherein X1 is any amino acid, wherein X2 is a nonpolar amino acid, wherein X3 is a nonpolar amino acid, wherein X4 is any amino acid, wherein X5 is a polar amino acid, wherein X6 is any amino acid, wherein X7 is any amino acid, wherein X8 is a polar amino acid, wherein X9 is a polar amino acid, and wherein X 10 is any amino acid. In some embodiments, X2 is proline, X3 is phenylalanine or tryptophan, X5 is aspartic acid or glutamic acid, X8 is tyrosine, and X9 is tyrosine.
[0038] In any of the foregoing embodiments, the epitope includes ELTK residues of SEQ ID NO: 3 (corresponding to amino acid residues 111-114 of SEQ ID NO: 3). In some embodiments, the epitope includes ELTK of SEQ ID NO: 3 (corresponding to amino acid residues 111-114 of SEQ ID NO: 3) and residues N126, I132, and P135 of SEQ ID NO: 3.
[0039] In any of the foregoing embodiments, the epitope is a non-linear epitope. In some embodiments, mutation of the K114 residue of human CD137 (SEQ ID NO: 3) abolishes binding of the antibody, or antigen-binding portion thereof, to human CD137.
[0040] In any of the foregoing embodiments, the antibody, or antigen-binding portion thereof, comprises a heavy chain CDR3 comprising the amino acid sequence DXPFXLDXXYYYYYX (SEQ ID NO: 128), where X is any amino acid. In some embodiments, mutation of residues D95, L100, Y100E, Y100G, Y100H, or a combination thereof, in the heavy chain CDR3 of an antibody, or antigen-binding portion thereof, described herein, results in loss of binding to human CD137. In some embodiments, mutation of residues P97, F98, D100A, Y100D, Y100F, or a combination thereof, in the heavy chain CDR3 of an antibody, or antigen-binding portion thereof, described herein, results in loss of binding to human CD137. In other embodiments, mutation of residues P97, F98, D100A, Y100D, Y100F, or combinations thereof, of the heavy chain CDR3 of an antibody or antigen-binding portion thereof described herein to any residue other than alanine results in increased binding to human CD137.
[0041] In any of the foregoing embodiments, the antibody or antigen-binding portion thereof has a (K D In any of the foregoing embodiments, the antibody or antigen-binding portion thereof binds to human CD137 with a (K) of about 45 nM to about 95 nM, about 50 to about 90 nM, about 55 to about 85 nM, about 60 to about 80 nM, about 65 to about 75 nM, about 55 to about 75 nM, about 40 to about 70 nM, about 50 to about 80 nM, or about 60 to about 90 nM. D ) binds to human CD137.
[0042] In any of the foregoing embodiments, the antibody or antigen-binding portion thereof comprises a heavy chain CDR and a light chain CDR, wherein the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO:68.
[0043] In any of the foregoing embodiments, the antibody or antigen-binding portion thereof comprises heavy chain and light chain CDRs selected from the group consisting of: (a) heavy chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 48, 56, and 68, respectively, and light chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 69, 78, and 89, respectively; and (b) Heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 51, 108 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively.
[0044] In any of the foregoing embodiments, the antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 4 and 101, and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 6.
[0045] In any of the foregoing embodiments, the antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region comprising an amino acid sequence selected from the group consisting of: (a) SEQ ID NOs: 4 and 6, respectively; and (b) SEQ ID NOs: 101 and 6, respectively.
[0046] In any of the foregoing embodiments, the antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 4 and 101, and wherein the light chain variable region comprises an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 6.
[0047] In any of the foregoing embodiments, the antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region comprising an amino acid sequence that is at least 90% identical to an amino acid sequence selected from the group consisting of: (a) SEQ ID NOs: 4 and 6, respectively; and (b) SEQ ID NOs: 101 and 6, respectively.
[0048] In any of the preceding embodiments, the antibody or antigen-binding portion of any one of claims 1 to 27, wherein the antibody or antigen-binding portion comprises a heavy chain and a light chain comprising an amino acid sequence selected from the group consisting of: (a) SEQ ID NOs: 129 and 133, respectively; and (b) SEQ ID NOs: 131 and 133, respectively.
[0049] In any of the foregoing embodiments, the isolated monoclonal antibody or antigen-binding portion thereof described herein is an agonist of human CD137 activity.
[0050] In any of the foregoing embodiments, the isolated monoclonal antibody or antigen-binding portion thereof described herein competes with mAb1 or an antigen-binding fragment of mAb1 for binding to an epitope on human CD137.
[0051] In some aspects, the disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to CD137, wherein the antibody or antigen-binding portion comprises a heavy chain CDR and a light chain CDR selected from the group consisting of: (a) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (b) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 70, 79 and 90, respectively; (c) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 71, 80 and 91, respectively; (d) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 72, 81 and 92, respectively; (e) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 73, 82 and 91, respectively; (f) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 74, 83 and 93, respectively; (g) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 75, 84 and 91, respectively; (h) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 74, 85 and 94, respectively; (i) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 76, 86 and 95, respectively; (j) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 77, 87 and 93, respectively; (k) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 88 and 90, respectively; (l) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 49, 57 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (m) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 49, 58 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (n) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 49, 59 and 68, respectively; and light chain CDR1, CDR2 and CDR3 set forth in SEQ ID NOs: 69, 78 and 89, respectively; (o) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 49, 60 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (p) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 50, 61 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (q) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 50, 58 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (r) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 51, 62 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (s) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 52, 63 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (t) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 50, 64 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (u) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 50, 65 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (v) heavy chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 51, 108, and 68, respectively, and light chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 69, 78, and 89, respectively; (w) heavy chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 107, 56, and 68, respectively, and light chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 69, 78, and 89, respectively; and (x) Heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 109, 110 and 92, respectively.
[0052] In another aspect, the disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, the antibody or antigen-binding portion thereof comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 101, and 103, and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, and 105.
[0053] In another aspect, the disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region encoded by a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 5 and 7, respectively; and (b) SEQ ID NOs: 102 and 7, respectively.
[0054] In another aspect, the disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region encoded by a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 5 and 7, respectively; (b) SEQ ID NOs: 5 and 29, respectively; (c) SEQ ID NOs: 5 and 31, respectively; (d) SEQ ID NOs: 5 and 33, respectively; (e) SEQ ID NOs: 5 and 35, respectively; (f) SEQ ID NOs: 5 and 37, respectively; (g) SEQ ID NOs: 5 and 39, respectively; (h) SEQ ID NOs: 5 and 41, respectively; (i) SEQ ID NOs: 5 and 43, respectively; (j) SEQ ID NOs: 5 and 45, respectively; (k) SEQ ID NOs: 5 and 47, respectively; (l) SEQ ID NOs: 9 and 7, respectively; (m) SEQ ID NOs: 11 and 7, respectively; (n) SEQ ID NOs: 13 and 7, respectively; (o) SEQ ID NOs: 15 and 7, respectively; (p) SEQ ID NOs: 17 and 7, respectively; (q) SEQ ID NOs: 19 and 7, respectively; (r) SEQ ID NOs: 21 and 7, respectively; (s) SEQ ID NOs: 23 and 7, respectively; (t) SEQ ID NOs: 25 and 7, respectively; (u) SEQ ID NOs: 27 and 7, respectively; (v) SEQ ID NOs: 102 and 7, respectively; (w) SEQ ID NOs: 104 and 7, respectively; and (x) SEQ ID NOs: 5 and 106, respectively.
[0055] In yet another aspect, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, the antibody or antigen-binding portion thereof comprising a heavy chain CDR and a light chain CDR, wherein the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 68.
[0056] In another aspect, the disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, the antibody or antigen-binding portion thereof comprising a heavy chain CDR and a light chain CDR, wherein the heavy chain CDR3 comprises the amino acid sequence DXXXXLXXXXYXYYX (SEQ ID NO: 126), where X is any amino acid. In some aspects, X is any amino acid except alanine.
[0057] In some embodiments, the disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, the antibody or antigen-binding portion thereof comprising a heavy chain CDR and a light chain CDR, wherein the heavy chain CDR3 comprises the amino acid sequence DXPFXLDXXYYYYYX (SEQ ID NO: 127), where X is any amino acid. In some embodiments, X is any amino acid except alanine.
[0058] In yet another aspect, the disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, the antibody or antigen-binding portion thereof comprising a heavy chain CDR and a light chain CDR, wherein the heavy chain CDR3 comprises the amino acid sequence DXXXXLXXXXYXYYX (SEQ ID NO: 126), where X is any amino acid, and mutation of residues D95, L100, Y100E, Y100G, Y100H, or a combination thereof, results in loss of binding to human CD137. .
[0059] In another aspect, the disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion thereof comprises a heavy chain CDR and a light chain CDR, wherein the heavy chain CDR3 comprises the amino acid sequence DXPFXLDXXYYYYYX (SEQ ID NO: 127), where X is any amino acid, and mutation of residues P97, F98, D100A, Y100D, Y100F, or combinations thereof, to alanine results in reduced binding to human CD137.
[0060] In some aspects, the disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion thereof comprises a heavy chain CDR and a light chain CDR, wherein the heavy chain CDR3 comprises the amino acid sequence DXPFXLDXXYYYYYX (SEQ ID NO: 127), where X is any amino acid, and mutation of residues P97, F98, D100A, Y100D, Y100F, or combinations thereof to any residue other than alanine results in increased binding to human CD137.
[0061] In yet another aspect, the disclosure provides an isolated monoclonal antibody, or antigen-binding portion thereof, that specifically binds to human CD137, the antibody, or antigen-binding portion thereof, comprising a heavy chain CDR and a light chain CDR, wherein the heavy chain CDR3 comprises the amino acid sequence DX1X2X3X4LX5X6X7X8YX9YYX10 (SEQ ID NO: 128), wherein X1 is any amino acid, wherein X2 is a nonpolar amino acid, wherein X3 is a nonpolar amino acid, wherein X4 is any amino acid, wherein X5 is a polar amino acid, wherein X6 is any amino acid, wherein X7 is any amino acid, wherein X8 is a polar amino acid, wherein X9 is a polar amino acid, and wherein X10 is any amino acid. In some embodiments, wherein X2 is proline, wherein X3 is phenylalanine or tryptophan, wherein X5 is aspartic acid or glutamic acid, wherein X8 is tyrosine, and wherein X9 is tyrosine.
[0062] In some aspects, the disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region comprising an amino acid sequence selected from the group consisting of: (a) SEQ ID NOs: 4 and 6, respectively; (b) SEQ ID NOs: 4 and 28, respectively; (c) SEQ ID NOs: 4 and 30, respectively; (d) SEQ ID NOs: 4 and 32, respectively; (e) SEQ ID NOs: 4 and 34, respectively; (f) SEQ ID NOs: 4 and 36, respectively; (g) SEQ ID NOs: 4 and 38, respectively; (h) SEQ ID NOs: 4 and 40, respectively; (i) SEQ ID NOs: 4 and 42, respectively; (j) SEQ ID NOs: 4 and 44, respectively; (k) SEQ ID NOs: 4 and 46, respectively; (l) SEQ ID NOs: 8 and 6, respectively; (m) SEQ ID NOs: 10 and 6, respectively; (n) SEQ ID NOs: 12 and 6, respectively; (o) SEQ ID NOs: 14 and 6, respectively; (p) SEQ ID NOs: 16 and 6, respectively; (q) SEQ ID NOs: 18 and 6, respectively; (r) SEQ ID NOs: 20 and 6, respectively; (s) SEQ ID NOs: 22 and 6, respectively; (t) SEQ ID NOs: 24 and 6, respectively; (u) SEQ ID NOs: 26 and 6, respectively; (v) SEQ ID NOs: 101 and 6, respectively; (w) SEQ ID NOs: 103 and 6, respectively; and (x) SEQ ID NOs: 4 and 105, respectively.
[0063] In another aspect, the disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, the antibody or antigen-binding portion thereof comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence that is at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 101, and 103, and the light chain variable region comprises an amino acid sequence that is at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, and 105.
[0064] In some aspects, the disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region comprising an amino acid sequence that is at least 90% identical to an amino acid sequence selected from the group consisting of: (a) SEQ ID NOs: 4 and 6, respectively; (b) SEQ ID NOs: 4 and 28, respectively; (c) SEQ ID NOs: 4 and 30, respectively; (d) SEQ ID NOs: 4 and 32, respectively; (e) SEQ ID NOs: 4 and 34, respectively; (f) SEQ ID NOs: 4 and 36, respectively; (g) SEQ ID NOs: 4 and 38, respectively; (h) SEQ ID NOs: 4 and 40, respectively; (i) SEQ ID NOs: 4 and 42, respectively; (j) SEQ ID NOs: 4 and 44, respectively; (k) SEQ ID NOs: 4 and 46, respectively; (l) SEQ ID NOs: 8 and 6, respectively; (m) SEQ ID NOs: 10 and 6, respectively; (n) SEQ ID NOs: 12 and 6, respectively; (o) SEQ ID NOs: 14 and 6, respectively; (p) SEQ ID NOs: 16 and 6, respectively; (q) SEQ ID NOs: 18 and 6, respectively; (r) SEQ ID NOs: 20 and 6, respectively; (s) SEQ ID NOs: 22 and 6, respectively; (t) SEQ ID NOs: 24 and 6, respectively; (u) SEQ ID NOs: 26 and 6, respectively; (v) SEQ ID NOs: 101 and 6, respectively; (w) SEQ ID NOs: 103 and 6, respectively; and (x) SEQ ID NOs: 4 and 105, respectively.
[0065] In some aspects, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion thereof comprises a heavy chain sequence and a light chain sequence comprising an amino acid sequence selected from the group consisting of: (a) SEQ ID NOs: 129 and 133, respectively; and (b) SEQ ID NOs: 131 and 133, respectively.
[0066] In some aspects, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion thereof comprises heavy chain and light chain sequences having the amino acid sequences set forth in SEQ ID NOs: 129 and 133, respectively.
[0067] In some aspects, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion thereof comprises heavy chain and light chain sequences having the amino acid sequences set forth in SEQ ID NOs: 131 and 133, respectively.
[0068] In any of the foregoing embodiments, the antibody or antigen-binding portion thereof specifically binds to and agonizes human CD137.
[0069] In any of the foregoing aspects, the isolated monoclonal antibody or antigen-binding portion thereof exhibits at least one or more of the following properties selected from the group consisting of: (a) Induction or enhancement of CD137 trimer dimerization; (b) induction or enhancement of multimerization of CD137 trimers; (c) induction or enhancement of T cell activation; (d) induction or enhancement of cytotoxic T cell responses; (e) induction or enhancement of T-cell proliferation; (f) induction or enhancement of cytokine production; and (g) Any combination of characteristics (a) through (f).
[0070] In any of the foregoing embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, exhibits at least one or more of the following properties selected from the group consisting of: (a) does not induce or enhance intrahepatic T cell activation; (b) does not induce or enhance intrahepatic T-cell proliferation; (c) does not induce or enhance intrasplenic T cell activation; (d) does not induce or enhance intrasplenic T-cell proliferation; (e) does not induce or enhance macrophage activation; (f) does not induce or enhance macrophage differentiation; (g) does not induce or enhance alanine aminotransferase (ALT) activity; and (h) Any combination of properties (a)-(g). In some embodiments, the reference antibody is urelumab.
[0071] In any of the foregoing embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, induces or enhances human CD137-mediated T cell activation in the tumor microenvironment, but does not induce or enhance human CD137-mediated T cell activation to a significant extent in the spleen and / or liver.
[0072] In any of the foregoing embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, induces or enhances T cell activation in the tumor microenvironment, but does not induce or enhance T cell activation to a significant extent in the spleen and / or liver.
[0073] In any of the foregoing embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, induces or enhances a human CD137-mediated cytotoxic T cell response in the tumor microenvironment, but does not significantly induce or enhance a human CD137-mediated cytotoxic T cell response in the spleen and / or liver.
[0074] In any of the foregoing embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, induces or enhances a cytotoxic T cell response in the tumor microenvironment, but does not significantly induce or enhance a cytotoxic T cell response in the spleen and / or liver.
[0075] In any of the foregoing embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, induces human CD137-mediated T cell proliferation in the tumor microenvironment, but does not induce significant human CD137-mediated T cell proliferation in the spleen and / or liver.
[0076] In any of the foregoing embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, induces T cell proliferation in the tumor microenvironment, but to a lesser extent in the spleen and / or liver.
[0077] In any of the foregoing embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, induces human CD137-mediated T cell infiltration in the tumor microenvironment, but does not induce significant human CD137-mediated T cell infiltration in the spleen and / or liver.
[0078] In any of the foregoing embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, induces T cell infiltration in the tumor microenvironment, but to a lesser extent in the spleen and / or liver.
[0079] In any of the foregoing embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof induces or enhances human CD137-mediated cytokine production in the tumor microenvironment, but does not significantly induce or enhance human CD137-mediated cytokine production in the spleen and / or liver.
[0080] In any of the foregoing embodiments, the properties of the antibodies or antigen-binding portions thereof described herein are not dependent on Fc gamma receptor binding. In some embodiments, the properties of the antibodies or antigen-binding portions thereof described herein are enhanced by Fc gamma receptor binding.
[0081] In any of the foregoing embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, cross-competes with mAb1 (i.e., an antibody comprising the heavy chain variable and light chain variable sequences of SEQ ID NOs: 4 and 6, respectively). In some embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, cross-competes with mAb1 (i.e., an antibody comprising the heavy chain variable and light chain variable sequences of SEQ ID NOs: 4 and 6, respectively), mab8 (i.e., an antibody comprising the heavy chain variable and light chain variable sequences of SEQ ID NOs: 101 and 6, respectively), or mAb10 (i.e., an antibody comprising the heavy chain variable and light chain variable sequences of SEQ ID NOs: 26 and 6, respectively). In some embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, cross-competes with mab8 (i.e., an antibody comprising the heavy chain variable and light chain variable sequences of SEQ ID NOs: 101 and 6, respectively). In some embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, cross-competes with mAb10 (i.e., an antibody comprising the heavy chain variable and light chain variable sequences of SEQ ID NOs: 26 and 6, respectively).
[0082] In any of the foregoing embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, comprises at least a functional characteristic of mAb1 (i.e., an antibody comprising the heavy chain variable and light chain variable sequences of SEQ ID NOs: 4 and 6, respectively). In some embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, comprises at least a functional characteristic of mAb1 (i.e., an antibody comprising the heavy chain variable and light chain variable sequences of SEQ ID NOs: 4 and 6, respectively), mab8 (i.e., an antibody comprising the heavy chain variable and light chain variable sequences of SEQ ID NOs: 101 and 6, respectively), or mAb10 (i.e., an antibody comprising the heavy chain variable and light chain variable sequences of SEQ ID NOs: 26 and 6, respectively). In some embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, comprises at least a functional characteristic of mab8 (i.e., an antibody comprising the heavy chain variable and light chain variable sequences of SEQ ID NOs: 101 and 6, respectively). In some embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, comprises at least a functional characteristic of mAb10 (i.e., an antibody comprising the heavy chain variable and light chain variable sequences of SEQ ID NOs: 26 and 6, respectively).
[0083] In any of the foregoing embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, has a K at least equivalent to that of mAb1 (i.e., an antibody comprising the heavy chain variable sequences and light chain variable sequences of SEQ ID NOs: 4 and 6, respectively). D In some embodiments, the isolated monoclonal antibody or antigen-binding portion thereof has a K value at least equivalent to that of mAb1 (i.e., an antibody comprising the heavy and light chain variable sequences of SEQ ID NOs: 4 and 6, respectively), mab8 (i.e., an antibody comprising the heavy and light chain variable sequences of SEQ ID NOs: 101 and 6, respectively), or mAb10 (i.e., an antibody comprising the heavy and light chain variable sequences of SEQ ID NOs: 26 and 6, respectively). D In some embodiments, the isolated monoclonal antibody or antigen-binding portion thereof has a K value at least equivalent to that of mab8 (i.e., an antibody comprising the heavy chain variable sequences and light chain variable sequences of SEQ ID NOs: 101 and 6, respectively). DIn some embodiments, the isolated monoclonal antibody or antigen-binding portion thereof has a K value at least equivalent to that of mAb10 (i.e., an antibody comprising the heavy chain variable sequence and light chain variable sequence of SEQ ID NOs: 26 and 6, respectively). D It has a value.
[0084] In any of the foregoing embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, cross-reacts with cynomolgus monkey CD137 and / or mouse CD137.
[0085] In any of the foregoing embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE antibodies. In some embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, is an IgG1 antibody or an IgG4 antibody.
[0086] In any of the foregoing embodiments, the isolated monoclonal antibody comprises a heavy chain constant region of a wild-type IgG1 or a wild-type IgG4. In some embodiments, the isolated monoclonal antibody comprises a heavy chain constant region of a mutant IgG1. In some embodiments, the isolated monoclonal antibody comprises a heavy chain constant region of a mutant IgG4. In some embodiments, the heavy chain constant region of the mutant IgG4 comprises a substitution at Ser228. In some embodiments, the heavy chain constant region of the mutant IgG4 comprises a S228P substitution.
[0087] In any of the foregoing embodiments, the isolated monoclonal antibody, or antigen-binding portion thereof, binds to an epitope of CD137, and the amino acid residues comprising the epitope bound by the antibody are located within 4 angstroms of the amino acid residues comprising the paratope of the mAb1 antibody described herein.
[0088] In any of the foregoing embodiments, the isolated monoclonal antibody or antigen-binding portion thereof binds to an epitope of CD137, and mutation of the epitope bound by the antibody inhibits, reduces or prevents binding to both the antibody and the mAb1 antibody.
[0089] In any of the foregoing embodiments, the isolated antibody or antigen-binding portion thereof is fully human or humanized (i.e., a fully human antibody or fully humanized antibody or antigen-binding portion thereof).
[0090] In some aspects, the present disclosure provides a pharmaceutical composition comprising an isolated monoclonal antibody or antigen-binding portion thereof described herein and a pharmaceutically acceptable carrier.
[0091] In other aspects, the present disclosure provides a nucleic acid comprising a nucleotide sequence encoding the light chain, the heavy chain, or both the light and heavy chains of an isolated monoclonal antibody, or antigen-binding portion thereof, described herein. In some embodiments, the nucleic acid comprises SEQ ID NOs: 5 and 7. In some embodiments, the nucleic acid comprises SEQ ID NOs: 102 and 7. In some embodiments, the present disclosure provides an expression vector comprising the nucleic acid described herein. In other aspects, the present disclosure provides a cell transformed with the expression vector described herein.
[0092] In another aspect, the present disclosure provides a method of making an isolated monoclonal antibody, or antigen-binding portion thereof, that specifically binds human CD137, the method comprising maintaining a cell described herein under conditions that allow for expression of the monoclonal antibody, or antigen-binding portion thereof. In some aspects, the method of making a monoclonal antibody, or antigen-binding portion thereof, that specifically binds human CD137 further comprises obtaining the monoclonal antibody, or antigen-binding portion thereof.
[0093] In yet another aspect, the present disclosure provides a method for inducing or enhancing dimerization of human CD137 trimers in a subject, the method comprising administering to a subject in need thereof an effective amount of an isolated monoclonal antibody or antigen-binding portion thereof described herein, or a pharmaceutical composition described herein.
[0094] In another aspect, the present disclosure provides a method for inducing or enhancing multimerization of human CD137 trimers in a subject, the method comprising administering to a subject in need thereof an effective amount of an isolated monoclonal antibody or antigen-binding portion thereof described herein, or a pharmaceutical composition described herein.
[0095] In another aspect, the present disclosure provides a method of inducing or enhancing human CD137-mediated T cell activation in a subject, the method comprising administering to a subject in need thereof an effective amount of an isolated monoclonal antibody or antigen-binding portion thereof described herein, or a pharmaceutical composition described herein. In some embodiments, T cell activation occurs in the tumor microenvironment. In other embodiments, T cell activation does not occur significantly in the spleen and / or liver of the subject.
[0096] In another aspect, the present disclosure provides a method of inducing or enhancing a cytotoxic T cell response mediated by human CD137 in a subject, the method comprising administering to a subject in need thereof an effective amount of an isolated monoclonal antibody or antigen-binding portion thereof described herein, or a pharmaceutical composition described herein. In some embodiments, the cytotoxic T cell response is generated in the tumor microenvironment. In other embodiments, the cytotoxic T cell response is not significantly generated in the spleen and / or liver of the subject.
[0097] In some embodiments, the present disclosure provides a method of inducing or enhancing human CD137-mediated cytokine production in a subject, the method comprising administering to a subject in need thereof an effective amount of an isolated monoclonal antibody or antigen-binding portion thereof described herein, or a pharmaceutical composition described herein. In some embodiments, the cytokine produced is IL-2, TNFα, IL-13, IFNγ, or a combination thereof. In some embodiments, the cytokine produced is IL-2. In some embodiments, the cytokine produced is TNFα. In some embodiments, the cytokine produced is IL-13. In some embodiments, the cytokine produced is IFNγ. In some embodiments, the cytokine produced is IL-2 and TNFα. In some embodiments, the cytokine produced is IL-2 and IL-13. In some embodiments, the cytokine produced is IL-2 and IFNγ. In some embodiments, the cytokine produced is TNFα and IL-13. In some embodiments, the cytokine produced is TNFα and IFNγ. In some embodiments, the cytokines produced are IL-13 and IFNγ. In some embodiments, the cytokines produced are IL-2, TNFα, and IL-13. In some embodiments, the cytokines produced are IL-2, TNFα, and IFNγ. In some embodiments, the cytokines produced are IFNγ, TNFα, and IL-13. In other embodiments, cytokine production occurs in the tumor microenvironment. In still other embodiments, cytokine production does not occur significantly in the spleen and / or liver of the subject.
[0098] In another aspect, the present disclosure provides a method of inducing or enhancing human CD137-mediated T cell proliferation in a subject, the method comprising administering to a subject in need thereof an effective amount of an isolated monoclonal antibody or antigen-binding portion thereof described herein, or a pharmaceutical composition described herein. In some embodiments, T cell proliferation occurs in the tumor microenvironment. In other embodiments, T cell proliferation does not occur significantly in the spleen and / or liver of the subject.
[0099] In another aspect, the present disclosure provides a method of reducing or inhibiting tumor growth, the method comprising administering to a subject in need thereof an effective amount of an isolated monoclonal antibody or antigen-binding portion thereof described herein, or a pharmaceutical composition described herein.
[0100] In yet another aspect, the present disclosure provides a method of treating a disorder mediated by human CD137 in a subject, the method comprising administering to a subject in need thereof an effective amount of an isolated monoclonal antibody or antigen-binding portion thereof described herein, or a pharmaceutical composition described herein.
[0101] In some embodiments, the present disclosure provides a method of treating cancer in a subject, the method comprising administering to a subject in need thereof an effective amount of an isolated monoclonal antibody or antigen-binding portion thereof described herein, or a pharmaceutical composition described herein. In some embodiments, the cancer is selected from the group consisting of melanoma, glioma, renal cancer, breast cancer, hematological cancer, and head and neck cancer. In some embodiments, the hematological cancer is B-cell lymphoma.
[0102] In some aspects, the present disclosure provides a method of inducing an anti-tumor memory immune response, the method comprising administering to a subject in need thereof an effective amount of an isolated monoclonal antibody or antigen-binding portion thereof described herein, or a pharmaceutical composition described herein.
[0103] In any of the foregoing embodiments, after administration of the antibody or antigen-binding portion, infiltration of immune cells into the tumor microenvironment is increased. In some embodiments, the immune cells express CD45.
[0104] In any of the foregoing embodiments, the amount of T regulatory (Treg) cells is reduced in the tumor microenvironment following administration of the antibody or antigen-binding portion. In some embodiments, the Treg cells express CD4, FOXP-3, and CD24.
[0105] In any of the foregoing embodiments, the amount of macrophage cells is reduced in the tumor microenvironment after administration of the monoclonal antibody or antigen-binding portion. In some embodiments, the macrophages express CD45 and CD11b.
[0106] In any of the foregoing embodiments, after administration of the antibody or antigen-binding portion, T cell exhaustion is reduced. In some embodiments, the reduced T cell exhaustion comprises a decrease in expression of TIGIT, PD-1, LAG-3, or a combination thereof. In some embodiments, the reduced T cell exhaustion comprises a decrease in expression of TIGIT and PD-1.
[0107] In any of the foregoing embodiments, depletion of CD4+ T cells, CD8+ T cells, natural killer cells, or a combination thereof reduces the effectiveness of the antibody or antigen-binding portion thereof.
[0108] In another aspect, the present disclosure provides a method for detecting the presence or absence of human CD137 in a biological sample, the method comprising: (a) contacting a biological sample with an antibody or antigen-binding portion described herein, wherein the antibody or antigen-binding portion is labeled with a detectable substance; and (b) detecting the antibody or antigen-binding portion that binds to human CD137, thereby detecting the presence or absence of human CD137 in the biological sample.
[0109] In another aspect, the disclosure provides a kit comprising a container containing an antibody or antigen-binding portion described herein and optionally a pharmaceutically acceptable carrier, or a pharmaceutical composition described herein, and a package insert containing instructions for administering the antibody or pharmaceutical composition to treat or delay the progression of cancer, or to reduce or inhibit tumor growth in a subject in need thereof.
[0110] In another aspect, the disclosure provides a kit comprising a container containing an antibody or antigen-binding portion described herein and optionally a pharmaceutically acceptable carrier, or a pharmaceutical composition described herein, and a package insert containing instructions for administering the antibody or pharmaceutical composition, alone or in combination with another agent, to treat or delay the progression of cancer, or to reduce or inhibit tumor growth, in a subject in need thereof.
[0111] In another aspect, the present disclosure provides the use of an isolated monoclonal antibody, or an antigen-binding portion thereof, described herein to induce or enhance human CD137-mediated T cell activation in a subject. In another aspect, the present disclosure provides the use of an isolated monoclonal antibody, or an antigen-binding portion thereof, described herein to induce or enhance human CD137 trimer multimerization in a subject. In another aspect, the present disclosure provides the use of an isolated monoclonal antibody, or an antigen-binding portion thereof, described herein to induce or enhance human CD137-mediated cytotoxic T cell response in a subject. In another aspect, the present disclosure provides the use of an isolated monoclonal antibody, or an antigen-binding portion thereof, described herein to induce or enhance human CD137-mediated cytokine production in a subject. In another aspect, the present disclosure provides the use of an isolated monoclonal antibody, or an antigen-binding portion thereof, described herein to induce or enhance human CD137-mediated T cell proliferation in a subject.
[0112] In another aspect, the present disclosure provides for the use of an isolated monoclonal antibody, or antigen-binding portion thereof, described herein to reduce or inhibit tumor growth in a subject in need thereof. In another aspect, the present disclosure provides for the use of an isolated monoclonal antibody, or antigen-binding portion thereof, described herein to treat a disorder mediated by human CD137 in a subject in need thereof. In another aspect, the present disclosure provides for the use of an isolated monoclonal antibody, or antigen-binding portion thereof, described herein to treat cancer in a subject in need thereof.
[0113] In another aspect, the disclosure provides for the use of an isolated monoclonal antibody, or antigen-binding portion thereof, described herein for the manufacture of a medicament for treating or delaying the progression of cancer, or reducing or inhibiting tumor growth in a subject in need thereof. In another aspect, the disclosure provides for an isolated monoclonal antibody, or antigen-binding portion thereof, described herein in the manufacture of a medicament for treating or delaying the progression of cancer, or reducing or inhibiting tumor growth in a subject in need thereof. In another aspect, the disclosure provides for an isolated monoclonal antibody, or antigen-binding portion thereof, described herein for use as a medicament. The present invention provides, for example, the following items. (Item 1) An isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137. The antibody or antigen-binding portion has an affinity (K D ) an isolated monoclonal antibody or antigen-binding portion thereof that binds to human CD137. (Item 2) 2. The isolated monoclonal antibody or antigen-binding portion of item 1, wherein the antibody or antigen-binding portion binds to an epitope on human CD137 comprising K114 of SEQ ID NO: 3. (Item 3) 3. The isolated monoclonal antibody or antigen-binding portion of item 2, wherein the epitope comprises residues E111, T113 and K114 of SEQ ID NO:3. (Item 4) the epitope comprises residues E111, T113, K114, N126 and I132 of SEQ ID NO: 3. Item 4. The isolated monoclonal antibody or antigen-binding portion thereof according to any one of Items 2 to 3. (Item 5) The epitope comprises residues E111, T113, K114, N126, I132 and P135 of SEQ ID NO:3. 5. The isolated monoclonal antibody or antigen-binding portion according to any one of items 2 to 4. (Item 6) The epitope comprises one of residues E111, T113, K114, N126, I132 and P135 of SEQ ID NO: 3. 2. The isolated monoclonal antibody or antigen-binding portion of item 1, comprising: (Item 7) The antibody or antigen-binding portion thereof may comprise one amino acid sequence corresponding to amino acids 111 to 135 of SEQ ID NO:3. or a sequence of multiple amino acid residues. Monoclonal antibodies or antigen-binding portions. (Item 8) The epitope is selected from the group consisting of amino acids 2, 3, 4, 5, 6, and 7, which correspond to amino acids 111 to 135 of SEQ ID NO: 3. 8. The isolated monoclonal antibody or antigen-binding portion of item 7, comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 amino acid residues. (Item 9) The antibody or antigen-binding portion thereof is a polypeptide corresponding to amino acid residues 111 to 114 of ELTK (SEQ ID NO: 3). 2. The isolated monoclonal antibody according to item 1, which binds to an epitope comprising its antigen-binding portion. (Item 10) The epitope further comprises one or more of residues N126, I132 and P135 of SEQ ID NO:3. 10. The isolated monoclonal antibody or antigen-binding portion of item 9, including: (Item 11) 11. The isolated monoclonal antibody or antigen-binding portion of any one of items 2 to 10, wherein the epitope is a non-linear epitope. (Item 12) Mutation of residue K114 of SEQ ID NO: 3 abolishes binding of the antibody or antigen-binding portion thereof. 12. The isolated monoclonal antibody or antigen-binding portion according to any one of items 2 to 11. (Item 13) the antibody or antigen-binding portion has an affinity (K D Item 14. The isolated monoclonal antibody or antigen-binding portion according to any one of items 1 to 12, which binds to human CD137 at the nucleotide sequence (SEQ ID NO: 1). the antibody or antigen-binding portion thereof binds to a non-ligand binding region of the extracellular domain of human CD137. 14. The isolated monoclonal antibody or antigen-binding portion of any one of items 1 to 13, which binds to (Item 15) An isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137. wherein the antibody or antigen-binding portion comprises: (i) Affinity (K) of approximately 30–100 nM D ) binds to human CD137; (ii) binds to a non-ligand binding region of the extracellular domain of human CD137; and (iii) an isolated monoclonal antibody that binds to an epitope on human CD137 that includes K114 of SEQ ID NO: 3; A cloned antibody or antigen-binding portion thereof. (Item 16) An isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137. wherein the antibody or antigen-binding portion comprises: (i) Affinity (K) of approximately 30–100 nM D ) binds to human CD137; (ii) does not inhibit the interaction between human CD137 and human CD137 ligand; and (iii) an isolated monoclonal antibody that binds to an epitope on human CD137 that includes K114 of SEQ ID NO: 3; A cloned antibody or antigen-binding portion thereof. (Item 17) 16. The isolated monoclonal antibody or antigen-binding portion of any one of paragraphs 1 to 15, wherein the antibody or antigen-binding portion does not inhibit the interaction between CD137 and CD137L. (Item 18) The non-ligand binding region is located in cysteine-rich domain (CRD) III and CRD IV. 16. The isolated monoclonal antibody or its antigen-binding fragment thereof according to any one of items 14 to 15. portion. (Item 19) 19. The antibody or antigen-binding portion of any one of items 1 to 18, wherein the antibody or antigen-binding portion comprises a heavy chain CDR3 comprising the amino acid sequence DXXXXLXXXXYXYYX (SEQ ID NO: 126), wherein X is any amino acid. An isolated monoclonal antibody or antigen-binding portion thereof. (Item 20) 20. The isolated monoclonal antibody or antigen-binding portion of any one of items 1, 2, 3, and 11-19, wherein the epitope comprises E111, T113, K114, and P135 of SEQ ID NO:3. (Item 21) 20. The antibody or antigen-binding portion of any one of items 1 to 19, wherein the antibody or antigen-binding portion comprises a heavy chain CDR3 comprising the amino acid sequence DXPFXLDXXYYYYYX (SEQ ID NO: 127), wherein X is any amino acid. An isolated monoclonal antibody or antigen-binding portion. (Item 22) 22. The isolated monoclonal antibody or antigen-binding portion of any one of paragraphs 19 to 21, wherein mutation of residues D95, L100, Y100E, Y100G, Y100H, or combinations thereof, in the heavy chain CDR3 to alanine results in loss of binding to human CD137. (Item 23) Mutation of residues P97, F98, D100A, Y100D, Y100F, or their combinations to alanine 23. The isolated monoclonal antibody or antigen-binding portion of any one of items 19 to 22, which results in reduced binding to human CD137. (Item 24) the antibody or antigen-binding portion does not inhibit trimer formation of CD137:CD137L monomers; 24. The isolated monoclonal antibody or antigen-binding portion according to any one of items 1 to 23. (Item 25) The antibody or antigen-binding portion is located within amino acid residues 111 to 135 of SEQ ID NO:3. 25. The isolated monoclonal antibody or antigen-binding portion thereof according to any one of items 1, 13, 14, 17 to 19 and 21 to 24, which binds to an epitope (Item 26) 26. The isolated monoclonal antibody or antigen-binding portion of item 25, wherein the epitope is a non-linear epitope. (Item 27) 27. The isolated monoclonal antibody or antigen-binding portion of any one of items 1 to 26, wherein the antibody or antigen-binding portion comprises a heavy chain CDR and a light chain CDR, and the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 68. (Item 28) the antibody or antigen-binding portion thereof, (a) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; and (b) The isolated monoclonal antibody or antigen-binding portion of any one of items 1 to 27, comprising heavy chain CDRs and light chain CDRs selected from the group consisting of heavy chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 51, 108, and 68, respectively, and light chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 69, 78, and 89, respectively. (Item 29) 28. The antibody or antigen-binding portion thereof according to any one of items 1 to 27, wherein the antibody or antigen-binding portion comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4 and 101, and the light chain variable region comprising the amino acid sequence of SEQ ID NO: 6. An isolated monoclonal antibody or antigen-binding portion thereof. (Item 30) the antibody or antigen-binding portion thereof, (a) SEQ ID NOs: 4 and 6, respectively; and (b) a group comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 101 and 6, respectively; 28. The isolated monoclonal antibody or antigen-binding portion of any one of items 1 to 27, comprising a light chain variable region and a light chain variable region. (Item 31) 28. The antibody or antigen-binding portion thereof according to any one of items 1 to 27, wherein the antibody or antigen-binding portion comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence that is at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 4 and 101, and the light chain variable region comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 6. 2. An isolated monoclonal antibody or antigen-binding portion thereof according to claim 1. (Item 32) the antibody or antigen-binding portion thereof, (a) SEQ ID NOs: 4 and 6, respectively; and (b) to an amino acid sequence selected from the group consisting of SEQ ID NOs: 101 and 6, respectively: comprising a heavy chain variable region and a light chain variable region comprising amino acid sequences that are at least 90% identical; 28. The isolated monoclonal antibody or antigen-binding portion according to any one of items 1 to 27. (Item 33) the antibody or antigen-binding portion thereof, (a) SEQ ID NOs: 129 and 133, respectively; and (b) The isolated monoclonal antibody or antigen-binding portion thereof according to any one of items 1 to 27, comprising a heavy chain and a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 131 and 133, respectively. (Item 34) An isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137. wherein the antibody or antigen-binding portion thereof is (a) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (b) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 70, 79 and 90, respectively; (c) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 71, 80 and 91, respectively; (d) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 72, 81 and 92, respectively; (e) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 73, 82 and 91, respectively; (f) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 74, 83 and 93, respectively; (g) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 75, 84 and 91, respectively; (h) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 74, 85 and 94, respectively; (i) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 76, 86 and 95, respectively; (j) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 77, 87 and 93, respectively; (k) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 88 and 90, respectively; (l) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 49, 57 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (m) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 49, 58 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (n) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 49, 59 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (o) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 49, 60 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (p) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 50, 61 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (q) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 50, 58 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (r) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 51, 62 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (s) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 52, 63 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (t) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 50, 64 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (u) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 50, 65 and 68, respectively; and the light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (v) heavy chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 51, 108, and 68, respectively, and light chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 69, 78, and 89, respectively; (w) heavy chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 107, 56, and 68, respectively, and light chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 69, 78, and 89, respectively; and (x) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively; and light chain CDR1, CDR2 and CDR3 set forth in SEQ ID NOs: 109, 110 and 92, respectively. (Item 35) An isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137. wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 101, and 103, and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, and 105. 2. An isolated monoclonal antibody or antigen-binding portion thereof, comprising a nucleotide sequence. (Item 36) An isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137. wherein the antibody or antigen-binding portion thereof comprises a heavy chain CDR and a light chain CDR, and the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 68. (Item 37) An isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137. wherein the antibody or antigen-binding portion thereof comprises a heavy chain CDR and a light chain CDR, wherein the heavy chain CDR3 comprises the amino acid sequence DXXXXLXXXXYXYYX (SEQ ID NO: 126), where X is any amino acid; An isolated monoclonal antibody or antigen-binding portion thereof. (Item 38) An isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137. wherein the antibody or antigen-binding portion thereof comprises a heavy chain CDR and a light chain CDR, wherein the heavy chain CDR3 comprises the amino acid sequence DXPFXLDXXYYYYYX (SEQ ID NO: 128), where X is any amino acid; An isolated monoclonal antibody or antigen-binding portion thereof. (Item 39) the antibody or antigen-binding portion thereof, (a) SEQ ID NOs: 5 and 7, respectively; and (b) a nucleotide sequence selected from the group consisting of SEQ ID NOs: 102 and 7, respectively; 28. The isolated monoclonal antibody or antigen-binding portion of any one of items 1 to 27, comprising a heavy chain variable region and a light chain variable region encoded by the same. (Item 40) 40. The isolated monoclonal antibody or antigen-binding portion of any one of paragraphs 37 to 39, wherein mutation of residues D95, L100, Y100E, Y100G, Y100H, or combinations thereof, to alanine results in loss of binding to human CD137. (Item 41) Mutation of residues P97, F98, D100A, Y100D, Y100F, or their combinations to alanine 41. The isolated monoclonal antibody or antigen-binding portion of any one of paragraphs 37 to 40, which results in reduced binding to human CD137. (Item 42) the antibody or antigen-binding portion thereof, (a) SEQ ID NOs: 5 and 7, respectively; and (b) for a nucleotide sequence selected from the group consisting of SEQ ID NOs: 102 and 7, respectively and a heavy chain variable region encoded by a nucleotide sequence having at least 90% identity thereto. 28. The isolated monoclonal antibody or antigen-binding portion of any one of items 1 to 27, comprising a light chain variable region and a light chain variable region. (Item 43) 43. The isolated monoclonal antibody or antigen-binding portion of claim 42, wherein the antibody or antigen-binding portion comprises a heavy chain variable region and a light chain variable region encoded by a nucleotide sequence having at least 90% identity to SEQ ID NOs: 5 and 7, respectively. (Item 44) An isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137. wherein the antibody or antigen-binding portion thereof is (a) SEQ ID NOs: 5 and 7, respectively; (b) SEQ ID NOs: 5 and 29, respectively; (c) SEQ ID NOs: 5 and 31, respectively; (d) SEQ ID NOs: 5 and 33, respectively; (e) SEQ ID NOs: 5 and 35, respectively; (f) SEQ ID NOs: 5 and 37, respectively; (g) SEQ ID NOs: 5 and 39, respectively; (h) SEQ ID NOs: 5 and 41, respectively; (i) SEQ ID NOs: 5 and 43, respectively; (j) SEQ ID NOs: 5 and 45, respectively; (k) SEQ ID NOs: 5 and 47, respectively; (l) SEQ ID NOs: 9 and 7, respectively; (m) SEQ ID NOs: 11 and 7, respectively; (n) SEQ ID NOs: 13 and 7, respectively; (o) SEQ ID NOs: 15 and 7, respectively; (p) SEQ ID NOs: 17 and 7, respectively; (q) SEQ ID NOs: 19 and 7, respectively; (r) SEQ ID NOs: 21 and 7, respectively; (s) SEQ ID NOs: 23 and 7, respectively; (t) SEQ ID NOs: 25 and 7, respectively; (u) SEQ ID NOs: 27 and 7, respectively; (v) SEQ ID NOs: 102 and 7, respectively; (w) SEQ ID NOs: 104 and 7, respectively; and (x) An isolated monoclonal antibody or antigen-binding portion thereof, comprising a heavy chain variable region and a light chain variable region encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOs: 5 and 106, respectively. (Item 45) An isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137. wherein the antibody or antigen-binding portion thereof is (a) SEQ ID NOs: 4 and 6, respectively; (b) SEQ ID NOs: 4 and 28, respectively; (c) SEQ ID NOs: 4 and 30, respectively; (d) SEQ ID NOs: 4 and 32, respectively; (e) SEQ ID NOs: 4 and 34, respectively; (f) SEQ ID NOs: 4 and 36, respectively; (g) SEQ ID NOs: 4 and 38, respectively; (h) SEQ ID NOs: 4 and 40, respectively; (i) SEQ ID NOs: 4 and 42, respectively; (j) SEQ ID NOs: 4 and 44, respectively; (k) SEQ ID NOs: 4 and 46, respectively; (l) SEQ ID NOs: 8 and 6, respectively; (m) SEQ ID NOs: 10 and 6, respectively; (n) SEQ ID NOs: 12 and 6, respectively; (o) SEQ ID NOs: 14 and 6, respectively; (p) SEQ ID NOs: 16 and 6, respectively; (q) SEQ ID NOs: 18 and 6, respectively; (r) SEQ ID NOs: 20 and 6, respectively; (s) SEQ ID NOs: 22 and 6, respectively; (t) SEQ ID NOs: 24 and 6, respectively; (u) SEQ ID NOs: 26 and 6, respectively; (v) SEQ ID NOs: 101 and 6, respectively; (w) SEQ ID NOs: 103 and 6, respectively; and (x) a group comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4 and 105, An isolated monoclonal antibody or antigen-binding portion thereof, comprising a chain variable region and a light chain variable region. (Item 46) An isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137. wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region has an amino acid sequence that is at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 101, and 103. and the light chain variable region comprises SEQ ID NOs: 6, 28, 30, 32, 34, 36, 38, 40, 42, 44 1. An isolated monoclonal antibody or antigen-binding portion thereof, comprising an amino acid sequence that is at least 90% identical to an amino acid sequence selected from the group consisting of: 46 and 105. (Item 47) An isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137. wherein the antibody or antigen-binding portion thereof is (a) SEQ ID NOs: 4 and 6, respectively; (b) SEQ ID NOs: 4 and 28, respectively; (c) SEQ ID NOs: 4 and 30, respectively; (d) SEQ ID NOs: 4 and 32, respectively; (e) SEQ ID NOs: 4 and 34, respectively; (f) SEQ ID NOs: 4 and 36, respectively; (g) SEQ ID NOs: 4 and 38, respectively; (h) SEQ ID NOs: 4 and 40, respectively; (i) SEQ ID NOs: 4 and 42, respectively; (j) SEQ ID NOs: 4 and 44, respectively; (k) SEQ ID NOs: 4 and 46, respectively; (l) SEQ ID NOs: 8 and 6, respectively; (m) SEQ ID NOs: 10 and 6, respectively; (n) SEQ ID NOs: 12 and 6, respectively; (o) SEQ ID NOs: 14 and 6, respectively; (p) SEQ ID NOs: 16 and 6, respectively; (q) SEQ ID NOs: 18 and 6, respectively; (r) SEQ ID NOs: 20 and 6, respectively; (s) SEQ ID NOs: 22 and 6, respectively; (t) SEQ ID NOs: 24 and 6, respectively; (u) SEQ ID NOs: 26 and 6, respectively; (v) SEQ ID NOs: 101 and 6, respectively; (w) SEQ ID NOs: 103 and 6, respectively; and (x) to an amino acid sequence selected from the group consisting of SEQ ID NOs: 4 and 105, respectively; comprising a heavy chain variable region and a light chain variable region comprising amino acid sequences that are at least 90% identical; An isolated monoclonal antibody or antigen-binding portion thereof. (Item 48) An isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137. wherein the antibody or antigen-binding portion thereof is (a) SEQ ID NOs: 129 and 133, respectively; and (b) an isolated monoclonal antibody or antigen-binding portion thereof, comprising a heavy chain sequence and a light chain sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 131 and 133, respectively. (Item 49) An isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137. wherein the antibody or antigen-binding portion thereof comprises a heavy chain sequence and a light chain sequence having the amino acid sequences set forth in SEQ ID NOs: 129 and 133, respectively. (Item 50) An isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion thereof comprises heavy chain and light chain sequences having the amino acid sequences set forth in SEQ ID NOs: 131 and 133, respectively. (Item 51) the antibody or antigen-binding portion specifically binds to and agonizes human CD137. 51. The isolated monoclonal antibody or antigen-binding portion according to any one of Items 1 to 50. (Item 52) the antibody or antigen-binding portion thereof, (a) Induction or enhancement of dimerization of CD137 trimers; (b) induction or enhancement of multimerization of CD137 trimers; (c) induction or enhancement of T cell activation; (d) induction or enhancement of cytotoxic T cell responses; (e) induction or enhancement of T cell proliferation; (f) induction or enhancement of immune cell cytokine production; and (g) any combination of characteristics (a) through (f). 52. The isolated monoclonal antibody or antigen-binding portion of any one of items 1 to 51, exhibiting at least one or more of: (Item 53) The antibody or antigen-binding portion exhibits, compared to a reference antibody that binds to human CD137: (a) does not induce or enhance intrahepatic T cell activation; (b) does not induce or enhance intrahepatic T-cell proliferation; (c) does not induce or enhance intrasplenic T cell activation; (d) does not induce or enhance intrasplenic T-cell proliferation; (e) does not induce or enhance macrophage activation; (f) does not induce or enhance macrophage differentiation; (g) does not induce or enhance alanine aminotransferase (ALT) activity; and Beauty (h) any combination of properties (a) to (g). Antibodies or antigen-binding portions. (Item 54) 54. The isolated monoclonal antibody or antigen-binding portion of claim 53, wherein the reference antibody is urelumab. (Item 55) 55. The isolated monoclonal antibody or antigen-binding portion of any one of paragraphs 52 to 54, wherein the properties of the antibody or antigen-binding portion are not dependent on Fc receptor binding. (Item 56) 55. The isolated monoclonal antibody or antigen-binding portion of any one of paragraphs 52 to 54, wherein the properties of the antibody or antigen-binding portion are enhanced by Fc receptor binding. (Item 57) 57. The isolated monoclonal antibody or antigen-binding portion of any one of paragraphs 1 to 56, wherein the antibody or antigen-binding portion cross-reacts with cynomolgus monkey CD137, mouse CD137, or both. (Item 58) The antibodies include IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE antibodies. 58. The isolated monoclonal antibody or antigen-binding portion according to any one of items 1 to 47 and 51 to 57, selected from the group consisting of: (Item 59) 59. The isolated monoclonal antibody or antigen-binding portion of item 58, wherein the antibody is an IgG1 antibody or an IgG4 antibody. (Item 60) Items 1 to 47. The antibody comprises a heavy chain constant region of wild-type human IgG1 or wild-type human IgG4. 58. The isolated monoclonal antibody or antigen-binding portion of any one of items 51 to 57. (Item 61) 58. The isolated monoclonal antibody or antigen-binding portion according to any one of items 1 to 47 and 51 to 57, wherein the antibody comprises a mutated IgG1 heavy chain constant region. (Item 62) 58. The isolated monoclonal antibody or antigen-binding portion according to any one of items 1 to 47 and 51 to 57, wherein the antibody comprises a mutated IgG4 heavy chain constant region. (Item 63) 63. The isolated monoclonal antibody or antigen-binding portion thereof of item 62, wherein the mutated IgG4 heavy chain constant region comprises a substitution at Ser228. (Item 64) 64. The isolated monoclonal antibody of claim 63, wherein the mutated IgG4 heavy chain constant region comprises a S228P substitution. A cloned antibody or antigen-binding portion thereof. (Item 65) 65. A pharmaceutical composition comprising the isolated monoclonal antibody or antigen-binding portion thereof according to any one of items 1 to 64, and a pharmaceutically acceptable carrier. (Item 66) 65. A nucleic acid comprising a nucleotide sequence encoding the light chain, the heavy chain, or both the light and heavy chains of the isolated monoclonal antibody or antigen-binding portion of any one of items 1 to 64. (Item 67) 67. An expression vector comprising the nucleic acid of item 66. (Item 68) A cell transformed with the expression vector according to Item 67. (Item 69) Producing a monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137 70. A method comprising maintaining the cell of item 68 under conditions that allow expression of the monoclonal antibody or antigen-binding portion thereof. (Item 70) 70. The method of claim 69, further comprising obtaining the monoclonal antibody or antigen-binding portion thereof. (Item 71) A method for inducing or enhancing dimerization of human CD137 trimers in a subject, comprising: 66. A method comprising administering to a subject in need thereof an effective amount of the isolated monoclonal antibody or antigen-binding portion thereof according to any one of items 1 to 64, or the pharmaceutical composition according to item 65. (Item 72) A method for inducing or enhancing multimerization of human CD137 trimers in a subject, comprising: 66. A method comprising administering to a subject in need thereof an effective amount of the isolated monoclonal antibody or antigen-binding portion thereof according to any one of items 1 to 64, or the pharmaceutical composition according to item 65. (Item 73) A method of inducing or enhancing T cell activation in a subject in need thereof. 66. A method comprising administering to a subject a therapeutically effective amount of the isolated monoclonal antibody or antigen-binding portion thereof according to any one of items 1 to 64, or the pharmaceutical composition according to item 65, (Item 74) 74. The method of claim 73, wherein the T cell activation occurs in a tumor microenvironment. (Item 75) A method of inducing or enhancing a cytotoxic T cell response in a subject, comprising administering to said subject a therapeutically effective amount of a cytotoxic T cell response to said subject. 66. A method comprising administering to a subject an effective amount of the isolated monoclonal antibody or antigen-binding portion thereof according to any one of items 1 to 64, or the pharmaceutical composition according to item 65. (Item 76) 76. The method of claim 75, wherein the cytotoxic T cell response is generated in the tumor microenvironment. . (Item 77) 66. A method for inducing or enhancing immune cell cytokine production in a subject, comprising administering to a subject in need thereof an effective amount of the isolated monoclonal antibody or antigen-binding portion thereof according to any one of items 1 to 64, or the pharmaceutical composition according to item 65. (Item 78) The cytokines produced are IL-2, TNFα, IL-13, IFNγ, or a combination thereof. Item 78. The method according to Item 77. (Item 79) 79. The method of claim 77 or 78, wherein the cytokine production occurs in a tumor microenvironment. (Item 80) A method of inducing or enhancing T cell proliferation in a subject, comprising administering to a subject in need thereof 66. A method comprising administering an effective amount of the isolated monoclonal antibody or antigen-binding portion thereof according to any one of items 1 to 64, or the pharmaceutical composition according to item 65. (Item 81) 81. The method of item 80, wherein the T cell proliferation occurs in a tumor microenvironment. (Item 82) 1. A method for reducing or inhibiting tumor growth, comprising administering to a subject in need thereof a compound according to any one of items 1 to 64. 66. The isolated monoclonal antibody or antigen-binding portion of any one of claims 1 to 5, or A method comprising administering an effective amount of the pharmaceutical composition described. (Item 83) A method of treating a disorder mediated by human CD137 in a subject, comprising administering to a subject in need thereof 66. A method comprising administering to a subject an effective amount of the isolated monoclonal antibody or antigen-binding portion thereof according to any one of items 1 to 64, or the pharmaceutical composition according to item 65. (Item 84) A method of treating cancer in a subject, comprising administering to a subject in need thereof any of the compounds of items 1 to 64. 65. The isolated monoclonal antibody or antigen-binding portion of any one of claims 1 to 4, or the isolated monoclonal antibody or antigen-binding portion of any one of claims 1 to 4, The method comprises administering an effective amount of the pharmaceutical composition described above. (Item 85) 85. The method of any one of paragraphs 82-84, wherein administration of the isolated monoclonal antibody or antigen-binding portion increases infiltration of immune cells into the tumor microenvironment. (Item 86) 86. The method of claim 85, wherein the immune cells express CD45. (Item 87) and (b) administering the isolated monoclonal antibody or antigen-binding portion thereof to a subject in need thereof. 87. The method of any one of items 82 to 86, wherein the amount of thymic (Treg) cells is reduced. (Item 88) 88. The method of claim 87, wherein the Treg cells express CD4, FOXP-3, and CD25. (Item 89) 89. The method of any one of paragraphs 82-88, wherein the amount of macrophages in the tumor microenvironment is reduced after administration of the isolated monoclonal antibody or antigen-binding portion. (Item 90) 89. The method of claim 89, wherein the macrophages express CD45 and CD11b. (Item 91) T cells in the tumor microenvironment after administration of the isolated monoclonal antibody or antigen-binding portion. 91. The method according to any one of items 82 to 90, wherein wasting is reduced. (Item 92) Decreased T cell exhaustion includes decreased expression of TIGIT, PD-1, LAG-3, or a combination thereof. Item 91. (Item 93) 93. The method according to any one of items 84 to 92, wherein the cancer is selected from the group consisting of melanoma, glioma, renal cancer, breast cancer, blood cancer and head and neck cancer. (Item 94) 84. The method of claim 83, wherein the hematological cancer is B-cell lymphoma. (Item 95) A method for inducing an anti-tumor memory immune response, comprising administering to a subject in need thereof a compound according to any one of items 1 to 64. 66. The isolated monoclonal antibody or antigen-binding portion of any one of items 64 to 65. A method comprising administering an effective amount of the pharmaceutical composition described. (Item 96) 96. Any one of items 71 to 95, wherein the antibody or antigen-binding portion binds to an Fc gamma receptor. The method described in paragraph . (Item 97) 96. The antibody of any one of items 82 to 95, wherein depletion of CD4+ T cells, CD8+ T cells, natural killer cells, or a combination thereof reduces the efficacy of the antibody or antigen-binding portion thereof. How to post. (Item 98) 1. A method for detecting the presence or absence of human CD137 in a biological sample, comprising: (i) contacting a biological sample with the antibody or antigen-binding portion according to any one of items 1 to 64; contacting, wherein the antibody or antigen-binding portion is labeled with a detectable substance; and (ii) detecting said antibody or antigen-binding portion bound to human CD137, thereby detecting said antibody or antigen-binding portion bound to human CD137; Detecting the presence or absence of human CD137 in a biological sample. (Item 99) 66. A kit comprising a container containing the isolated monoclonal antibody or antigen-binding portion according to any one of items 1 to 64 and optionally a pharmaceutically acceptable carrier, or the pharmaceutical composition according to item 65, and a package insert containing instructions for administering the antibody or pharmaceutical composition for treating or delaying the progression of cancer, or for reducing or inhibiting tumor growth in a subject in need thereof. (Item 100) 66. A kit comprising a container containing the isolated monoclonal antibody or antigen-binding portion according to any one of items 1 to 64 and optionally a pharmaceutically acceptable carrier, or the pharmaceutical composition according to item 65, and a package insert containing instructions for administering the antibody or pharmaceutical composition alone, or in combination with another agent, for treating or delaying the progression of cancer, or for reducing or inhibiting tumor growth in a subject in need thereof. (Item 101) 65. Use of the isolated monoclonal antibody or antigen-binding portion of any one of paragraphs 1 to 64 for the manufacture of a medicament for treating or delaying the progression of cancer, or reducing or inhibiting tumor growth in a subject in need thereof. (Item 102) 65. The isolated monoclonal antibody or antigen-binding portion of any one of paragraphs 1 to 64 in the manufacture of a medicament for treating or delaying the progression of cancer, or reducing or inhibiting tumor growth in a subject in need thereof. (Item 103) 65. The isolated monoclonal antibody or antigen-binding portion of any one of items 1 to 64 for use as a medicament. [Brief explanation of the drawings]
[0114] [Figure 1] FIG. 1 presents a graph showing the binding affinity distribution for affinity matured clones of the parent anti-CD137 antibody mAb1. [Figure 2] Figure 2 presents a schematic showing the results of mAb1 CDRH3 alanine scanning as measured by binding affinity (KD) to human or mouse CD137. [Figure 3A] FIG. 3A shows the amino acid sequence of human CD137, with residues containing the epitopes bound by mAb1, mAb4, or mAb5 shown in bold. [Figure 3B] FIG. 3B is a graph showing kinetic binding data of mAb1 to the extracellular domain of mouse and rat CD137 as determined by surface plasmon resonance. [Figure 3C] Figure 3C: X-ray crystallography image of human CD137 bound to CD137L (shown in gray). Residues E111, T113, K114, and P135 are circled. [Figure 3D] Figure 3D. X-ray crystallography image of human CD137 bound to trimerized CD137L (shown in gray). Residues E111, T113, K114, and P135 are circled. [Figure 4-1] Figure 4A presents scatter plots of flow cytometry data showing an increase in the expression of TIGIT (top) or PD-1 (bottom) on CD44+ T cells in response to anti-CD137 antibody. [Figure 4-2]Figure 4B presents graphs showing quantification of CD8+CD44+ T cells expressing TIGIT (top) or PD-1 (bottom) in mouse spleens after treatment with anti-CD137 antibodies. Figure 4C presents graphs showing quantification of CD8+ T cells in mouse spleens after treatment with anti-CD137 antibodies, as a percentage of CD45+ cells (left) or as the number of cells per spleen (right). [Figure 5-1] FIG. 5A presents a graph showing individual CT26 tumor volumes in mice after treatment with the indicated doses of anti-CD137 antibody. [Figure 5-2] Figure 5B is a graph showing the mean tumor volume presented in Figure 5A. Figure 5C is a Kaplan-Meier graph showing overall survival of tumor-bearing mice after treatment with anti-CD137 antibody. Figure 5D is a graph showing tumor volume in mice re-challenged with tumorigenic CT26 cells. [Figure 6A] FIG. 6A presents a graph showing individual CT26 tumor volumes in mice after treatment with parental and affinity-matured anti-CD137 antibodies. [Figure 6B] FIG. 6B is a graph showing the mean tumor volumes presented in FIG. 6A. [Figure 7] FIG. 7 presents graphs showing the percentage of CD8+ or CD4+ T cells from splenic T cells (top) and tumor-infiltrating leukocytes (bottom) after treatment with anti-CD137 antibody at the indicated doses. [Figure 8] Figure 8 presents graphs showing individual tumor volumes when mice were treated with mAb1 with or without lymphodepleting antibodies. CD4+ T cells were depleted with GK1.5 (middle graph). CD8+ T cells were depleted with YTS169.4 (second graph from the right). NK cells were depleted with anti-asialo-GM1 antibody (far right graph). [Figure 9] Figure 9 presents a graph showing individual tumor volumes in mice bearing either CT26 tumors (colon cancer), EMT-6 tumors (breast cancer), A20 tumors (B-cell lymphoma), or MC38 tumors (colon cancer) and treated with mAb8 or an isotype control antibody. [Figure 10]10A-10C show the in vivo anti-tumor efficacy of anti-CD137 antibodies administered at 150 μg / mouse. Individual tumor volumes are shown in 10A. Mean tumor volumes are shown in 10B. Survival rates are shown in 10C. [Figure 11] 11A-11C show the in vivo anti-tumor efficacy of anti-CD137 antibodies administered at 20 μg / mouse. Individual tumor volumes are shown in 11A. Mean tumor volumes are shown in 11B. Survival rates are shown in 11C. [Figure 12] FIG. 12 presents a graph showing individual tumor volumes in mice bearing CT26 tumors and treated with various doses of mAb1 (i.e., 12.5, 25, 50, 100, or 200 μg) or isotype control. [Figure 13A] Figures 13A and 13B show the contribution of Fc binding to the anti-tumor efficacy of mAb1. Figure 13A shows mAb1 as an IgG4 isotype or an IgG4 aglycosylated isotype. The mean tumor volume is shown above and individual tumor volumes are shown below. Figure 13B shows mAb1 as an IgG4 isotype or an IgG1 aglycosylated isotype. The mean tumor volume is shown above and individual tumor volumes are shown below. [Figure 13B] Same as above. [Figure 14-1] 14A-14D show the in vivo anti-tumor efficacy of anti-CD137 antibodies in mice bearing large, established tumors (i.e., 500 mm3) before treatment. Individual tumor volumes are shown in 14A and 14D. Mean tumor volumes are shown in 14B. Survival fractions are shown in 14C. [Figure 14-2] Same as above. [Figure 15] Figure 15 presents Kaplan-Meier survival graphs showing protective anti-tumor immunity in mice previously treated and considered cured with mAb1, mAb8 or isotype control from Figures 14A-14C and re-challenged with CT26 cells in the opposite flank. [Figure 16A] FIG. 16A presents scatter plots of flow cytometry data showing CD45+ intrahepatic T cell expansion after treatment with anti-CD137 antibody at the indicated doses. [Figure 16B] FIG. 16B presents graphs showing quantification of intrahepatic CD8+ T cells (left) and CD4+ T cells (right) after treatment with anti-CD137 antibody at the indicated doses. [Figure 17A] FIG. 17A presents a graph showing the percentage of CD3+, CD4+, or CD8+ T cells from splenic T cells after treatment of mice with affinity-matured anti-CD137 antibodies. [Figure 17B] FIG. 17B presents a graph showing the percentage of CD3+, CD4+, or CD8+ T cells from liver T cells after treatment of mice with affinity-matured anti-CD137 antibodies. [Figure 18A] Figure 18A presents a graph showing the percentage of splenic CD8+CD44+ T cells expressing TIGIT, PD-1, or LAG3 after treatment of mice with affinity-matured anti-CD137 antibodies. [Figure 18B] Figure 18B presents a graph showing the percentage of liver CD8+CD44+ T cells expressing TIGIT, PD-1, or LAG3 after treatment of mice with affinity-matured anti-CD137 antibodies. [Figure 19A] Figure 19A presents a graph showing the percentage of splenic CD4+CD44+ T cells expressing TIGIT, PD-1, or LAG3 after treatment of mice with affinity-matured anti-CD137 antibodies. [Figure 19B] Figure 19B presents a graph showing the percentage of liver CD4+CD44+ T cells expressing TIGIT, PD-1, or LAG3 after treatment of mice with affinity-matured anti-CD137 antibodies. [Figure 20-1] Figures 20A-20C show graphs of in vivo toxicity indicators resulting from multiple administration of anti-CD137 antibodies mAb1, mAb8, or 3H3 at various doses. Figure 20A shows a graph showing the percentage of CD8+ T cells in the liver after administration of anti-CD137 antibodies. Figure 20B shows a graph showing alanine aminotransferase (ALT) activity in the plasma of mice administered anti-CD137 antibodies. Figure 20C shows a graph showing TNFα levels in the plasma of mice administered anti-CD137 antibodies. [Figure 20-2] Same as above. [Figure 21] Figure 21 presents representative images of hematoxylin and eosin (H&E) stained liver sections from mice treated with mAb1, mAb8, 3H3, or isotype control as described in Figures 20A-20C. Arrows indicate infiltrating immune cells. [Figure 22-1] Figures 22A-22D present representative FACS plots showing immune cell reprogramming in the tumor microenvironment. Mice bearing CT26 tumors were administered multiple doses of mAb8 or isotype control (days 0, 3, 6, and 9). Figure 22A shows overall immune cell infiltration based on CD45 expression. Figure 22B shows a reduction in Treg cells, as measured by FOXP-3 and CD25 expression. Figure 22C shows a reduction in T cell exhaustion, as measured by PD-1 and TIGIT expression. Figure 22D shows a reduction in tumor-associated macrophages, as measured by F4 / 80 and CD11b expression. [Figure 22-2] Same as above. [Figure 23] FIG. 23 shows immunophenotypic analysis of spleens from mice bearing CT26 tumors and treated with either the anti-CD137 antibodies mAb1 and 3H3 or an isotype control. [Figure 24] Figure 24 is a graph showing the concentration of IL-2 (pg / ml) produced by mouse T cells upon stimulation with the indicated anti-CD137 antibodies in an OVA stimulation assay. Atezolizumab (an anti-PD-L1 antibody) was used with mouse anti-PD-1 (RMP1-14) as a comparator. [Figure 25] Figures 25A and 25B are graphs showing the percentage of mouse CD8+ T cells expressing either CD25 (25A) or TIGIT (25B) upon stimulation with the indicated anti-CD137 antibodies in an OVA stimulation assay. Atezolizumab (an anti-PD-L1 antibody) was used along with mouse anti-PD-1 (RMP1-14) and mouse anti-CD137 (3H3) as comparators. [Figure 26]Figure 26 presents a bar graph showing quantification of cytokines (IL-2, TNFα, IL-13, and IFNγ) produced by CD3+ T cells after incubation with plate-bound anti-CD137 antibody. Cytokine levels are shown as fold increase over baseline activation with anti-CD3 antibody. [Figure 27-1] 27A-27C present graphs showing the dose response of IFNγ production in mixed lymphocyte responses after treatment with anti-CD137 antibodies. Anti-PD1 antibodies (Keytruda; Merck) were used as controls. [Figure 27-2] Same as above. [Figure 28] Figure 28 is a graph showing IFNγ production from human T cells co-cultured with CHO cells engineered to express CD32 (CHO-CD32 cells) in the presence of anti-CD137 antibodies mAb1, mAb8, mAb4, or mAb5, or an isotype control. [Figure 29] Figure 29 is a graph showing the proliferation of Treg cells co-cultured with CHO cells engineered to express CD32 (CHO-CD32 cells) in the presence or absence of anti-CD137 antibodies mAb1, mAb8, mAb4, or mAb5, or an isotype control. [Figure 30] FIG. 30 presents graphs showing NFκβ and SRF signaling in CCL-119 cells transduced with luciferase reporters for NFκβ or SRF in the presence of various concentrations of mAb1, mAB8, mAb4, or mAb5. [Figure 31] Figure 31 presents graphs showing the induction of IL-6, TNFα or IL-27 by bone marrow-derived murine macrophages stimulated with the TLR9 agonist CpG in the presence of anti-CD137 antibodies mAb1, 3H3 or LOB12.3 or an isotype control. [Figure 32]FIG. 32 presents a graph showing the induction of TNFα by human monocyte-derived murine macrophages stimulated with LPS in the presence of anti-CD137 antibodies mAb1, mAb4, or mAb5 or an isotype control. [Figure 33] Figure 33 presents a graph showing the effect of anti-CD137 antibodies on macrophage differentiation, as determined by CD64 expression, of THP1 monocytes cultured with PMA in the presence of anti-CD137 antibodies mAb1, mAb4, or mAb5 or an isotype control. [Figure 34] 34A-34C present graphs showing the percentage of hCD45+, hCD8+, or hCD4+ in human PBMCs and immunocompetent mice administered anti-CD137 antibodies mAb1, mAb4, or mAb5, or an isotype control. DETAILED DESCRIPTION OF THE INVENTION
[0115] Cancer treatment with agonistic anti-CD137 antibodies has been shown to induce immune-mediated tumor rejection in mice, and this type of analogue is currently being tested in cancer patients. Previous reports have shown that administration of anti-CD137 antibodies can induce a significant accumulation of polyclonal T lymphocyte infiltration in the liver (Dubrot et al., (2010) Cancer Immunology, Immunotherapy 59(8):1223-1233), suggesting the possibility of liver inflammation and drug-induced hepatotoxicity. A recent report on the clinical evaluation of an agonistic anti-CD137 antibody (urelumab, BMS-663513; Bristol-Myers Squibb) reported that treatment-related adverse events were observed in human subjects, including signs of severe hepatotoxicity (hypertransaminasemia) that correlated with the antibody dose (Segal et al., (2016) Clin Cancer Res 23(8):1929-1936).
[0116] The present disclosure provides an isolated monoclonal antibody, or antigen-binding portion thereof, that specifically binds to and agonizes an epitope on human CD 137. In some embodiments, the antibody or antigen-binding portion thereof competes with mAb1 for binding to the epitope on human CD 137. In some embodiments, the anti-CD137 agonistic antibodies of the present disclosure induce cytokine production and CD8+ T cell expansion in the tumor microenvironment, as well as protective anti-tumor immunity in vivo, while reducing the likelihood of toxicity-related events, compared to the anti-mouse CD137 3H3 antibody (Melero et al. (1997) Nature Medicine 3(6):682-685; Uno et al. (2006) Nature Medicine 12(6):693-696) and at least two anti-human CD137 antibodies in clinical development (BMS-663513 / Urelumab, Bristol-Meyers Squibb and PF-05082566 / Utomilumab, Pfizer).
[0117] definition Terms used in the claims and specification, unless otherwise specified, are defined as set forth below.
[0118] It should be noted that as used in the specification and the appended claims, the singular forms (a, an, and the) include plural referents unless the context clearly dictates otherwise. Further, unless the context requires otherwise, singular terms shall include plurals and plural terms shall include the singular.
[0119] As used herein, "about" will be understood by one of ordinary skill in the art and will vary to some extent depending on the context in which it is used. If there are uses of the term that are not clear to persons of ordinary skill in the art given the context in which it is used, "about" will mean up to plus or minus 10% of the particular value.
[0120] As used herein, the term "agonist" refers to any molecule that partially or fully promotes, induces, increases, and / or activates the biological activity of a native polypeptide (e.g., CD137) disclosed herein. Suitable agonistic molecules include, among others, agonistic antibodies or antibody fragments, fragments or amino acid sequence variants of native polypeptides, peptides, antisense oligonucleotides, small molecules, etc. In some embodiments, activation in the presence of an agonist is observed in a dose-dependent manner. In some embodiments, the measured signal (e.g., biological activity) is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% higher than the signal measured using a negative control under comparable conditions. Also disclosed herein are methods for identifying agonists suitable for use in the disclosed methods. For example, these methods include, but are not limited to, binding assays such as enzyme-linked immunosorbent assay (ELISA), the Forte Bio(c) system, and radioimmunoassays (RIAs). These assays determine the ability of an agonist to bind to a polypeptide of interest (e.g., a receptor or ligand, e.g., CD137). Thus, it is indicative of the ability of an agonist to promote, increase, or activate the activity of a polypeptide. The efficacy of an agonist, such as the ability of an agonist to activate or promote the function of a polypeptide, can also be determined using a functional assay. For example, a functional assay may involve contacting a polypeptide with a candidate agonist molecule and measuring a detectable change in one or more biological activities normally associated with the polypeptide. The efficacy of an agonist is typically measured by its EC 50 The EC value (the concentration required to activate 50% of the agonist response) is defined as the EC 50The lower the value, the more potent the agonist and the lower the concentration required to activate the maximal biological response.
[0121] As used herein, the term "alanine scanning" refers to a technique used to determine the contribution of a particular wild-type residue to the stability or function (e.g., binding affinity, etc.) of a given protein or polypeptide. This technique involves substituting an alanine residue for the wild-type residue in a polypeptide, then evaluating the stability or function (e.g., binding affinity, etc.) of the alanine-substituted derivative or mutant polypeptide and comparing it with the wild-type polypeptide. Techniques for substituting alanine for wild-type residues in polypeptides are known in the art.
[0122] The term "ameliorate" refers to any therapeutically beneficial outcome, including prevention, attenuation of the severity or progression, remission, or cure, in the treatment of a disease state, such as cancer.
[0123] As used herein, the term "amino acid" refers to natural amino acids and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to natural amino acids.Natural amino acids are those encoded by genetic code, as well as amino acids that are subsequently modified, such as hydroxyproline, γ-carboxyglutamate, and O-phosphoserine.Amino acid analogs refer to compounds that have the same basic chemical structure as natural amino acids, i.e., carbons bonded to hydrogen, carboxyl groups, amino groups, and R groups, such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium.Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as natural amino acids.Amino acid mimetics refer to compounds that have a structure that is different from the general chemical structure of amino acids, but function in a manner similar to natural amino acids.
[0124] Amino acids may be referred to herein by either their commonly known three-letter symbols or the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides may also be referred to by their commonly accepted one-letter codes. As used herein, a "polar amino acid" refers to an amino acid containing a side chain that preferentially resides in an aqueous environment. In some embodiments, a polar amino acid is selected from the group consisting of arginine, asparagine, aspartic acid, glutamic acid, glutamine, histidine, lysine, serine, threonine, and tyrosine. Polar amino acids may be positively, negatively, or neutrally charged. As used herein, a "nonpolar amino acid" refers to an amino acid selected from the group consisting of alanine, cysteine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, and valine.
[0125] As used herein, "amino acid substitution" refers to the replacement of at least one existing amino acid residue in a specified amino acid sequence (the amino acid sequence of the starting polypeptide) with a second, different "replacement" amino acid residue. "Amino acid insertion" refers to the incorporation of at least one additional amino acid into a specified amino acid sequence. Insertions typically consist of the insertion of one or two amino acid residues, although larger "peptide insertions" can also be made. For example, insertions of about 3 to about 5, or even up to about 10, 15, or 20 amino acid residues can also be made. The inserted residues can be natural or non-natural residues, as described above. "Amino acid deletion" refers to the removal of at least one amino acid residue from a specified amino acid sequence.
[0126] As used herein, the terms "amount" or "level" refer to a detectable quantity, level, or abundance of a substance. When referring to polypeptides such as those described herein, the terms "level of expression" or "expression level" are generally used interchangeably and generally refer to a detectable amount of the polypeptide in a biological sample (e.g., on a cell surface).
[0127] As used herein, the term "anti-CD137 agonistic antibody" (used interchangeably with the term "anti-CD137 antibody") refers to an antibody that specifically binds to CD137 and partially or fully promotes, induces, enhances, and / or activates CD137 biological activities, responses, and / or downstream pathways mediated by CD137 signaling, or other CD137-mediated functions. In some embodiments, an anti-CD137 agonistic antibody binds to CD137 and enables CD137L binding. In some embodiments, an anti-CD137 agonistic antibody binds to CD137 and induces CD137 multimerization. In some embodiments, an anti-CD137 agonistic antibody binds to CD137 and induces dimerization of CD137 trimers. In some embodiments, an anti-CD137 agonistic antibody binds to CD137 and induces multimerization of CD137 trimers. Examples of anti-CD137 agonistic antibodies are provided herein. Methods for detecting the formation of trimer:trimer complexes are known to those skilled in the art. For example, electron microscopy has been shown to detect such complexes. See, for example, Won, E. The Journal of Biological Chemistry, Vol. 285 (12): 9202-9210 (2010).
[0128] As used herein, the term "anti-CD137 mAb1" (used interchangeably with "mAb1") refers to the following variable heavy chain (V H ) Amino acid sequence: EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDSPFLLDDYYYYYYMDVWGKGTTVTVSS (SEQ ID NO: 4), and the following variable light chains (V L ) Amino acid sequence: DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHLFPITFGGGTKVEIK (SEQ ID NO: 6).
[0129] As used herein, the term "anti-CD137 mAb8" (used interchangeably with "mAb8") refers to a mAb comprising the following variable heavy chain (V H ) Amino acid sequence: EVQLLESGGGLVQPGGSLRLSCAASGFTFRNYAMSWVRQAPGKGLEWVSAISGSGDTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDSPFLLDDYYYYYYMDVWGKGTTVTVSS (SEQ ID NO: 101), and the following variable light chains (V L ) Amino acid sequence: DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHLFPITFGGGTKVEIK (SEQ ID NO: 6).
[0130] As used herein, the term "anti-CD137 mAb10" (used interchangeably with "mAb10") refers to the following variable heavy chain (V H ) Amino acid sequence: EVQLLESGGGLVQPGGSLRLSCAASGFTFYGYAMSWVRQAPGKGLEWVAAISGSGDSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDSPFLLDDYYYYYYMDVWGKGTTVTVSS (SEQ ID NO: 26), and the following variable light chains (V L ) Amino acid sequence: DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHLFPITFGGGTKVEIK (SEQ ID NO: 6).
[0131] As used herein, the term "antibody" refers to a whole antibody comprising two light polypeptide chains and two heavy polypeptide chains. Whole antibodies include various antibody isotypes, including IgM, IgG, IgA, IgD, and IgE antibodies. The term "antibody" includes polyclonal antibodies, monoclonal antibodies, chimeric or chimeric antibodies, humanized antibodies, primatized antibodies, deimmunized antibodies, and fully human antibodies. Antibodies may be produced in or derived from any of a variety of mammalian species, including humans, non-human primates (e.g., orangutans, baboons, or chimpanzees), horses, cats, pigs, sheep, goats, dogs, cats, rabbits, guinea pigs, gerbils, hamsters, rats, and mice. Antibodies may be purified or recombinant.
[0132] As used herein, the terms "antibody fragment," "antigen-binding fragment," "antigen-binding portion," or similar terms refer to a fragment of an antibody that retains the ability to bind to a target antigen (e.g., CD137) and inhibit the activity of the target antigen. Such fragments include, for example, single-chain antibodies, single-chain Fv fragments (scFv), Fd fragments, Fab fragments, Fab' fragments, or F(ab')2 fragments. An scFv fragment is a single polypeptide chain that contains both the heavy and light chain variable regions of the antibody from which the scFv is derived. Additionally, intrabodies, minibodies, triabodies, and diabodies are included within the definition of antibody and are suitable for use in the methods described herein. See, e.g., Todorovska et al., (2001) J. Immunol. Methods 248(1):47-66; Hudson and Kortt, (1999) J. Immunol. Methods 231(1):177-189; Poljak, (1994) Structure 2(12):1121-1123; Rondon and Marasco, (1997) Annu. Rev. Microbiol. 51:257-283, the disclosures of each of which are incorporated herein by reference in their entireties.
[0133] As used herein, the term "antibody fragment" also includes single-domain antibodies, such as camelized single-domain antibodies. See, for example, Muyldermans et al., (2001) Trends Biochem. Sci. 26:230-235; Nuttall et al., (2000) Curr. Pharm. Biotech. 1:253-263; Reichmann et al., (1999) J. Immunol. Meth. 231:25-38; PCT International Patent Application Publications WO 94 / 04678 and WO 94 / 25591, and U.S. Patent No. 6,005,079, all of which are incorporated herein by reference in their entireties. In some embodiments, the present disclosure provides single-domain antibodies comprising two VH domains with modifications to form single-domain antibodies.
[0134] In some embodiments, the antigen-binding fragment comprises the variable region of a heavy chain polypeptide and the variable region of a light chain polypeptide. In some embodiments, the antigen-binding fragment described herein comprises the CDRs of the light and heavy chain polypeptides of the antibody.
[0135] The term "antigen-presenting cell" or "APC" refers to a cell that presents foreign antigens complexed with MHC on its surface. T cells recognize this complex using the T cell receptor (TCR). Examples of APCs include, but are not limited to, dendritic cells (DCs), peripheral blood mononuclear cells (PBMCs), monocytes (e.g., THP-1), B lymphoblastoid cells (e.g., C1R.A2, 1518 B-LCL), and monocyte-derived dendritic cells (DCs). Some APCs internalize antigens by either phagocytosis or receptor-mediated endocytosis.
[0136] The term "antigen presentation" refers to the process by which APCs capture antigens and make them recognized by T cells, for example as components of MHC-I and / or MHC-II complexes.
[0137] As used herein, the term "apoptosis" refers to the process of programmed cell death that occurs in multicellular organisms (e.g., humans). Highly regulated biochemical and molecular events lead to apoptosis, which can result in observable and characteristic morphological changes in cells, including membrane blebbing, cell volume reduction, chromatin DNA compaction and fragmentation, and mRNA decay. A common method for identifying cells, including T cells, undergoing apoptosis is to expose them to a fluorophore-binding protein (Annexin V). Annexin V is commonly used to detect apoptotic cells due to its ability to bind to phosphatidylserine on the outer leaflet of the cell membrane, providing an early indicator that cells are undergoing the apoptotic process.
[0138] As used herein, the term "binds to immobilized CD137" refers to the ability of a human antibody of the present disclosure to bind to CD137 expressed, for example, on a cell surface or attached to a solid support.
[0139] As used herein, the term "bispecific" or "bifunctional antibody" refers to an artificial hybrid antibody having two different heavy / light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods, including hybridoma fusion or linking of Fab' fragments. See, e.g., Songsivilai & Lachmann, (1990) Clin. Exp. Immunol. 79:315-321; Kostelny et al., (1992) J. Immunol. 148:1547-1553.
[0140] Traditionally, recombinant production of bispecific antibodies has been based on the coexpression of two immunoglobulin heavy / light chain pairs, each with a different specificity (Milstein and Cuello, (1983) Nature 305:537-539). Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) may be fused to an immunoglobulin constant domain sequence. Fusion of a heavy chain variable region with an immunoglobulin heavy chain constant domain comprising at least part of the hinge, CH2, and CH3 regions is preferred. For further details regarding exemplary methods currently known for producing bispecific antibodies, see, e.g., Suresh et al., (1986) Methods Enzymol. 121:210; PCT International Patent Application Publication No. WO 96 / 27011; Brennan et al., (1985) Science 229:81; Shalaby et al., J. Exp. Med. (1992) 175:217-225; Kostelny et al., (1992) J. Immunol. 148(5):1547-1553; Hollinger et al., (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Gruber et al., (1994) J. Immunol. 152:5368; and Tutt et al., (1991) J. Immunol. 147:60. Bispecific antibodies also include cross-linked or heteroconjugate antibodies. Heteroconjugate antibodies may be made using any convenient cross-linking method. Suitable cross-linking agents are known in the art, and are disclosed in U.S. Pat. No. 4,676,980, along with a number of cross-linking methods.
[0141] Various methods for producing and isolating bispecific antibody fragments directly from recombinant cell culture have also been reported. For example, bispecific antibodies have been produced using leucine zippers. See, e.g., Kostelny et al. (1992) J Immunol 148(5):1547-1553. The leucine zipper peptide, derived from the Fos and Jun proteins, can link the Fab' portions of two different antibodies by gene fusion. Antibody homodimers can be reduced at the hinge region to form monomers and reoxidized to form heterodimeric antibodies. This method can also be used to produce homodimeric antibodies. The "diabody" method, described by Hollinger et al. (1993) Proc Natl Acad Sci USA 90:6444-6448, offers another mechanism for producing bispecific antibody fragments. These fragments comprise a heavy chain variable domain (VH) connected to a light chain variable domain (VL) by a linker. The linker is too short to allow pairing between the two domains on the same chain. Thus, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites. Another method for producing bispecific antibodies using single-chain Fv (scFv) dimers has also been reported. See, e.g., Gruber et al. (1994) J Immunol 152:5368. Alternatively, the antibodies may be "linear antibodies," as described, e.g., in Zapata et al. (1995) Protein Eng. 8(10):1057-1062. Briefly, these antibodies comprise a pair of tandem Fd segments (VH-CH1-VH-CH1), which form a pair of antigen-binding regions. Linear antibodies may be bispecific or monospecific.
[0142] Antibodies with more than two valencies (eg, trispecific antibodies) are also contemplated and are described, for example, in Tutt et al. (1991) J Immunol 147:60.
[0143] The present disclosure also encompasses variant forms of multispecific antibodies, such as dual variable domain immunoglobulin (DVD-Ig) molecules, described, for example, in Wu et al. (2007) Nat Biotechnol 25(11): 1290-1297. DVD-Ig molecules are designed in such a way that two different light chain variable domains (VL) derived from two different parent antibodies are linked in tandem by recombinant DNA technology, either directly or via a short linker, and then linked to a light chain constant domain. Similarly, the heavy chain comprises two different heavy chain variable domains (VH) linked in tandem, followed by a constant domain CH1 and an Fc region. Methods for producing DVD-Ig molecules from two parent antibodies are described in detail, for example, in PCT International Patent Application Publications WO08 / 024188 and WO07 / 024715. In some embodiments, a bispecific antibody is a Fab-in-Tandem immunoglobulin, which is an immunoglobulin in which a light chain variable region with a second specificity is fused to a heavy chain variable region of a whole antibody. Such antibodies are described, for example, in International Patent Application Publication WO2015 / 103072.
[0144] As used herein, "cancer antigen" refers to (i) tumor-specific antigens, (ii) tumor-associated antigens, (iii) cells expressing tumor-specific antigens, (iv) cells expressing tumor-associated antigens, (v) embryonic antigens on tumors, (vi) autologous tumor cells, (vii) tumor-specific membrane antigens, (viii) tumor-associated membrane antigens, (ix) growth factor receptors, (x) growth factor ligands, and (xi) any other type of antigen or antigen-presenting cell or substance associated with cancer.
[0145] The term "cancer" is art-recognized and refers to malignant tumors of epithelial and endocrine tissues, including cancers of the respiratory system, gastrointestinal system, genitourinary system, testicular cancer, breast cancer, prostate cancer, endocrine system cancer, and melanoma. The anti-CD137 antibodies described herein can be used to treat patients who have, are suspected of having, or may be at high risk of developing any type of cancer, including renal cancer or melanoma. Exemplary cancers include cancers that form in tissues of the cervix, lung, prostate, breast, head and neck, colon, and ovary. The term also includes carcinosarcomas, which include malignant tumors composed of carcinomatous and sarcomatous tissues. "Adenocarcinoma" refers to cancers that originate in glandular tissue or in which tumor cells form recognizable glandular structures.
[0146] As used herein, the term "compete," when used in the context of antigen binding proteins (e.g., immunoglobulins, antibodies, or antigen-binding fragments thereof) that compete for binding to the same epitope, refers to an interaction between the antigen binding proteins as determined by an assay (e.g., competitive binding assay, cross-inhibition assay, etc.) where the test antigen binding protein (e.g., test antibody) inhibits (e.g., reduces or prevents) the specific binding of a reference antigen binding protein (e.g., a reference antibody, e.g., mAb1) to a common antigen (e.g., CD137 or a fragment thereof).
[0147] In some embodiments, the antibodies described herein cross-compete with mAb1 (i.e., an antibody comprising the heavy and light chain variable sequences of SEQ ID NOs: 4 and 6, respectively), mab8 (i.e., an antibody comprising the heavy and light chain variable sequences of SEQ ID NOs: 101 and 6, respectively), or mAb10 (i.e., an antibody comprising the heavy and light chain variable sequences of SEQ ID NOs: 26 and 6, respectively).
[0148] A polypeptide or amino acid sequence "derived from" a specified polypeptide or protein refers to the origin of the polypeptide. Preferably, a polypeptide or amino acid sequence derived from a particular sequence has an amino acid sequence that is essentially identical to that sequence or a portion thereof, where the portion consists of at least 10-20 amino acids, preferably at least 20-30 amino acids, more preferably at least 30-50 amino acids, or has an amino acid sequence that is recognizable to one of skill in the art as having that origin in sequence. A polypeptide derived from another peptide may have one or more mutations compared to the starting polypeptide, for example, one or more amino acid residues substituted for other amino acid residues, or one or more amino acid residues inserted or deleted.
[0149] Polypeptides may contain non-naturally occurring amino acid sequences. Such variants necessarily have less than 100% sequence identity or similarity with the starting molecule. In certain embodiments, variants have less than about 75% to 100%, more preferably less than about 80% to 100%, more preferably less than about 85% to 100%, more preferably less than about 90% to 100%, (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%), and most preferably less than about 95% to 100% amino acid sequence identity or similarity over the entire length of the variant molecule to the amino acid sequence of the starting polypeptide.
[0150] In certain embodiments, there is one amino acid difference between the starting polypeptide sequence and the sequence derived therefrom. Identity or similarity with respect to this sequence is defined herein as the percentage of amino acid residues in a candidate sequence that are identical (i.e., the same residues) to the starting amino acid residues after aligning the sequences and inserting gaps, if necessary, to achieve the maximum percentage of sequence identity. In certain embodiments, a polypeptide consists of, consists essentially of, or comprises an amino acid sequence selected from the sequences set forth in Table 3 or Table 4. In certain embodiments, a polypeptide comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from the sequences set forth in Table 3 or Table 4. In certain embodiments, a polypeptide comprises a contiguous amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a contiguous amino acid sequence selected from the sequences set forth in Table 3 or Table 4. In certain embodiments, a polypeptide comprises an amino acid sequence having at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 300, 400 or 500 (or any integer between these numbers) contiguous amino acids of an amino acid sequence selected from the sequences set forth in Table 3 or Table 4.
[0151] In certain embodiments, the antibodies of the present disclosure are encoded by a nucleotide sequence. The nucleotide sequences of the present invention may be useful for many applications, including cloning, gene therapy, protein expression and purification, mutagenesis, DNA vaccination of hosts in need thereof, antibody generation for, e.g., passive immunization, PCR, primer and probe generation, and the like. In certain embodiments, the nucleotide sequences of the present invention consist of, consist essentially of, or comprise a nucleotide sequence selected from the sequences set forth in Table 3 or Table 4. In certain embodiments, the nucleotide sequence comprises a nucleotide sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a nucleotide sequence selected from the sequences set forth in Table 3 or Table 4. In certain embodiments, the nucleotide sequence comprises a contiguous nucleotide sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a contiguous nucleotide sequence selected from the sequences set forth in Table 3 or Table 4. In certain embodiments, the polypeptide comprises a nucleotide sequence having at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 300, 400 or 500 (or any integer between these numbers) contiguous nucleotides of a nucleotide sequence selected from the sequences set forth in Table 3 or Table 4.
[0152] Those skilled in the art will also understand that antibodies suitable for use in the methods disclosed herein can be modified to differ in sequence from the native or naturally occurring sequence from which they are derived while retaining the desired activity of the native sequence. For example, nucleotide or amino acid substitutions leading to conservative substitutions or changes of "non-essential" amino acid residues can be made. Mutations can be introduced by standard methods, such as site-directed mutagenesis and PCR-mediated mutagenesis.
[0153] Antibodies suitable for use in the methods disclosed herein may contain conservative amino acid substitutions at one or more amino acid residues, e.g., essential or non-essential amino acid residues. A "conservative amino acid substitution" is one in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues with similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, non-essential amino acid residues in a binding polypeptide are preferably replaced with another amino acid residue from the same side chain family. In certain embodiments, a consecutive sequence of amino acids may be replaced with a structurally similar consecutive sequence that differs in the order and / or composition of side chain family members. Alternatively, in certain embodiments, mutations may be randomly introduced along all or part of the coding sequence, e.g., by saturation mutagenesis, and the resulting mutations may be incorporated into a binding polypeptide of the invention and screened for the ability to bind to a desired target.
[0154] As used herein, the term antigen "cross-presentation" refers to the presentation of foreign protein antigens to T cells via MHC class I and class II molecules on APCs.
[0155] As used herein, the term "cross-reactivity" refers to the ability of an antibody of the present disclosure to bind to CD137 from a different species. For example, an antibody of the present disclosure that binds to human CD137 may also bind to CD137 from another species. As used herein, cross-reactivity is measured by detecting specific reactivity with purified antigen in a binding assay (e.g., SPR, ELISA), or by detecting binding to or otherwise functional interaction with cells that physiologically express CD137. Methods for determining cross-reactivity include standard binding assays described herein, such as Biacore™ surface plasmon resonance (SPR) analysis using a Biacore™ 2000 SPR instrument (Biacore AB, Uppsala, Sweden) or flow cytometry.
[0156] As used herein, the term "cytotoxic T lymphocyte (CTL) response" refers to an immune response induced by cytotoxic T cells. CTL responses are primarily CD8 + It is mediated by T cells.
[0157] As used herein, the term "dimerization" refers to the formation of a macromolecular complex by two usually non-covalently bound macromolecules, such as proteins or protein multimers. Homodimerization refers to the process of dimerization when the properties of the macromolecules (e.g., proteins) are identical. Heterodimerization refers to the process of dimerization when the properties of the macromolecules (e.g., proteins) are not identical. Methods for measuring dimerization are known to those skilled in the art. For example, such methods include, but are not limited to, yeast two-hybrid assays, fluorescence resonance energy transfer (FRET), bioluminescence resonance energy transfer (BRET), protein mass spectrometry, evanescent wave methods, size exclusion chromatography, analytical ultracentrifugation, scattering methods, NMR spectroscopy, isothermal titration calorimetry, fluorescence anisotropy, fluorescence correlation spectroscopy (FCS), fluorescence recovery after photobleaching (FRAP), proximity imaging (PRIM), and fluorescent protein reconstitution (BiFC) (see, e.g., Gell DA, Grant RP, Mackay JP (2012) The Detection and Quantitation of Protein Oligomerization. In: Matthews JM (eds) Protein Dimerization and Oligomerization in Biology. Advances in Experimental Medicine and Biology, vol 747. Springer, New York, NY; and Xie, Q. et al. Methods Mol Biol, 2011; 680: 3-28).
[0158] As used herein, "CD137 dimerization" refers to the dimerization of two CD137 trimers. In some embodiments, the anti-CD137 agonistic antibodies described herein induce or enhance CD137 dimerization. In some embodiments, the anti-CD137 agonistic antibodies described herein induce or enhance CD137 dimerization compared to the amount of dimerization in the absence of the anti-CD137 agonistic antibody. In some embodiments, the anti-CD137 agonistic antibodies described herein induce or enhance CD137 dimerization compared to the amount of dimerization in the presence of a reference anti-CD137 agonistic antibody. In some embodiments, dimerization is increased by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.
[0159] As used herein, "EC 50 " refers to the concentration of an antibody or antigen-binding portion thereof that induces 50% of the maximal response, i.e., a response that is halfway between the maximal response and a reference, in either an in vitro or in vivo assay.
[0160] As used herein, the term "effective dosage" or "effective dose" is defined as an amount sufficient to achieve or at least partially achieve the desired effect. The term "therapeutically effective dosage" is defined as an amount sufficient to cure or at least partially halt the disease and complications in patients already suffering from the disease. The amount effective for this purpose depends on the severity of the disorder being treated and the general state of the patient's own immune system.
[0161] As used herein, the term "epitope" or "antigenic determinant" refers to a determinant or site on an antigen (e.g., CD137) to which an antigen-binding protein (e.g., an immunoglobulin, antibody, or antigen-binding fragment) specifically binds. Epitopes of protein antigens can be divided into "linear epitopes" and "conformational epitopes." As used herein, the term "linear epitope" refers to an epitope formed from a continuous linear sequence of linked amino acids. Linear epitopes of protein antigens are typically maintained even when exposed to chemical denaturants (e.g., acids, bases, solvents, cross-linking reagents, chaotropic agents, disulfide bond-reducing agents) or physical denaturation (e.g., heat, radiation, or mechanical shear or stress). In some embodiments, epitopes are non-linear and are also referred to as interrupted epitopes. As used herein, the term "conformational epitope" or "non-linear epitope" refers to an epitope formed from non-contiguous amino acids juxtaposed by tertiary folding of a polypeptide. Conformational epitopes are typically lost upon treatment with denaturing agents. Typically, an epitope comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids in a unique spatial conformation. In some embodiments, an epitope comprises fewer than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, or 5 amino acids in a unique spatial conformation. Generally, an antibody or antigen-binding fragment thereof specific for a particular target molecule preferentially recognizes and binds to a specific epitope on the target molecule within a complex mixture of proteins and / or macromolecules. In some embodiments, the epitope does not include all amino acids of the extracellular domain of human CD137.
[0162] Also encompassed by the present disclosure are antibodies that bind to epitopes on CD137, including all or part of the epitopes recognized by the specific antibodies described herein (e.g., the same or overlapping regions, or regions between or spanning regions).
[0163] As used herein, the term "epitope mapping" refers to the process or method of identifying the binding site or epitope of an antibody or antigen-binding fragment thereof, or its target protein antigen. Epitope mapping methods and techniques are presented herein.
[0164] As used herein, the term "CD137" refers to a specific member of the tumor necrosis factor receptor (TNFR) family of transmembrane proteins. Other names and acronyms for CD137 in the art include "tumor necrosis factor receptor superfamily member 9" (TNFRSF9), 4-1BB, and "induced by lymphocyte activation" (ILA) (Alderson et al., (1994) Eur J Immunol 24(9):2219-2227; Schwarz et al., (1993) Gene 134(2):295-298). An example of the amino acid sequence of full-length human CD137, including the leader domain, transmembrane domain, and cytoplasmic domain, is shown in Table 4 (SEQ ID NO: 3) and is set forth below: MGNSCYNIVATLLLVLNFERTRSLQDPCSNCPAGTFCDNNRNQICSPCPPNSFSSAGGQRTCDICRQCKGVFRTRKECSSTSNAECDCTPGFHCLGAGCSMCEQDCKQGQELTKKGCKDCCFGTFNDQ KRGICRPWTNCSLDGKSVLVNGTKERDVVCGPSPADLSPGASSVTPPAPAREPGHSPQIISFFLALTSTALLFLLFFLTLRFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL.
[0165] As used herein, the term "CD137L" or "CD137 ligand" refers to a member of the tumor necrosis factor (TNF) family of transmembrane proteins. Other names and acronyms for CD137L in the art include tumor necrosis factor superfamily member 9 (TNFSF9) and 4-1BB ligand (4-1BBL) (Alderson et al., (1994) Eur J Immunol 24(9):2219-2227). An exemplary amino acid sequence of full-length CD137L is set forth in Table 4 (SEQ ID NO: 97).
[0166] As used herein, the term "Fc-mediated effector function" or "Fc effector function" refers to the primary function of an antibody and other biological activities of the antibody besides its intended purpose. For example, the effector function of a therapeutic agonistic antibody is a biological activity other than the activation of a target protein or pathway. Examples of antibody effector functions include C1q binding and complement-dependent cytotoxicity, Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, downregulation of cell surface receptors (e.g., B cell receptors), lack of activation of platelets expressing Fc receptors, and B cell activation. Many effector functions are initiated by Fc binding to an Fcγ receptor.
[0167] As used herein, the term "Fc receptor" refers to a polypeptide present on the surface of immune effector cells that is bound to the Fc region of an antibody. In some embodiments, the Fc receptor is an Fcγ receptor. There are three subclasses of Fcγ receptors: FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16). All four IgG isotypes (IgG1, IgG2, IgG3, and IgG4) bind to and activate the Fc receptors FcγRI, FcγRIIA, and FcγRIIIA. FcγRIIB is an inhibitory receptor; therefore, antibody binding to this receptor does not activate complement and cellular responses. FcγRI is a high-affinity receptor that binds to monomeric IgG. On the other hand, FcγRIIA and FcγRIIA are low-affinity receptors that bind only to polymeric IgG. Binding of antibodies to Fc receptors and / or C1q is directed by specific residues or domains within the Fc region. Binding also depends on residues within the hinge region and CH2 portion of the antibody. In some embodiments, the agonistic and / or therapeutic activity of the antibodies described herein depends on binding of the Fc region to an Fc receptor (e.g., FcγR). In some embodiments, the agonistic and / or therapeutic activity of the antibodies described herein is enhanced by binding of the Fc region to an Fc receptor (e.g., FcγR).
[0168] As used herein, the term "glycosylation pattern" is defined as the pattern of sugar units covalently attached to a protein, more specifically, an immunoglobulin protein. The glycosylation pattern of a heterologous antibody can be characterized as being substantially similar to the glycosylation pattern naturally present on antibodies produced by a non-human transgenic animal species if one skilled in the art recognizes that the glycosylation pattern of the heterologous antibody is more similar to the glycosylation pattern in the non-human transgenic animal species than to the species from which the transgenic CH gene is derived.
[0169] As used herein, the term "blood cancer" includes lymphoma, leukemia, myeloma or lymphatic malignant tumor, and cancer of the spleen and lymph nodes.Examples of lymphoma include both B-cell lymphoma (blood cancer of B cells) and T-cell lymphoma.B-cell lymphoma includes both Hodgkin's lymphoma and most non-Hodgkin's lymphoma. Non-limiting examples of B-cell lymphomas include diffuse large B-cell lymphoma, follicular lymphoma, mucosa-associated lymphoid tissue lymphoma, small cell lymphocytic lymphoma (overlaps with chronic lymphocytic leukemia), mantle cell lymphoma (MCL), Burkitt's lymphoma, mediastinal large B-cell lymphoma, Waldenstrom's macroglobulinemia, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, and lymphomatoid granulomatosis. Non-limiting examples of T-cell lymphomas include extranodal T-cell lymphoma, cutaneous T-cell lymphoma, anaplastic large cell lymphoma, and angioimmunoblastic T-cell lymphoma. Hematological malignancies include, but are not limited to, secondary leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, and acute lymphoblastic leukemia.Hematological malignancies also include, but are not limited to, multiple myeloma and smoldering multiple myeloma.Other hematological cancers and / or B-cell-related or T-cell-related cancers are also included in the term hematological malignancies.
[0170] As used herein, the term "human antibody" includes antibodies having variable and, if present, constant regions derived from human germline immunoglobulin sequences. The human antibodies of the present disclosure may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo) (see, e.g., Lonberg et al., (1994) Nature 368(6474): 856-859; Lonberg, (1994) Handbook of Experimental Pharmacology 113:49-101; Lonberg & Huszar, (1995) Intern. Rev. Immunol. 13:65-93, and Harding & Lonberg, (1995) Ann. NY Acad. Sci. 764:536-546). However, the term "human antibody" does not include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences (i.e., humanized antibodies).
[0171] As used herein, the term "heterologous antibody" is defined in relation to the transgenic non-human organism that produces the antibody. This term refers to an antibody that has an amino acid sequence or encoding nucleic acid sequence that corresponds to a sequence present in an organism that is not part of the transgenic non-human animal and that is generally derived from a species that is not the transgenic non-human animal.
[0172] The terms "inducing an immune response" and "enhancing an immune response" are used interchangeably and refer to the stimulation (i.e., passive or active) of an immune response to a particular antigen. The term "inducing" when used in reference to the induction of CDC or ADCC refers to the stimulation of a specific direct cell-killing mechanism.
[0173] As used herein, a subject "in need of prevention," "in need of treatment," or "in need thereof" refers to one who, according to the judgment of a competent medical professional (e.g., a physician, nurse, or nursing intern in the case of a human, or a veterinarian in the case of a non-human mammal), would reasonably benefit from a given treatment (e.g., treatment with a composition comprising an anti-CD137 antibody).
[0174] The term "in vivo" refers to a process that occurs in a living organism.
[0175] As used herein, the term "isolated antibody" is intended to refer to an antibody that is substantially free of other antibodies having different antigen specificities (e.g., an isolated antibody that specifically binds to human CD137 is substantially free of antibodies that specifically bind to antigens other than CD137). An isolated antibody that specifically binds to an epitope may, however, have cross-reactivity to other CD137 proteins from different species. However, the antibody will continue to exhibit specific binding to human CD137 in the specific binding assays described herein. Furthermore, an isolated antibody is typically substantially free of other cellular material and / or chemicals. In some embodiments, a combination of "isolated" antibodies with different CD137 specificities are combined in a well-defined composition.
[0176] As used herein, the term "isolated nucleic acid molecule" refers to an antibody or antibody moiety that binds to CD137 (e.g., V H , V L , CDR3), and is intended to refer to nucleic acid molecules in which the nucleotide sequence encoding an antibody or antibody portion does not contain other nucleotide sequences encoding antibodies or antibody portions that bind to antigens other than CD137, such other sequences may naturally flank the nucleic acid in human genomic DNA. For example, a sequence selected from the sequences set forth in Table 3 or Table 4 may be used to encode a heavy chain variable region (V ) of an anti-CD137 antibody monoclonal antibody described herein. H ) and the light chain variable region (VL ) corresponds to a nucleotide sequence containing
[0177] As used herein, "isotype" refers to the class of antibody (e.g., IgM or IgG1) encoded by the heavy chain constant region genes. In some embodiments, the human monoclonal antibodies of this disclosure are of the IgG1 isotype. In some embodiments, the human monoclonal antibodies of this disclosure are of the IgG1 isotype and comprise a mutation. In some embodiments, the human monoclonal antibodies of this disclosure are of the IgG2 isotype. In some embodiments, the human monoclonal antibodies of this disclosure are of the IgG3 isotype. In some embodiments, the human monoclonal antibodies of this disclosure are of the IgG4 isotype. In some embodiments, the human monoclonal antibodies of this disclosure are of the IgG4 isotype and comprise a mutation. In some embodiments, the mutation is a substitution of Ser228. In some embodiments, the substitution of Ser228 is S228P.
[0178] As used herein, the term "isotype switching" refers to the phenomenon in which the class or isotype of an antibody changes from one Ig class to another Ig class isotype.
[0179] As used herein, "KD" or "K D The term "K" refers to the equilibrium dissociation constant of the binding reaction between an antibody and an antigen. D The value is a numerical expression of the ratio of the antibody dissociation rate constant (kd) to the antibody association rate constant (ka). D The K value is inversely related to the binding affinity of the antibody for the antigen. D The smaller the value, the higher the affinity of the antibody for its antigen. Affinity is the strength of binding of a single molecule to its ligand and is typically expressed as the equilibrium dissociation constant (K D ), which is used to assess and rank the strength of bimolecular interactions.
[0180] As used herein, "Kd" or "k d (or "koff" or "k off The term kd is intended to refer to the dissociation rate constant for an antibody to dissociate from an antibody / antigen complex. The kd value is a numerical representation of the fraction of complex that dissociates or dissociates per second, and is used to refer to the dissociation rate constant for an antibody to dissociate from an antibody / antigen complex. -1 It is expressed in units of:
[0181] As used herein, "ka" or "k a " (or "kon" or "k on The term "k" is intended to refer to the association rate constant for the association of an antibody with an antigen. The k value is a numerical representation of the number of antibody / antigen complexes formed per second in a 1 molar (1M) solution of antibody and antigen, and M -1 sec -1 It is expressed in units of .
[0182] As used herein, the terms "linked," "fused," or "fusion" are used interchangeably. These terms refer to the joining of two or more elements or components or domains by any means, including chemical conjugation or recombinant means. Methods of chemical conjugation (e.g., the use of heterobifunctional cross-linking agents) are known in the art.
[0183] As used herein, "local administration" or "local delivery" refers to delivery that does not rely on transport of a composition or agent to a desired target tissue or target site via the vascular system. For example, a composition may be delivered by injection or implantation of the composition or agent, or by injection or implantation of a device containing the composition or agent. After local administration in the vicinity of the target tissue or target site, the composition or agent, or one or more components thereof, may diffuse to the desired target tissue or target site.
[0184] As used herein, "MHC molecule" refers to two types of molecules: MHC class I and MHC class II. MHC class I molecules present antigens to specific CD8+ T cells, and MHC class II molecules present antigens to specific CD4+ T cells. The antigens exogenously delivered to APCs are mainly processed to associate with MHC class II. In contrast, the antigens endogenously delivered to APCs are mainly processed to associate with MHC class I.
[0185] As used herein, the term "monoclonal antibody" refers to an antibody that displays a single binding specificity and affinity for a particular epitope. Accordingly, the term "human monoclonal antibody" refers to an antibody that displays a single binding specificity and has variable and optionally constant regions derived from human germline immunoglobulin sequences. In some embodiments, human monoclonal antibodies are produced by hybridomas comprising B cells obtained from a transgenic non-human animal, e.g., a transgenic mouse, whose genome includes human heavy chain and light chain transgenes, and fused with an immortalized cell.
[0186] As used herein, the term "multimerization" refers to the formation of an anti-molecular complex containing three or more macromolecules, such as proteins, typically bound via non-covalent interactions. Methods for measuring multimerization are known to those skilled in the art and are described above with respect to dimerization. In some embodiments, the anti-CD137 agonistic antibodies described herein induce or enhance CD137 multimerization. In some embodiments, the anti-CD137 agonistic antibodies described herein induce or enhance CD137 multimerization compared to the amount of multimerization in the absence of the anti-CD137 agonistic antibody. In some embodiments, the anti-CD137 agonistic antibodies described herein induce or enhance CD137 multimerization compared to the amount of multimerization in the presence of a reference anti-CD137 agonistic antibody. In some embodiments, multimerization is increased by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.
[0187] As used herein, the term "naturally occurring" when applied to an object refers to the fact that the object can exist in nature. For example, a polypeptide or polynucleotide sequence that exists in an organism (including viruses) that can be isolated from a source in nature and has not been intentionally modified by humans in a laboratory is naturally occurring.
[0188] As used herein, the term "nonswitched isotype" refers to the class of heavy chain isotypes produced when isotype switching has not occurred. The CH gene encoding the nonswitched isotype is usually the first CH gene immediately downstream of the functionally rearranged VDJ gene. Isotype switching is classified as classical isotype switching or nonclassical isotype switching. Classical isotype switching occurs through recombination events involving at least one switch sequence region in the transgene. Nonclassical isotype switching is, for example, the class of heavy chain isotypes produced when isotype switching has not occurred in human σμ and human Σ μ Alternative non-classical switching mechanisms, such as inter-transgene and / or inter-chromosomal recombination, specifically allow isotype switching to occur and be effective.
[0189] As used herein, the term "nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single-stranded or double-stranded form. Unless otherwise specified, the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to natural nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also encompasses implicitly conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences as well as the explicitly indicated sequence. Specifically, degenerate codon substitutions can be made by creating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081, 1991; Ohtsuka et al., Biol. Chem. 260:2605-2608, 1985; and Cassol et al., 1992; Rossolini et al., Mol. Cell. Probes 8:91-98, 1994). For arginine and leucine, modifications at the second base can also be conservative. The term nucleic acid is used interchangeably with gene, cDNA, and mRNA encoded by a gene.
[0190] As used herein, a polynucleotide may be composed of any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA, or modified RNA or DNA. For example, a polynucleotide may be composed of single-stranded and double-stranded DNA, DNA that is a mixture of single-stranded and double-stranded regions, single-stranded and double-stranded RNA, RNA that is a mixture of single-stranded and double-stranded regions, or hybrid molecules containing DNA and RNA, which may be single-stranded or, more typically, double-stranded, or a mixture of single-stranded and double-stranded regions. Furthermore, a polynucleotide may be composed of RNA, DNA, or triple-stranded regions containing both RNA and DNA. A polynucleotide may also contain one or more modified bases, or a DNA or RNA backbone, modified for stability or other reasons. Examples of "modified" bases include tritylated bases and unusual bases, such as inosine. Various modifications may be made to DNA and RNA. Thus, "polynucleotide" encompasses chemically, enzymatically, or metabolically modified forms.
[0191] A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence. With respect to transcriptional regulatory sequences, operably linked means that the linked DNA sequences are contiguous, and, where necessary to join two protein-coding regions, contiguous and in reading frame. With respect to switch sequences, operably linked indicates that the sequences are capable of effecting switch recombination.
[0192] As used herein, the term "paratope" or "antigen-binding site" refers to an antibody or antigen-binding fragment thereof, which recognizes and binds to an epitope on an antigen, comprising a set of complementarity-determining regions (CDRs) located within the variable heavy and variable light chains.
[0193] As used herein, "parenteral administration," "administered parenterally," and other grammatically equivalent terms refer to modes of administration other than enteral and topical administration, typically by injection, including, but not limited to, intravenous, intranasal, intraocular, intramuscular, intra-arterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intrathecal, epidural, intracerebral, intracranial, intracarotid, and substernal injection and infusion.
[0194] As used herein, the term "patient" includes human and other mammalian subjects receiving either prophylactic or therapeutic treatment.
[0195] In the context of two or more nucleic acid or polypeptide sequences, the term "percent identity" refers to two or more sequences or subsequences that have a specified percentage of identical nucleotides or amino acid residues when compared and aligned for maximum correspondence, as determined using one of the sequence comparison algorithms described below (e.g., BLASTP and BLASTN, or other algorithms available to those skilled in the art), or by visual inspection. Depending on the application, the "percent identity" may extend over a region of the compared sequences, such as a functional domain, or alternatively, over the entire length of the two sequences being compared. For sequence comparison, typically, one sequence serves as a reference sequence to which a verification sequence is compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity of the test sequence relative to the reference sequence based on the designated program parameters.
[0196] Optimal sequence alignment for comparison may be performed, for example, by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computer-implemented algorithms thereof (GAP, BESTFIT, FASTA, and TFASTA, Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wisconsin), or by visual inspection (see generally Ausubel et al., supra).
[0197] One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al., J. Mol. Biol. 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information website.
[0198] As generally used herein, "pharmaceutically acceptable" refers to those compounds, substances, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues, organs and / or body fluids of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0199] As used herein, "pharmaceutically acceptable carrier" refers to and includes all physiologically compatible solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc. The compositions may also contain pharmaceutically acceptable salts, such as acid addition salts or base addition salts (e.g., as described in Berge et al. (1977) J Pharm Sci 66 :1-19).
[0200] As used herein, the terms "polypeptide," "peptide," and "protein" are used interchangeably to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of corresponding naturally occurring amino acids, and to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.
[0201] As used herein, the term "preventing," when used in reference to a condition, refers to the administration of a composition that reduces the frequency or delays the onset of a medical condition in a subject compared to a subject not administered the composition.
[0202] As used herein, the terms "purified" or "isolated" when applied to any of the proteins (antibodies or fragments) described herein refer to a polypeptide that has been separated or purified from components (e.g., proteins or other naturally occurring biological or organic molecules) that naturally accompany it in the prokaryotic organism that expresses the protein, such as other proteins, lipids, and nucleic acids. Typically, a polypeptide is purified when it constitutes at least 60% by weight (e.g., at least 65, 70, 75, 80, 85, 90, 92, 95, 97, or 99% by weight) of the total protein in a sample.
[0203] As used herein, the term "rearranged" refers to the configuration of a heavy or light chain immunoglobulin locus in which the V segment is essentially a complete V Hor V L The rearranged immunoglobulin loci are located adjacent to the DJ or J segments, respectively, in a domain-encoding structure. Rearranged immunoglobulin loci can be identified by comparison with germline DNA. Rearranged loci contain at least one recombined heptamer / nonamer homology element.
[0204] As used herein, the term "receptor clustering" refers to a cellular process that results in the grouping or local accumulation of a set of receptors at a specific cellular location, often inducing or amplifying a signaling response. Many protein receptors bind to and cluster with their cognate ligands; that is, they form dimers, trimers, oligomers, or multimers upon binding to their cognate ligands. For example, members of the PDGF receptor and TNF receptor superfamily form dimers and trimers, respectively, upon binding to their ligands. Cognate ligand-induced clustering (e.g., dimerization, multimerization) induces signaling through the receptor. Thus, an antibody or antigen-binding fragment thereof of the present disclosure can activate receptors by binding to two or more receptors and induce or stabilize dimerization, trimerization, and / or multimerization with or without cognate ligand binding.
[0205] Receptor clustering and multimerization are required for TNFR signaling (Wajant (2015) Cell Death Differ 22(11):1727-1741), particularly for TNFRSF activation. 4-1BB (CD137), CD40, GITR, CD27, DR3, DR5, and Fas are some of the TNFSF receptors known to require clustering to trigger downstream signaling. Experimental evidence that the 4-1BB receptor must be crosslinked to signal transduction was reported by Rabu et al. These authors reported that the monotrimeric form of human 4-1BBL had no activating effect on human T cells, whereas crosslinking this protein to two or more trimers resulted in strong activation of the protein (Rabu et al., (2005) J Biol Chem 280:41472-41481). Thus, in some embodiments, the anti-CD137 agonistic antibody induces multimerization of two or more trimers of CD137.
[0206] As used herein, the term "recombinant host cell" (or simply "host cell") is intended to refer to a cell into which a recombinant expression vector has been introduced. It should, of course, be understood that the term is intended to refer not only to the particular subject cell but also to the progeny of that cell. Because certain modifications may occur in subsequent generations due to either mutation or environmental influences, such progeny may not actually be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.
[0207] As used herein, the term "recombinant human antibody" includes all human antibodies prepared, expressed, produced, or isolated by recombinant means, such as (a) antibodies isolated from animals (e.g., mice) transgenic or transchromosomal for human immunoglobulin genes or hybridomas prepared from such animals, (b) antibodies isolated from host cells, e.g., transfectomas, transformed to express the antibody, (c) antibodies isolated from a recombinant combinatorial human antibody library, and (d) antibodies prepared, expressed, produced, or isolated by any other means, including splicing human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies contain variable and constant regions that utilize specific human germline immunoglobulin sequences, as encoded by germline genes, but also include subsequent rearrangements and mutations that occur, for example, during antibody maturation. As is known in the art (see, e.g., Lonberg (2005) Nature Biotech. 23(9):1117-1125), variable regions contain antigen-binding domains, which are encoded by different genes that rearrange to form antibodies specific to foreign antigens. In addition to rearrangement, the variable regions can be further modified by multiple single amino acid changes (termed somatic mutation or hypermutation) to increase the affinity of the antibody for the foreign antigen. The constant regions change in further response to antigen (i.e., isotype switching). Thus, nucleic acid molecules that encode light and heavy chain immunoglobulin polypeptides and that are rearranged and somatically mutated in response to antigen may not have sequence identity to the original nucleic acid molecules, but instead are substantially identical or similar (i.e., have at least 80% identity).
[0208] As used herein, the term "reference antibody" (used interchangeably with "reference mAb") or "reference antigen-binding protein" refers to an antibody or antigen-binding fragment thereof that binds to a specific epitope on human CD137 and is used to establish a relationship between itself and one or more distinct antibodies. In some embodiments, the relationship is the binding of the reference antibody to the same epitope on CD137 by one or more distinct antibodies. As used herein, the term also refers to an anti-CD137 antibody that is useful as a competitor in a test or assay, such as the tests or assays described herein (e.g., competitive binding assays). In this case, the assay is useful for discovering, identifying, or developing one or more distinct antibodies that bind to the same epitope. The variable heavy chain (V) of an exemplary reference antibody (mAb1) is H ) and variable light chain (V L The amino acid sequences of V H 1, SEQ ID NO: 4; V H 2, SEQ ID NO: 6). In some embodiments, the term connotes an anti-CD137 antibody useful in a test or assay as a comparator, where the assay is useful for distinguishing characteristics of the antibody (e.g., hepatotoxicity, anti-tumor efficacy). In some embodiments, the reference antibody is urelumab. In some embodiments, the reference antibody is utomilumab.
[0209] As used herein, the terms "specific binding," "selective binding," "selectively binds," and "specifically binds" refer to an antibody that binds to an epitope on a specified antigen. Typically, an antibody binds to an epitope of approximately 10 as determined by surface plasmon resonance (SPR) technology on a BIACORE2000 instrument using recombinant human CD137 as the analyte and an antibody as the ligand. -6 Less than M, e.g., about 10 -7 Under M, 10 -8 Under M, 10 -9 Less than M or 10 -10 The equilibrium dissociation constant (KD ) and binds to a predetermined antigen with an affinity that is at least two-fold higher than the affinity of the binding to a nonspecific antigen other than the predetermined antigen or a closely related antigen (e.g., BSA, casein, etc.). The phrases "antibody recognizing an antigen" and "antibody specific for an antigen" are used interchangeably herein with the term "antibody that specifically binds to an antigen."
[0210] As used herein, the term "switch sequence" refers to the DNA sequences involved in switch recombination. The "switch donor" sequence, typically the μ switch region, is 5' (i.e., upstream) of the construct region that is deleted during switch recombination. The "switch acceptor" region is between the construct region that is deleted and the replacement constant region (e.g., γ, ε, etc.). Because there are no specific sites where recombination always occurs, the final gene sequence is usually not predictable from the construct.
[0211] As used herein, the term "subject" includes any human or non-human animal. For example, the methods and compositions of the present invention can be used to treat subjects with immune disorders. The term "non-human animal" includes all vertebrates, such as mammals and non-mammals, including non-human primates, sheep, dogs, cows, chickens, amphibians, reptiles, etc.
[0212] With respect to nucleic acids, the term "substantial homology" indicates that two nucleic acids or designated sequences, when optimally aligned and compared, are identical in at least about 80% of the nucleotides, usually at least about 90%-95% of the nucleotides, and more preferably at least about 98%-99.5% of the nucleotides, with appropriate nucleotide insertions or deletions. Alternatively, substantial homology exists when the segments will hybridize under selective hybridization conditions to the complement of the strand.
[0213] The percentage identity between two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = # of identical positions / total # of positions x 100), taking into account the number of gaps and the length of each gap that need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of the percentage identity between two sequences may be performed using a mathematical algorithm, such as that described in the non-limiting examples below.
[0214] The percent identity between two nucleotide sequences may be determined using the GAP program in the GCG software package (available at http: / / www.gcg.com) using the NWSgapdna.CMP matrix and gap weights of 40, 50, 60, 70, or 80, and length weights of 1, 2, 3, 4, 5, or 6. The percent identity between two nucleotide or amino acid sequences may also be determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989)) incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. Furthermore, the percent identity between two amino acid sequences may be determined using the algorithm of Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970)) incorporated into the GAP program of the GCG software package (available at http: / / www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and gap weights of 16, 14, 12, 10, 8, 6, or 4, and length weights of 1, 2, 3, 4, 5, or 6.
[0215] The nucleic acid and protein sequences of the present disclosure may also be used as "query sequences" to conduct searches against public databases, for example, to identify related sequences. Such searches may be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches may be performed with the NBLAST program, score = 100, word length = 12, to obtain nucleotide sequences homologous to the nucleic acid molecules of the present invention. BLAST protein searches may be performed with the XBLAST program, score = 50, word length = 3, to obtain amino acid sequences homologous to the protein molecules of the present invention. To obtain gapped alignments for comparison purposes, Gapped BLAST may be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See http: / / www.ncbi.nlm.nih.gov.
[0216] Nucleic acids may be present in whole cells, cell lysates, or in a partially purified or substantially pure form. Nucleic acids are "isolated" or "substantially pure" when purified from other cellular components or other contaminants, such as other cellular nucleic acids or proteins, by standard techniques, including alkaline / SDS treatment, CsCl banding, column chromatography, agarose gel electrophoresis, and other methods known in the art. See F. Ausubel, et al., ed., Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York (1987).
[0217] The nucleic acid compositions of the present disclosure are often naturally occurring sequences (excluding modified restriction enzyme sites, etc.) from cDNA, genomes, or mixtures thereof, but may be mutated according to standard techniques to obtain gene sequences. For coding sequences, these mutations may have a desired effect on the amino acid sequence. In particular, DNA sequences that are substantially homologous to or derived from naturally occurring V, D, J, constant, switch, and other such sequences described herein are contemplated (where "derived" indicates that the sequence is identical to or modified from another sequence).
[0218] As used herein, the term "tumor microenvironment" (or "cancer microenvironment," abbreviated as TME) refers to the cellular milieu or environment in which a tumor or neoplasm resides, including surrounding blood vessels and non-cancerous cells, including, but not limited to, immune cells, fibroblasts, bone marrow-derived inflammatory cells, and lymphocytes. Signaling molecules and the extracellular matrix also comprise the TME. Tumors and the surrounding microenvironment are closely associated and constantly interact. Tumors can influence the microenvironment by releasing extracellular signals, promoting tumor angiogenesis, and inducing immune tolerance in peripheral tissues. Meanwhile, immune cells in the microenvironment can influence the growth and evolution of tumor cells.
[0219] The term "T cell" refers to a type of white blood cell that can be distinguished from other white blood cells by the presence of a T cell receptor on the cell surface. There are several subsets of T cells, including but not limited to T helper cells (T H cells or CD4 + T cells) and T H 1. T H 2. T H 3. T H 17, T H 9 and T FH cells and their subtypes, including cytotoxic T cells (i.e., T C cells, CD8 + T cells, cytotoxic T lymphocytes, T-killer cells, killer T cells), memory T cells and central memory T cells (T CMcells), effector memory T cells (T EM and T EMRA cells) and resident memory T cells (T RM cells), and their subtypes, including regulatory T cells (T reg cells or suppressor T cells) and CD4 + FOXP3 + T reg cells, CD4 + FOXP3 - T reg cells, Tr1 cells, Th3 cells and T reg 17 cells, natural killer T cells (also known as NKT cells), mucosal-associated invariant T cells (MAITs), and gamma delta T cells (γδ T cells), including Vγ9 / Vδ2 T cells. Any one or more of the T cells mentioned above or not mentioned may be a target cell type for the methods of use of the present invention.
[0220] As used herein, the term "T cell activation" or "T cell activation" refers to the cellular process by which mature T cells, expressing antigen-specific T cell receptors on their surface, recognize their cognate antigen and respond by entering the cell cycle, secreting cytokines or lytic enzymes, and initiating or becoming capable of exerting cellular effector function. Activation of T cells requires at least two signals to become fully activated. The first signal occurs after engagement of the T cell antigen-specific receptor (TCR) with the antigen-major histocompatibility complex (MHC), and the second signal occurs upon subsequent engagement with costimulatory molecules (e.g., CD28). These signals are transduced to the nucleus and result in T cell clonal expansion, upregulation of activation markers on the cell surface, differentiation into effector cells, induction of cytotoxic activity or cytokine secretion, induction of apoptosis, or a combination thereof.
[0221] As used herein, the term "T cell mediated response" refers to, but is not limited to, effector T cells (e.g., CD8 +cells) and helper T cells (e.g., CD4 + The term "T cell-mediated response" refers to any response mediated by T cells, including T cells. T cell-mediated responses include, for example, T cell cytotoxicity and proliferation.
[0222] As used herein, the term "therapeutically effective amount" or "therapeutically effective dose" or similar terms used herein is intended to mean an amount of an agent (e.g., an anti-CD137 antibody or antigen-binding fragment thereof) that elicits a desired biological or medical response (e.g., amelioration of one or more symptoms of cancer).
[0223] As used herein, the terms "treat," "treating," and "treatment" refer to therapeutic or prophylactic measures as described herein. "Treatment" methods employ administering a human antibody of the present disclosure to a subject in need of such treatment, e.g., a subject in need of an enhanced immune response to a particular antigen, or a subject who may ultimately acquire immunity to such a disorder and thereby prevent, cure, delay, reduce the severity of, or ameliorate one or more symptoms of the disorder, or prolong the subject's survival beyond that expected in the absence of such treatment.
[0224] As used herein, the term "unrearranged" or "germline configuration" refers to a configuration in which a V segment has not undergone recombination to become immediately adjacent to a D or J segment.
[0225] As used herein, the term "vector" is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid," which refers to a circular double-stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, in which additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operably linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply "expression vectors"). Generally, the practical form of expression vectors in recombinant DNA techniques is often in the form of a plasmid. As used herein, "plasmid" and "vector" may be used interchangeably, as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (eg, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.
[0226] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this application belongs. Preferred methods and materials are described below, but similar or equivalent methods and materials to those described herein can also be used to carry out or test the disclosed methods and compositions. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.
[0227] Anti-CD137 antibodies and antigen-binding fragments thereof The present disclosure provides antibodies that specifically bind and agonize CD137. In some aspects, the present disclosure provides anti-CD137 agonistic antibodies useful for treating cancer. In some embodiments, the anti-CD137 agonistic antibodies induce cytokine production. In some embodiments, the anti-CD137 agonistic antibodies increase the number of CD8+ T cells in the tumor microenvironment. In some embodiments, the anti-CD137 agonistic antibodies induce protective anti-tumor immunity. The present disclosure further provides anti-CD137 agonistic antibodies that do not substantially increase CD4+ T cell populations and / or CD8+ T cell populations in the spleen or liver upon in vivo administration.
[0228] Human CD137 is a 255-amino acid transmembrane polypeptide (SEQ ID NO: 3; Accession Nos. NM_001561; NP_001552) and a phylogenetically conserved member of the tumor necrosis factor receptor (TNFR) superfamily. CD137 (also known as 4-1BB, TNFR superfamily 9) and its ligand (CD137L) are involved in regulating a wide range of immune activities. CD137 ligand crosslinks its receptor, CD137, expressed on activated T cells, costimulating T cell activity. CD137 is an activation-induced costimulatory molecule. Recent studies have revealed that CD137-mediated anticancer effects are highly dependent on its ability to activate T cells, particularly to induce cytotoxic T lymphocyte (CTL) responses and cytokine production, particularly high levels of IFNγ (Ye et al., (2014) Clin Cancer Res 20(1):44-55). The CD137 ligand is a transmembrane protein on the cell surface that transmits signals into the cell where it is expressed (a phenomenon called "reverse signaling" or "back signaling"). Expression of the CD137 ligand is found on most types of leukocytes and some non-immune cells. In monocytic cells (monocytes, macrophages, and DCs), CD137 ligand signaling induces activation, migration, survival, and differentiation.
[0229] Thus, in some embodiments, an isolated anti-CD137 agonistic antibody, or antigen-binding fragment thereof, described herein binds to and agonizes CD137, allowing or promoting binding of CD137L. In some embodiments, an isolated anti-CD137 agonistic antibody, or antigen-binding fragment thereof, described herein binds to and agonizes CD137. In some embodiments, an anti-CD137 antibody provided by the present disclosure binds to and agonizes CD137 to costimulate T cell activation.
[0230] In some embodiments, the isolated anti-CD137 agonistic antibody, or antigen-binding fragment thereof, described herein has one or more of the following properties or characteristics: a) specifically binds to human CD137; b) binds to human and cynomolgus monkey CD137; and c) Binds to human and mouse CD137.
[0231] In some embodiments, the anti-CD137 agonistic antibodies, or antigen-binding fragments thereof, described herein bind to CD137 and costimulate T cell activity. In some embodiments, the anti-CD137 agonistic antibodies, or antigen-binding fragments thereof, described herein bind to CD137 and induce or enhance T cell activation, cytotoxic T lymphocyte (CTL) responses, T cell proliferation, cytokine production, or a combination thereof. In some embodiments, the anti-CD137 agonistic antibodies, or antigen-binding fragments thereof, described herein bind to CD137 and induce or enhance T cell activation, cytotoxic T lymphocyte (CTL) responses, T cell proliferation, cytokine production, or a combination thereof in the tumor microenvironment. In some embodiments, the anti-CD137 antibodies, or antigen-binding fragments thereof, described herein do not significantly induce or enhance T cell activation and / or T cell proliferation in the liver and / or spleen. In some embodiments, the anti-CD137 antibodies described herein bind to CD137 and induce IFNγ production. In some embodiments, the antibodies provided by the present disclosure bind to CD137 and induce the production of IL-2, TNF-α, IL-13, or a combination thereof.
[0232] In some embodiments, the anti-CD137 antibodies described herein specifically bind to and agonize CD137. In some embodiments, CD137 agonism is measured by determining the concentration of cytokines produced by immune cells. Methods for analyzing cytokine production are known in the art and are utilized in the Examples. In some embodiments, increased cytokine production by immune cells indicates CD137 agonism. In some embodiments, CD137 agonism is measured by analyzing T cell proliferation. In some embodiments, increased T cell proliferation indicates CD137 agonism. In some embodiments, CD137 agonism is measured by measuring the level of cell signaling, either through quantification of phosphorylation of relevant molecules or quantification of expression of a gene reporter following an associated promoter. In some embodiments, increased cell signaling indicates CD137 agonism. In some embodiments, CD137 agonism is measured by measuring tumor volume. In some embodiments, a decrease in tumor volume is indicative of CD137 agonism.
[0233] In some embodiments, the anti-CD137 antibodies described herein induce, increase, or stabilize the oligomerization, multimerization, or other higher order clustering of CD137. In some embodiments, the clustering of CD137 on the cell surface is observed via fluorescence microscopy.
[0234] Provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that binds to and agonizes CD137. In some embodiments, the antibody or antigen-binding fragment thereof has (i) an affinity (K D ), (ii) binds to an epitope of human CD137 described herein, and / or (iii) comprises a heavy chain CDR3 comprising the amino acid sequence DXXXXLXXXXYXYYX (SEQ ID NO: 126).
[0235] Affinity for CD137 In some embodiments, the isolated anti-CD137 agonistic antibody or antigen-binding fragment thereof described herein has an affinity (K D ) binds to human CD137. In some embodiments, the affinity of the anti-CD137 antibody for human CD137 is at least 2-fold (e.g., at least 3, 4, 5, 6, 7, 8, 9, or 10-fold) greater than the affinity of mAb10 for mouse CD137. In some embodiments, the affinity of the anti-CD137 antibody is 500, 450, 400, 350, 300, 250, 200, 250, 200, 175, 150, 125, 110, or 100 nM or less. In some embodiments, the affinity of an anti-CD137 antibody for human CD137 is at least 2-fold (e.g., at least 3, 4, 5, 6, 7, 8, 9, or 10-fold) higher than the affinity of mAb10 for mouse CD137, but is 500, 450, 400, 350, 300, 250, 200, 250, 200, 175, 150, 125, 110, or 100 nM or less. The affinity of an antibody is the strength of binding to a single CD137 polypeptide. In some embodiments, affinity is measured using the equilibrium dissociation constant (K D ) is shown by K D The value is inversely related to the binding affinity of the antibody for the antigen. D The lower the value, the higher the affinity of the antibody for its antigen.
[0236] Methods for determining the affinity of an antibody for its antigen are known in the art. An exemplary method for determining binding affinity employs surface plasmon resonance. Surface plasmon resonance is an optical phenomenon that allows for the analysis of biospecific interactions in real time by detecting changes in protein concentration within a biosensor matrix, for example, using a BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden, and Piscataway, New Jersey). For further details, see Jonsson, U., et al. (1993) Ann. Biol. Clin. 51: 19-26; Jonsson, U., i (1991) Biotechniques 11:620-627; Johnsson, B., et al. (1995) J. Mol. Recognit. 8: 125-131; and Johnsson, B., et al. (1991) Anal. Biochem. 198:268-277.
[0237] In some embodiments, the anti-CD137 antibodies described herein have an affinity (K D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 40-100 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 30-40 nM, 40-50 nM, 50-60 nM, 60-70 nM, 70-80 nM, 80-90 nM, 90-100 nM, 45-55 nM, 55-65 nM, 75-85 nM, 85-95 nM, 45-95 nM, 50-90 nM, 55-85 nM, 60-80 nM, 65-75 nM, 55-75 nM, 40-70 nM, 50-80 nM, or 60-90 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 60-80 nM. DIn some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 60-75 nM. D ) binds to human CD137.
[0238] In some embodiments, the anti-CD137 antibodies described herein have an affinity (K D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 50-80 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 40-70 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 55-75 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 65-75 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 60-80 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 55-85 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 50-90 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 45-95 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 85-95 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 75-85 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 75-85 nM.D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 55-65 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 45-55 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 80-90 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 70-80 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 60-70 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 50-60 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 40-50 nM. D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 30-40 nM. DIn some embodiments, the anti-CD137 antibodies described herein bind to human CD137 at a binding affinity of about 30 nM, about 31 nM, about 32 nM, about 33 nM, about 34 nM, about 35 nM, about 36 nM, about 37 nM, about 38 nM, about 39 nM, about 40 nM, about 41 nM, about 42 nM, about 43 nM, about 44 nM, about 45 nM, about 46 nM, about 47 nM, about 48 nM, about 49 nM, about 50 nM, about 51 nM, about 52 nM, about 53 nM, about 54 nM, about 55 nM, about 56 nM, about 57 nM, about 58 nM, about 59 nM, about 60 nM, about 61 nM, about 62 nM, about 63 nM, about 64 nM, about 65 nM, about 66 nM, about 67 nM, about 68 nM, about 69 nM, about 70 nM, about 71 nM, about 72 nM, about 73 nM, about 74 nM, about 75 nM, about 76 nM, about 77 nM, about 78 nM, about 79 nM, about 80 nM, about 81 nM, about 82 nM, about 83 nM, about 84 nM, about 85 nM, about 86 nM, about 87 nM, about 88 nM, about 89 nM, about 90 nM, about 91 nM, about 92 nM, about 93 nM, about 94 nM, about 95 nM, about 96 nM, about 97 nM, about 98 nM, about 7nM, approximately 48nM, approximately 49nM, approximately 50nM, approximately 51nM, approximately 52nM, approximately 53nM, approximately 54nM, approximately 55nM, approximately 56nM, approximately 57nM, approximately 58 nM, approximately 59nM, approximately 60nM, approximately 61nM, approximately 62nM, approximately 63nM, approximately 64nM, approximately 65nM, approximately 66nM, approximately 67nM, approximately 68nM, approximately 69n M, about 70nM, about 71nM, about 72nM, about 73nM, about 74nM, about 75nM, about 76nM, about 77nM, about 78nM, about 79nM, about 80nM , about 81nM, about 82nM, about 83nM, about 84nM, about 85nM, about 86nM, about 87nM, about 88nM, about 89nM, about 90nM, about 91nM, an affinity (K D ) binds to human CD137.
[0239] In some embodiments, the anti-CD137 antibodies described herein have a mAb of at least 30 nM but less than about 110 nM, at least 31 nM but less than about 109 nM, at least 32 nM but less than about 108 nM, at least 33 nM but less than about 107 nM, at least 34 nM but less than about 106 nM, at least 35 nM but less than about 105 nM, at least 36 nM but less than about 104 nM, at least 37 nM but less than about 103 nM at least 38 nM but less than about 102 nM, at least 39 nM but less than about 101 nM, at least 40 nM but less than about 100 nM, at least 41 nM but less than about 99 nM, at least 42 nM but less than about 98 nM, at least 43 nM but less than about 97 nM, at least 44 nM but less than about 96 nM, at least 45 nM but less than about 95 nM, at least 46 nM but less than about 94 nM, at least 47 nM but less than about 93 nM, at least 48 nM but less than about 92 nM, at least 49 nM but less than about 91 nM, at least 50 nM but less than about 90 nM, at least 51 nM but less than about 89 nM, at least 52 an affinity (K) of at least 53 nM but less than about 87 nM, at least 54 nM but less than about 86 nM, at least 55 nM but less than about 85 nM, at least 56 nM but less than about 84 nM, at least 57 nM but less than about 83 nM, at least 58 nM but less than about 82 nM, at least 59 nM but less than about 81 nM, at least 60 nM but less than about 80 nM, at least 61 nM but less than about 79 nM, at least 62 nM but less than about 78 nM, at least 63 nM but less than about 77 nM, at least 64 nM but less than about 76 nM, or at least 65 nM but less than about 75 nM; D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of at least 40 nM but less than about 100 nM. D ) binds to human CD137.
[0240] In some embodiments, the anti-CD137 antibodies described herein cross-react with CD137 polypeptides from more than one species. In some embodiments, the anti-CD137 antibodies described herein bind to cynomolgus monkey CD137 and human CD137. In some embodiments, the anti-CD137 antibodies described herein bind to mouse CD137 and human CD137. In some embodiments, the anti-CD137 antibodies described herein bind to human CD137, mouse CD137, and cynomolgus monkey CD137.
[0241] CD137 epitope binding In some embodiments, an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137 binds to an epitope on human CD137 that includes one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or all 25) amino acids 111-132 of SEQ ID NO: 3. In some embodiments, an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137 binds to an epitope within amino acids 111-132 of SEQ ID NO: 3. In some aspects, the present disclosure provides an isolated monoclonal antibody or antigen-binding portion thereof that specifically binds to human CD137, wherein the antibody or antigen-binding portion thereof binds to all or a portion of amino acids 111-132 of SEQ ID NO: 3. In some embodiments, an isolated anti-CD137 agonistic antibody, or antigen-binding fragment thereof, described herein binds to an epitope on human CD137 that includes the K114 residue of SEQ ID NO: 3. In some embodiments, an isolated anti-CD137 agonistic antibody, or antigen-binding fragment thereof, described herein binds to an epitope on human CD137 that includes the E111, T113, and K114 residues of SEQ ID NO: 3. In some embodiments, an isolated anti-CD137 agonistic antibody, or antigen-binding fragment thereof, described herein binds to an epitope on human CD137 that includes the E111, T113, K114, N126, and I132 residues of SEQ ID NO: 3. In some embodiments, an isolated anti-CD137 agonistic antibody, or antigen-binding fragment thereof, described herein binds to an epitope on human CD137 that includes the E111, T113, K114, N126, and I132 residues of SEQ ID NO: 3. In some embodiments, the isolated anti-CD137 agonistic antibody, or antigen-binding fragment thereof, described herein binds to an epitope of human CD137 that includes one or more residues E111, T113, K114, N126, I132, and P135 of SEQ ID NO:3.
[0242] In some embodiments, the isolated anti-CD137 agonistic antibody or antigen-binding fragment thereof described herein binds to an epitope of human CD137 comprising a sequence of one or more amino acid residues corresponding to amino acid positions 100-135, 101-135, 102-135, 103-135, 104-135, 105-135, 106-135, 107-135, 108-135, 109-135, 110-135, or 111-135 of SEQ ID NO:3.
[0243] In some embodiments, an isolated anti-CD137 agonistic antibody or antigen-binding fragment thereof described herein binds to an epitope of human CD137 comprising a sequence of one or more amino acid residues corresponding to amino acid positions 111-135 of SEQ ID NO: 3. In some embodiments, the epitope comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acid residues corresponding to amino acids 111-135 of SEQ ID NO: 3.
[0244] In some embodiments, an isolated anti-CD137 agonistic antibody or antigen-binding fragment thereof described herein binds to an epitope of human CD137 within amino acid positions 100-135, 101-135, 102-135, 103-135, 104-135, 105-135, 106-135, 107-135, 108-135, 109-135, 110-135, or 111-135 of SEQ ID NO: 3. In some embodiments, an isolated anti-CD137 agonistic antibody or antigen-binding fragment thereof described herein binds to an epitope of human CD137 within amino acid positions 111-135 of SEQ ID NO: 3. In some embodiments, the epitope comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acid residues corresponding to amino acids 111 to 135 of SEQ ID NO:3.
[0245] In some embodiments, the isolated anti-CD137 agonistic antibody, or antigen-binding fragment thereof, described herein binds to an epitope of human CD137 that includes ELTK (corresponding to amino acid residues 111-114 of SEQ ID NO: 3). In some embodiments, amino acid residue L112 can be another amino acid residue.
[0246] In some embodiments, the epitope is a non-linear epitope. In some embodiments, mutation of amino acid residue K114 abolishes binding of the isolated anti-CD137 agonistic antibody described herein, or antigen-binding fragment thereof, to human CD137.
[0247] In some embodiments, an isolated anti-CD137 agonistic antibody or antigen-binding fragment thereof described herein binds to an epitope of human CD137 comprising a sequence of one or more amino acid residues corresponding to amino acid positions 111-135 of SEQ ID NO: 3, wherein the epitope includes at least amino acid K114, and the antibody or antigen-binding portion thereof binds to mouse CD137 but not rat CD137. In some embodiments, the epitope is a non-linear epitope. In some embodiments, the antibody or antigen-binding portion thereof binds to mouse CD137 and cynomolgus monkey CD137 but not rat CD137. In some embodiments, the binding of an isolated anti-CD137 agonistic antibody or antigen-binding fragment thereof described herein to human, mouse, rat, and cynomolgus monkey CD137 is determined by surface plasmon resonance (SPR).
[0248] In some embodiments, the antibody or antigen-binding portion thereof binds to mouse, cynomolgus monkey, or human CD137 with an affinity that is at least 10, 20, 30, 40, 50, 100, 200, 500, or 1000 times greater than the affinity of the antibody for rat CD137. In some embodiments, the antibody or antigen-binding portion thereof binds to mouse, cynomolgus monkey, or human CD137 with an affinity that is at least 10, 20, 30, 40, 50, 100, 200, 500, or 1000 times greater than the affinity of the antibody for rat CD137 that does not contain the lysine at position 114 relative to human CD137 of SEQ ID NO:3.
[0249] In some embodiments, an isolated anti-CD137 agonistic antibody, or antigen-binding fragment thereof, described herein binds to an epitope on human CD137 and competes with mAb1 for binding to an epitope on human CD137. In some embodiments, an isolated anti-CD137 agonistic antibody, or antigen-binding fragment thereof, described herein binds to and agonizes CD137. In some embodiments, an anti-CD137 antibody provided by the present disclosure binds to and agonizes CD137 to costimulate T cell activation.
[0250] The present disclosure provides antibodies that compete for binding to an epitope on CD137, including all or a portion of the epitope recognized by one or more particular reference antibodies (e.g., mAb1) described herein. In some embodiments, the anti-CD137 antibody binds to an epitope on human CD137 and competes with the reference antibody (e.g., mAb1) for binding to the epitope on human CD137, wherein the antibody or antigen-binding fragment thereof is at least 1x10 -6 The equilibrium dissociation constant K DIn some embodiments, the anti-CD137 antibody binds to an epitope on CD137, where one or more mutations in the epitope inhibit, reduce, or prevent binding to both the antibody and a reference antibody (e.g., mAb1). In some embodiments, the reference antibody is the mAb1 antibody described herein. In some embodiments, the reference antibody is any one of the antibodies presented in Table 3 or Table 4.
[0251] Thus, anti-CD137 antibodies provided by the present disclosure may be evaluated via x-ray crystallography of a crystal structure comprising the antibody, or a fragment or portion thereof, bound to CD 137. In some embodiments, the epitope bound by an antibody provided by the present disclosure is identified by determining residues on the human CD137 antigen that reside or are located within 4 angstroms (Å) of the paratope residues of the antibody, e.g., mAb1.
[0252] In some embodiments, the epitope bound by an anti-CD137 antibody described herein is at least 3 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is at least 4 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is at least 5 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is at least 6 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is at least 7 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is at least 8 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is at least 9 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is at least 10 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is at least 12 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is at least 3 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is at least 13 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is at least 14 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is at least 15 amino acid residues.
[0253] In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 25 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 24 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 23 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 22 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 21 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 20 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 19 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 18 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 17 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 16 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 15 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 14 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 13 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 12 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 11 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 10 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 9 amino acid residues.In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 8 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 7 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 6 amino acid residues. In some embodiments, the epitope bound by an anti-CD137 antibody described herein is fewer than 5 amino acid residues.
[0254] In some embodiments, the anti-CD137 antibodies described herein bind to an epitope with fewer than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, or 5 amino acids and include amino acid residue K114 of SEQ ID NO:3.
[0255] Variable region In some embodiments, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof comprising the heavy and light chain variable sequences set forth in Tables 3 and 4.
[0256] In some embodiments, the anti-CD137 antibodies described herein comprise heavy and light chain CDRs selected from the group consisting of: (a) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (b) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 70, 79 and 90, respectively; (c) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 71, 80 and 91, respectively; (d) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 72, 81 and 92, respectively; (e) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 73, 82 and 91, respectively; (f) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 74, 83 and 93, respectively; (g) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 75, 84 and 91, respectively; (h) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 74, 85 and 94, respectively; (i) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 76, 86 and 95, respectively; (j) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 77, 87 and 93, respectively; (k) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 88 and 90, respectively; (l) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 49, 57 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (m) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 49, 58 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (n) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 49, 59 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (o) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 49, 60 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (p) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 50, 61 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (q) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 50, 58 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (r) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 51, 62 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (s) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 52, 63 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (t) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 50, 64 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (u) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 50, 65 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively; (v) heavy chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 51, 108, and 68, respectively, and light chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 69, 78, and 89, respectively; (w) heavy chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 107, 56, and 68, respectively, and light chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 69, 78, and 89, respectively; and (x) Heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 109, 110 and 92, respectively.
[0257] In some embodiments, the anti-CD137 antibodies described herein comprise a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 101, and 103, and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, and 105.
[0258] In some embodiments, the anti-CD137 antibodies described herein comprise heavy and light chain CDRs, wherein the heavy chain CDR3 comprises the amino acid sequence set forth in SEQ ID NO:68.
[0259] In some embodiments, the anti-CD137 antibodies described herein comprise heavy and light chain variable regions comprising an amino acid sequence selected from the group consisting of: (a) SEQ ID NOs: 4 and 6, respectively; (b) SEQ ID NOs: 4 and 28, respectively; (c) SEQ ID NOs: 4 and 30, respectively; (d) SEQ ID NOs: 4 and 32, respectively; (e) SEQ ID NOs: 4 and 34, respectively; (f) SEQ ID NOs: 4 and 36, respectively; (g) SEQ ID NOs: 4 and 38, respectively; (h) SEQ ID NOs: 4 and 40, respectively; (i) SEQ ID NOs: 4 and 42, respectively; (j) SEQ ID NOs: 4 and 44, respectively; (k) SEQ ID NOs: 4 and 46, respectively; (l) SEQ ID NOs: 8 and 6, respectively; (m) SEQ ID NOs: 10 and 6, respectively; (n) SEQ ID NOs: 12 and 6, respectively; (o) SEQ ID NOs: 14 and 6, respectively; (p) SEQ ID NOs: 16 and 6, respectively; (q) SEQ ID NOs: 18 and 6, respectively; (r) SEQ ID NOs: 20 and 6, respectively; (s) SEQ ID NOs: 22 and 6, respectively; (t) SEQ ID NOs: 24 and 6, respectively; (u) SEQ ID NOs: 26 and 6, respectively; (v) SEQ ID NOs: 101 and 6, respectively; (w) SEQ ID NOs: 103 and 6, respectively; and (x) SEQ ID NOs: 4 and 105, respectively.
[0260] In some embodiments, the anti-CD137 antibodies described herein comprise a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 101, and 103, and the light chain variable region comprises an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, and 105.
[0261] In some embodiments, the anti-CD137 antibodies described herein comprise heavy and light chain variable regions comprising an amino acid sequence that is at least 90% identical to an amino acid sequence selected from the group consisting of: (a) SEQ ID NOs: 4 and 6, respectively; (b) SEQ ID NOs: 4 and 28, respectively; (c) SEQ ID NOs: 4 and 30, respectively; (d) SEQ ID NOs: 4 and 32, respectively; (e) SEQ ID NOs: 4 and 34, respectively; (f) SEQ ID NOs: 4 and 36, respectively; (g) SEQ ID NOs: 4 and 38, respectively; (h) SEQ ID NOs: 4 and 40, respectively; (i) SEQ ID NOs: 4 and 42, respectively; (j) SEQ ID NOs: 4 and 44, respectively; (k) SEQ ID NOs: 4 and 46, respectively; (l) SEQ ID NOs: 8 and 6, respectively; (m) SEQ ID NOs: 10 and 6, respectively; (n) SEQ ID NOs: 12 and 6, respectively; (o) SEQ ID NOs: 14 and 6, respectively; (p) SEQ ID NOs: 16 and 6, respectively; (q) SEQ ID NOs: 18 and 6, respectively; (r) SEQ ID NOs: 20 and 6, respectively; (s) SEQ ID NOs: 22 and 6, respectively; (t) SEQ ID NOs: 24 and 6, respectively; (u) SEQ ID NOs: 26 and 6, respectively; (v) SEQ ID NOs: 101 and 6, respectively; (w) SEQ ID NOs: 103 and 6, respectively; and (x) SEQ ID NOs: 4 and 105, respectively.
[0262] In some embodiments, provided herein is an antibody that specifically binds to human CD137, comprising heavy and light chain variable regions encoded by a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 5 and 7, respectively; (b) SEQ ID NOs: 5 and 29, respectively; (c) SEQ ID NOs: 5 and 31, respectively; (d) SEQ ID NOs: 5 and 33, respectively; (e) SEQ ID NOs: 5 and 35, respectively; (f) SEQ ID NOs: 5 and 37, respectively; (g) SEQ ID NOs: 5 and 39, respectively; (h) SEQ ID NOs: 5 and 41, respectively; (i) SEQ ID NOs: 5 and 43, respectively; (j) SEQ ID NOs: 5 and 45, respectively; (k) SEQ ID NOs: 5 and 47, respectively; (l) SEQ ID NOs: 9 and 7, respectively; (m) SEQ ID NOs: 11 and 7, respectively; (n) SEQ ID NOs: 13 and 7, respectively; (o) SEQ ID NOs: 15 and 7, respectively; (p) SEQ ID NOs: 17 and 7, respectively; (q) SEQ ID NOs: 19 and 7, respectively; (r) SEQ ID NOs: 21 and 7, respectively; (s) SEQ ID NOs: 23 and 7, respectively; (t) SEQ ID NOs: 25 and 7, respectively; (u) SEQ ID NOs: 27 and 7, respectively; (v) SEQ ID NOs: 102 and 7, respectively; (w) SEQ ID NOs: 104 and 7, respectively; and (x) SEQ ID NOs: 5 and 106, respectively.
[0263] In some embodiments, provided herein is an antibody that specifically binds to human CD137, comprising heavy and light chain variable regions encoded by a nucleotide sequence having at least 90% identity to a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 5 and 7, respectively; (b) SEQ ID NOs: 5 and 29, respectively; (c) SEQ ID NOs: 5 and 31, respectively; (d) SEQ ID NOs: 5 and 33, respectively; (e) SEQ ID NOs: 5 and 35, respectively; (f) SEQ ID NOs: 5 and 37, respectively; (g) SEQ ID NOs: 5 and 39, respectively; (h) SEQ ID NOs: 5 and 41, respectively; (i) SEQ ID NOs: 5 and 43, respectively; (j) SEQ ID NOs: 5 and 45, respectively; (k) SEQ ID NOs: 5 and 47, respectively; (l) SEQ ID NOs: 9 and 7, respectively; (m) SEQ ID NOs: 11 and 7, respectively; (n) SEQ ID NOs: 13 and 7, respectively; (o) SEQ ID NOs: 15 and 7, respectively; (p) SEQ ID NOs: 17 and 7, respectively; (q) SEQ ID NOs: 19 and 7, respectively; (r) SEQ ID NOs: 21 and 7, respectively; (s) SEQ ID NOs: 23 and 7, respectively; (t) SEQ ID NOs: 25 and 7, respectively; (u) SEQ ID NOs: 27 and 7, respectively; (v) SEQ ID NOs: 102 and 7, respectively; (w) SEQ ID NOs: 104 and 7, respectively; and (x) SEQ ID NOs: 5 and 106, respectively.
[0264] In some embodiments, the anti-CD137 antibodies described herein comprise a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOs: 5, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 102, and 104, and the light chain variable region is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOs: 7, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, and 106.
[0265] In some embodiments, the anti-CD137 antibodies described herein comprise a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region is encoded by a nucleotide sequence having at least 90% identity to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 5, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 102, and 104, and the light chain variable region is encoded by a nucleotide sequence having at least 90% identity to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 7, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, and 106.
[0266] In some embodiments, provided herein are anti-CD137 antibodies that specifically bind to human CD137 and comprise a heavy chain CDR3 having the amino acid sequence DXXXXLXXXXYXYYX (SEQ ID NO: 126), where X is any amino acid. In some embodiments, X is any amino acid except alanine. In some embodiments, mutation of residues D95, L100, Y100E, Y100G, and / or Y100H of SEQ ID NO: 126 results in loss of binding to human CD137.
[0267] In some embodiments, provided herein are anti-CD137 antibodies that specifically bind to human CD137 and comprise a heavy chain CDR3 having the amino acid sequence DXPFXLDXXYYYYYX (SEQ ID NO: 127), where X is any amino acid. In some embodiments, mutation of residues F98, D100A, Y100D, and / or Y100F, and / or Y100H of SEQ ID NO: 126 to alanine results in abolished binding to human CD137. In some embodiments, mutation of residues F98, D100A, Y100D, and / or Y100F, and / or Y100H of SEQ ID NO: 126 to any residue other than alanine results in increased binding to human CD137.
[0268] In some embodiments, the amino acid sequence DX1X2X3X4LX5X6X7X8YX9YYX described herein specifically binds to human CD137. 10(SEQ ID NO: 128), wherein X1 is any amino acid, wherein X2 is a nonpolar amino acid, wherein X3 is a nonpolar amino acid, wherein X4 is any amino acid, wherein X5 is a polar amino acid, wherein X6 is any amino acid, wherein X7 is any amino acid, wherein X8 is a polar amino acid, wherein X9 is a polar amino acid, and wherein X 10 is any amino acid. In some embodiments, X2 is proline, X3 is phenylalanine or tryptophan, X5 is aspartic acid or glutamic acid, X8 is tyrosine, and X9 is tyrosine.
[0269] The role of amino acid residues within the heavy chain CDR3 of an antibody or antigen-binding portion thereof in binding to a particular target (e.g., CD137) can be determined by methods known to those skilled in the art. In some embodiments, an initial analysis using alanine scanning is completed to determine residues important for antigen binding. As described herein, alanine scanning is a technique used to determine the contribution of specific wild-type residues to the stability or function (e.g., binding affinity) of a given protein or polypeptide. This technique involves substituting alanine residues for wild-type residues in a polypeptide, then evaluating the stability or function (e.g., binding affinity) of the alanine-substituted derivative or mutant polypeptide and comparing it with the wild-type polypeptide. In some embodiments, residues identified as not important are further evaluated for modulating antibody binding to the antigen (e.g., increasing or decreasing binding). A non-limiting example of such an analysis is deep mutational scanning. This method allows for the evaluation of a large number of mutations. In some embodiments, each amino acid residue in the heavy chain CDR3 is mutated to each amino acid residue (except alanine) and binding is assessed. Other methods for analyzing the effects of amino acid residue mutations are known in the art. In some embodiments, these methods are used to assess the role of all residues in the heavy and light chain CDRs in binding to human CD137.
[0270] Exemplary CD137-Binding Antibodies In some embodiments, the anti-CD137 antibodies described herein have an affinity (K D In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 40 to 100 nM (e.g., about 40 nM to about 100 nM). D) binds to human CD137. In some embodiments, the anti-CD137 antibodies described herein bind to an epitope on human CD137 described above (e.g., comprising K114). In some embodiments, the anti-CD137 antibodies described herein comprise a heavy chain CDR3 comprising the amino acid sequence DXXXXLXXXXYXYYX (SEQ ID NO: 126). In some embodiments, the anti-CD137 antibodies described herein bind to an epitope on human CD137 with an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM). D ) and binds to an epitope on human CD137 described above (e.g., including K114). In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM). D ) and comprises a heavy chain CDR3 comprising the amino acid sequence DXXXXLXXXXYXYYX (SEQ ID NO: 126). In some embodiments, the anti-CD137 antibodies described herein bind to the epitope on human CD137 described above (e.g., comprising K114) and comprise ... D ), binds to human CD137 at the CDR3 position described above (including, for example, K114), and comprises a heavy chain CDR3 comprising the amino acid sequence DXXXXLXXXXYXYYX (SEQ ID NO: 126).
[0271] In some embodiments, the anti-CD137 antibody (i) an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); D ) binds to human CD137; and (ii) amino acid sequence DX1X2X3X4LX5X6X7X8YX9YYX 10wherein X1 is any amino acid, wherein X2 is a nonpolar amino acid, wherein X3 is a nonpolar amino acid, wherein X4 is any amino acid, wherein X5 is a polar amino acid, wherein X6 is any amino acid, wherein X7 is any amino acid, wherein X8 is a polar amino acid, wherein X9 is a polar amino acid, and wherein X 10 is any amino acid.
[0272] In some embodiments, the anti-CD137 antibody (i) an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); D ) binds to human CD137; and (ii) binds to an epitope on human CD137 that includes one or more of residues E111, T113, K114, N126, I132 and P135 of SEQ ID NO:3.
[0273] In some embodiments, the anti-CD137 antibody (i) an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); D ) binds to human CD137; (ii) binds to an epitope on human CD137 that includes one or more of residues E111, T113, K114, N126, I132 and P135 of SEQ ID NO:3. (iii) a heavy chain CDR3 comprising the amino acid sequence DXXXXLXXXXYXYYX, where X is any amino acid; or (iv) A combination thereof.
[0274] In some embodiments, the anti-CD137 antibody (i) an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); D ) binds to human CD137; (ii) binds to an epitope on human CD137 that includes one or more of residues E111, T113, K114, N126, I132 and P135 of SEQ ID NO:3. (iii) Amino acid sequence DX1X2X3X4LX5X6X7X8YX9YYX 10 wherein X1 is any amino acid, wherein X2 is a nonpolar amino acid, wherein X3 is a nonpolar amino acid, wherein X4 is any amino acid, wherein X5 is a polar amino acid, wherein X6 is any amino acid, wherein X7 is any amino acid, wherein X8 is a polar amino acid, wherein X9 is a polar amino acid, and wherein X 10 is any amino acid; or (iv) A combination thereof.
[0275] In some embodiments, the anti-CD137 antibody (i) an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); D ) binds to human CD137; (ii) specifically binds to an epitope on human CD137 that includes one or more of residues E111, T113, K114, N126, I132, and P135 of SEQ ID NO: 3; and (iii) a heavy chain CDR3 comprising the amino acid sequence DXXXXLXXXXYXYYX, where X is any amino acid.
[0276] In some embodiments, the anti-CD137 antibody (i) an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); D ) binds to human CD137; (ii) binds to an epitope on human CD137 that includes one or more of residues E111, T113, K114, N126, I132, and P135 of SEQ ID NO: 3; and (iii) Amino acid sequence DX1X2X3X4LX5X6X7X8YX9YYX 10wherein X1 is any amino acid, wherein X2 is a nonpolar amino acid, wherein X3 is a nonpolar amino acid, wherein X4 is any amino acid, wherein X5 is a polar amino acid, wherein X6 is any amino acid, wherein X7 is any amino acid, wherein X8 is a polar amino acid, wherein X9 is a polar amino acid, and wherein X 10 is any amino acid.
[0277] In some embodiments, the anti-CD137 antibody (i) an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); D ) binds to human CD137; and (ii) binds to an epitope comprising a sequence of one or more amino acid residues corresponding to amino acids 111 to 135 of SEQ ID NO:3.
[0278] In some embodiments, the anti-CD137 antibody (i) an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); D ) binds to human CD137; (ii) binds to an epitope comprising a sequence of one or more amino acid residues corresponding to amino acids 111 to 135 of SEQ ID NO:3. (iii) a heavy chain CDR3 comprising the amino acid sequence DXXXXLXXXXYXYYX, where X is any amino acid; or (iv) A combination thereof.
[0279] In some embodiments, the anti-CD137 antibody (i) an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); D ) binds to human CD137; (ii) binds to an epitope comprising a sequence of one or more amino acid residues corresponding to amino acids 111 to 135 of SEQ ID NO:3. (iii) Amino acid sequence DX1X2X3X4LX5X6X7X8YX9YYX 10wherein X1 is any amino acid, wherein X2 is a nonpolar amino acid, wherein X3 is a nonpolar amino acid, wherein X4 is any amino acid, wherein X5 is a polar amino acid, wherein X6 is any amino acid, wherein X7 is any amino acid, wherein X8 is a polar amino acid, wherein X9 is a polar amino acid, and wherein X 10 is any amino acid; or (iv) A combination thereof.
[0280] In some embodiments, the anti-CD137 antibody (i) an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); D ) binds to human CD137; (ii) binds to an epitope comprising a sequence of one or more amino acid residues corresponding to amino acids 111 to 135 of SEQ ID NO: 3; and (iii) a heavy chain CDR3 comprising the amino acid sequence DXXXXLXXXXYXYYX, where X is any amino acid.
[0281] In some embodiments, the anti-CD137 antibody (i) an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); D ) binds to human CD137; (ii) binds to an epitope comprising a sequence of one or more amino acid residues corresponding to amino acids 111 to 135 of SEQ ID NO: 3; and (iii) Amino acid sequence DX1X2X3X4LX5X6X7X8YX9YYX 10 wherein X1 is any amino acid, wherein X2 is a nonpolar amino acid, wherein X3 is a nonpolar amino acid, wherein X4 is any amino acid, wherein X5 is a polar amino acid, wherein X6 is any amino acid, wherein X7 is any amino acid, wherein X8 is a polar amino acid, wherein X9 is a polar amino acid, and wherein X 10 is any amino acid.
[0282] In some embodiments, the anti-CD137 antibody (i) binds to human CD137 with an affinity of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); and (ii) binds to an epitope containing ELTK (corresponding to amino acid residues 111 to 114 of SEQ ID NO: 3).
[0283] In some embodiments, the anti-CD137 antibody (i) an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); D ) binds to human CD137; (ii) binds to an epitope containing ELTK (corresponding to amino acid residues 111 to 114 of SEQ ID NO: 3); (iii) a heavy chain CDR3 comprising the amino acid sequence DXXXXLXXXXYXYYX, where X is any amino acid; or (iv) A combination thereof.
[0284] In some embodiments, the anti-CD137 antibody (i) an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); D ) binds to human CD137; (ii) binds to an epitope containing ELTK (corresponding to amino acid residues 111 to 114 of SEQ ID NO: 3); (iii) Amino acid sequence DX1X2X3X4LX5X6X7X8YX9YYX 10 wherein X1 is any amino acid, wherein X2 is a nonpolar amino acid, wherein X3 is a nonpolar amino acid, wherein X4 is any amino acid, wherein X5 is a polar amino acid, wherein X6 is any amino acid, wherein X7 is any amino acid, wherein X8 is a polar amino acid, wherein X9 is a polar amino acid, and wherein X 10 is any amino acid; or (iv) A combination thereof.
[0285] In some embodiments, the anti-CD137 antibody (i) an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); D ) binds to human CD137; (ii) binds to an epitope containing ELTK (corresponding to amino acid residues 111 to 114 of SEQ ID NO: 3); and (iii) a heavy chain CDR3 comprising the amino acid sequence DXXXXLXXXXYXYYX, where X is any amino acid.
[0286] In some embodiments, the anti-CD137 antibody (i) an affinity (K) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM); D ) binds to human CD137; (ii) binds to an epitope containing ELTK (corresponding to amino acid residues 111 to 114 of SEQ ID NO: 3); and (iii) Amino acid sequence DX1X2X3X4LX5X6X7X8YX9YYX 10 wherein X1 is any amino acid, wherein X2 is a nonpolar amino acid, wherein X3 is a nonpolar amino acid, wherein X4 is any amino acid, wherein X5 is a polar amino acid, wherein X6 is any amino acid, wherein X7 is any amino acid, wherein X8 is a polar amino acid, wherein X9 is a polar amino acid, and wherein X 10 is any amino acid.
[0287] In some embodiments, the above-mentioned anti-CD137 antibodies comprise heavy and light chain CDRs selected from the group consisting of: (a) heavy chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 48, 56, and 68, respectively, and light chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 69, 78, and 89, respectively; and (b) Heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 51, 108 and 68, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 69, 78 and 89, respectively.
[0288] In some embodiments, the anti-CD137 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 4 and 101, and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 6.
[0289] In some embodiments, the anti-CD137 antibody comprises heavy and light chain variable regions comprising an amino acid sequence selected from the group consisting of: (a) SEQ ID NOs: 4 and 6, respectively; and (b) SEQ ID NOs: 101 and 6, respectively.
[0290] In some embodiments, the anti-CD137 antibody comprises heavy and light chain variable regions comprising an amino acid sequence selected from the group consisting of: (a) SEQ ID NOs: 4 and 6, respectively; (b) SEQ ID NOs: 101 and 6, respectively; and (c) SEQ ID NOs: 26 and 6, respectively.
[0291] In some embodiments, the anti-CD137 antibody comprises heavy and light chain variable regions encoded by a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 5 and 7, respectively; and (b) SEQ ID NOs: 102 and 7, respectively.
[0292] In some embodiments, the anti-CD137 antibody comprises heavy and light chain variable regions encoded by a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 5 and 7, respectively; (b) SEQ ID NOs: 102 and 7, respectively; and (c) SEQ ID NOs: 27 and 7, respectively.
[0293] In some embodiments, the anti-CD137 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 4 and 101, and wherein the light chain variable region comprises an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 6.
[0294] In some embodiments, the anti-CD137 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 26, and 101, and wherein the light chain variable region comprises an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 6.
[0295] In some embodiments, the anti-CD137 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region is encoded by a nucleotide sequence that is at least 90% identical to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 5 and 102, and wherein the light chain variable region is encoded by a nucleotide sequence that is at least 90% identical to the nucleotide sequence of SEQ ID NO: 7.
[0296] In some embodiments, the anti-CD137 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region is encoded by a nucleotide sequence that is at least 90% identical to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 5, 27, and 102, and wherein the light chain variable region is encoded by a nucleotide sequence that is at least 90% identical to the nucleotide sequence of SEQ ID NO: 7.
[0297] In some embodiments, the anti-CD137 antibody comprises heavy and light chain variable regions comprising amino acid sequences that are at least 90% identical to an amino acid sequence selected from the group consisting of: (a) SEQ ID NOs: 4 and 6, respectively; and (b) SEQ ID NOs: 101 and 6, respectively.
[0298] In some embodiments, the anti-CD137 antibody comprises heavy and light chain variable regions comprising amino acid sequences that are at least 90% identical to an amino acid sequence selected from the group consisting of: (a) SEQ ID NOs: 4 and 6, respectively; (b) SEQ ID NOs: 101 and 6, respectively; and (c) SEQ ID NOs: 26 and 6, respectively.
[0299] In some embodiments, the anti-CD137 antibody comprises heavy and light chain variable regions encoded by a nucleotide sequence that is at least 90% identical to a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 5 and 7, respectively; and (b) SEQ ID NOs: 102 and 7, respectively.
[0300] In some embodiments, the anti-CD137 antibody comprises heavy and light chain variable regions encoded by a nucleotide sequence that is at least 90% identical to a nucleotide sequence selected from the group consisting of: (a) SEQ ID NOs: 5 and 7, respectively; (b) SEQ ID NOs: 102 and 7, respectively; and (c) SEQ ID NOs: 27 and 7, respectively.
[0301] In some embodiments, the anti-CD137 antibodies described herein have at least the functional characteristics of mAb1 (i.e., an antibody comprising the heavy and light chain variable sequences of SEQ ID NOs: 4 and 6, respectively), mab8 (i.e., an antibody comprising the heavy and light chain variable sequences of SEQ ID NOs: 101 and 6, respectively), or mAb10 (i.e., an antibody comprising the heavy and light chain variable sequences of SEQ ID NOs: 26 and 6, respectively). In some embodiments, the functional characteristics of the antibodies described herein include, but are not limited to, the following: induction or enhancement of CD137 dimerization; induction or enhancement of CD137 multimerization; induction or enhancement of CD137-mediated T cell activation; induction or enhancement of CD137-mediated cytotoxic T cell responses; induction or enhancement of CD137-mediated T cell proliferation; induction or enhancement of CD137-mediated cytokine production; lack of induction or enhancement of intrahepatic and / or intrasplenic T cell activation and / or T cell proliferation; and reduction or inhibition of tumor growth.
[0302] In some embodiments, the anti-CD137 antibodies described herein have an equilibrium dissociation constant K at least equivalent to that of mAb1 (i.e., an antibody comprising the heavy and light chain variable sequences of SEQ ID NOs: 4 and 6, respectively), mab8 (i.e., an antibody comprising the heavy and light chain variable sequences of SEQ ID NOs: 101 and 6, respectively), or mAb10 (i.e., an antibody comprising the heavy and light chain variable sequences of SEQ ID NOs: 26 and 6, respectively). D It binds to human CD137.
[0303] In some embodiments, the anti-CD137 antibodies described herein comprise a human IgG1 heavy chain constant region or a human IgG4 heavy chain constant region. In some embodiments, the anti-CD137 antibodies described herein comprise a human wild-type IgG1 heavy chain constant region or a human wild-type IgG4 heavy chain constant region. In some embodiments, the anti-CD137 antibodies described herein comprise a human wild-type IgG1 heavy chain constant region set forth in SEQ ID NO: 1. In some embodiments, the anti-CD137 antibodies described herein comprise a mutant IgG1 heavy chain constant region or a mutant IgG4 heavy chain constant region. In some embodiments, the anti-CD137 antibodies described herein comprise a mutant IgG4 heavy chain constant region, wherein the mutant IgG4 heavy chain constant region comprises an amino acid substitution at residue Ser228. In some embodiments, the amino acid substitution at Ser228 is S228P. In some embodiments, the anti-CD137 antibodies described herein comprise an IgG4 heavy chain constant region, wherein the C-terminal lysine residue has been removed. In some embodiments, the anti-CD137 antibodies described herein comprise an IgG4 heavy chain constant region with the C-terminal lysine residue removed and comprising a S228P amino acid substitution, hi some embodiments, the anti-CD137 antibodies described herein comprise the IgG4 heavy chain constant region set forth in SEQ ID NO:2.
[0304] In some embodiments, the anti-CD137 antibodies described herein comprise heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 129 and 133, respectively.
[0305] In some embodiments, the anti-CD137 antibodies described herein comprise heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 130 and 133, respectively.
[0306] In some embodiments, the anti-CD137 antibodies described herein comprise heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 131 and 133, respectively.
[0307] In some embodiments, the anti-CD137 antibodies described herein comprise heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs: 132 and 133, respectively.
[0308] In some embodiments, the anti-CD137 antibodies described herein comprise heavy and light chains comprising amino acid sequences at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NOs: 129 and 133, respectively. In some embodiments, the anti-CD137 antibodies described herein comprise heavy and light chains comprising amino acid sequences at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NOs: 130 and 133, respectively. In some embodiments, the anti-CD137 antibodies described herein comprise heavy and light chains comprising amino acid sequences at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NOs: 131 and 133, respectively. In some embodiments, the anti-CD137 antibodies described herein comprise heavy and light chains comprising amino acid sequences having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to SEQ ID NOs: 132 and 133, respectively.
[0309] Characterization and function of CD137-binding antibodies I. Affinity In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (KD) of about 40-100 nM (e.g., about 40 nM to about 100 nM) as determined by antigen binding assays. In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (KD) of about 30-100 nM (e.g., about 30 nM to about 100 nM) as determined by antigen binding assays. In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (KD) of about 45-95 nM, 50-90 nM, 55-85 nM, 60-80 nM, 65-75 nM, 55-75 nM, 40-70 nM, 50-80 nM, or 60-90 nM as determined by antigen binding assays.
[0310] In some embodiments, the antigen binding assay determines the binding affinity of an anti-CD137 antibody to a CD137 polypeptide. In some embodiments, the antigen binding assay is surface plasmon resonance. Thus, in some embodiments, an anti-CD137 antibody described herein binds to human CD137 with an affinity (KD) of about 40 to 100 nM (e.g., about 40 nM to about 100 nM), as determined using surface plasmon resonance. In some embodiments, an anti-CD137 antibody described herein binds to human CD137 with an affinity (KD) of about 30 to 100 nM (e.g., about 30 nM to about 100 nM), as determined using surface plasmon resonance. In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (KD) of about 45-95 nM, 50-90 nM, 55-85 nM, 60-80 nM, 65-75 nM, 55-75 nM, 40-70 nM, 50-80 nM, or 60-90 nM, as determined using surface plasmon resonance.
[0311] The term "surface plasmon resonance" includes an optical phenomenon that allows for the analysis of biospecific interactions in real time by detecting changes in protein concentration within a biosensor matrix, for example, using the BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden, and Piscataway, New Jersey). For details, see Jonsson, U., et al. (1993) Ann. Biol. Clin. 51:19-26; Jonsson, U., et al. (1991) Biotechniques 11:620-627; Johnsson, B., et al. (1995) J. Mol. Recognit. 8:125-131; and Johnson, B., et al. (1991) Anal. Biochem. 198:268-277. In some embodiments, the antigen binding assay is biolayer interferometry (BLI). Thus, in some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (KD) of about 40-100 nM (e.g., about 40 nM to about 100 nM), as determined using bio-layer interferometry. In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (KD) of about 30-100 nM (e.g., about 30 nM to about 100 nM), as determined using bio-layer interferometry. In some embodiments, the anti-CD137 antibodies described herein bind to human CD137 with an affinity (KD) of about 45-95 nM, 50-90 nM, 55-85 nM, 60-80 nM, 65-75 nM, 55-75 nM, 40-70 nM, 50-80 nM, or 60-90 nM, as determined using bio-layer interferometry.
[0312] The term "biolayer interferometry" or "BLI" includes an optical phenomenon that allows for the measurement of subnanometer changes in the thickness of the optical layer of a detection surface. In some embodiments, biomolecules bind to the sensor surface, causing a change in the thickness of the optical layer. The magnitude of the change in thickness of the optical layer is proportional to the mass or molecular weight of the bound molecule. In some embodiments, CD137 is immobilized on the sensor surface and antibody binding is measured. In this case, binding causes a change in molecular weight, producing a corresponding change in the thickness of the optical layer. In some embodiments, BLI is performed on an OCTET system (ForteBio).
[0313] II. Immune cell effects In some embodiments, the anti-CD137 antibodies described herein induce or enhance cytokine production by immune cells as determined by a cytokine assay. In some embodiments, the cytokine assay determines the amount of at least one cytokine secreted by immune cells contacted with the anti-CD137 antibody, where an increase in the amount of the at least one cytokine indicates induction or enhancement of cytokine production by the anti-CD137 antibody. In some embodiments, the increase in cytokine production is at least 1-fold, 2-fold, 3-fold, 4-fold, or 5-fold greater than a control antibody (e.g., an antibody that does not bind to CD137 and does not induce cytokine production).
[0314] In some embodiments, the anti-CD137 antibodies described herein induce or enhance cytokine production by immune cells as determined by a cytokine assay, wherein the cytokine assay comprises the steps of: (i) contacting immune cells with an anti-CD137 antibody; and (ii) determining the amount of at least one cytokine produced by the immune cells; In this case, an increase in the amount of the at least one cytokine indicates that the anti-CD137 antibody induced or enhanced cytokine production by the immune cell.
[0315] In some embodiments, the anti-CD137 antibodies described herein induce or enhance cytokine production by immune cells as determined by a cytokine assay, wherein the cytokine assay comprises the steps of: (i) contacting immune cells with an anti-CD137 antibody; and (ii) determining the amount of at least one cytokine produced by the immune cells; and (iii) comparing the amount of the at least one cytokine produced by the immune cells with the amount secreted by a reference immune cell; In this case, the reference immune cells are contacted with a control antibody, and in this case, an increase in the amount of the at least one cytokine produced by the immune cells compared to the reference immune cells indicates induction or enhancement of human CD137-mediated cytokine production.
[0316] In some embodiments, the anti-CD137 antibodies described herein induce or enhance cytokine production by immune cells as determined by a cytokine assay, wherein the cytokine assay comprises the steps of: (i) contacting immune cells with an anti-CD137 antibody; (ii) determining the amount of at least one cytokine produced by the immune cells; and (iii) comparing the amount of the at least one cytokine produced by the immune cells with the amount or level secreted by a reference immune cell; In this case, the reference immune cells have not been contacted with an anti-CD137 antibody, and in this case, an increase in the amount of the at least one cytokine produced by the immune cells compared to the reference immune cells indicates human CD137-mediated induction or enhancement of cytokine production by the immune cells.
[0317] In some embodiments, the at least one cytokine is selected from the group consisting of IL-2, IFNγ, TNFα, IL-13, and combinations thereof. In some embodiments, the cytokine is IL-2. In some embodiments, the cytokine is IFNγ. In some embodiments, the cytokine is TNFα. In some embodiments, the cytokine is IL-13. In some embodiments, an anti-CD137 antibody induces or enhances the production of IL-2. In some embodiments, an anti-CD137 antibody induces or enhances the production of TNFα. In some embodiments, an anti-CD137 antibody induces or enhances the production of IL-13. In some aspects, the cytokine produced is IL-2. In some aspects, the cytokine produced is TNFα. In some aspects, the cytokine produced is IL-13. In some aspects, the cytokine produced is IFNγ. In some aspects, the cytokines produced are IL-2 and TNFα. In some aspects, the cytokines produced are IL-2 and IL-13. In some embodiments, the cytokines produced are IL-2 and IFNγ. In some embodiments, the cytokines produced are TNFα and IL-13. In some embodiments, the cytokines produced are TNFα and IFNγ. In some embodiments, the cytokines produced are IL-13 and IFNγ. In some embodiments, the cytokines produced are IL-2, TNFα, and IL-13. In some embodiments, the cytokines produced are IL-2, TNFα, and IFNγ. In some embodiments, the cytokines produced are IFNγ, TNFα, and IL-13.
[0318] In some embodiments, the immune cell is a T cell. In some embodiments, the reference immune cell is a T cell. In some embodiments, the T cell is a CD8+ T cell.
[0319] In some embodiments, the cytokine assay is a cytokine bead array assay. A cytokine bead array assay is a bead-based immunoassay that allows for flow cytometric determination of multiple analytes of multiple cytokines in a sample. The use of microspheres of different sizes or colors is the basis of a cytokine bead array assay, with each microsphere (or "bead") coated with an antibody that specifically binds to an antigen (e.g., a cytokine). The antibody-coated beads are then combined with a detection antibody and introduced into the sample. The bead:antigen:detection antibody complex is then analyzed by flow cytometry. Commercially available cytokine bead array assays include, but are not limited to, BD™ Cytometric Bead Array Systems (BD Biosciences) and Luminex® Assays (R&D Systems). In some embodiments, human CD137-mediated induction or enhancement of cytokine production is determined by a cytokine bead array assay. In some embodiments, human CD137-mediated induction or enhancement of cytokine production is determined by a Luminex® Assay.
[0320] In some embodiments, the cytokine assay is a Meso Scale Discovery (MSD) assay (Meso Scale Diagnostics; Rockville, MD). The MSD assay is a commercially available assay based on the detection of an electrochemiluminescent-labeled antibody that specifically binds to an antigen of interest (e.g., a cytokine). The MSD assay contains a high-binding carbon electrode at the bottom of a microplate well to which a biological reagent (e.g., a capture antibody specific for a cytokine) can be bound. The MSD assay uses an electrochemiluminescent label conjugated to a detection antibody. A sample is added to the microplate well, and the MSD instrument applies electricity to the plate electrodes, causing the electrochemiluminescent label to emit light. The intensity of the light is measured to quantify the amount of analyte (e.g., cytokine) in the sample. In some embodiments, the induction or enhancement of human CD137-mediated cytokine production is determined using the Meso Scale Discovery (MSD) assay.
[0321] In some embodiments, the anti-CD137 antibodies described herein induce or enhance T cell activation as determined by a T cell activation assay. In some embodiments, the T cell activation assay determines the amount of at least one cytokine secreted by T cells contacted with an anti-CD137 antibody described herein, where an increase in the amount of the at least one cytokine indicates induction or enhancement of T cell activation. In some embodiments, the increase in cytokine production is at least 1-fold, 2-fold, 3-fold, 4-fold, or 5-fold greater than a control antibody (e.g., an antibody that does not bind to CD137 and does not induce cytokine production).
[0322] In some embodiments, the anti-CD137 antibodies described herein induce or enhance T cell activation as determined by a T cell activation assay, wherein the T cell activation assay comprises the steps of: (i) isolating T cells from a subject; (ii) contacting the T cells with an anti-CD137 antibody; and (iii) after (ii), determining the amount of at least one cytokine secreted by the T cells; In this case, an increase in the level of the at least one cytokine indicates that the anti-CD137 antibody induced or enhanced T cell activation.
[0323] In some embodiments, the anti-CD137 antibodies described herein induce or enhance T cell activation as determined by a T cell activation assay, wherein the T cell activation assay comprises the steps of: (i) isolating T cells from a subject; (ii) contacting the T cells with an anti-CD137 antibody; (iii) determining the amount of at least one cytokine secreted by the T cells; and (iv) comparing the amount of the at least one cytokine produced by the T cells with the amount or level secreted by a reference T cell; In this case, the reference T cells have not been contacted with an anti-CD137 antibody, and in this case, an increase in the amount of the at least one cytokine produced by the T cells compared to the reference T cells indicates that the anti-CD137 antibody has induced or enhanced T cell activation.
[0324] In some embodiments, the anti-CD137 antibodies described herein induce or enhance T cell activation as determined by a T cell activation assay, wherein the T cell activation assay comprises the steps of: (i) isolating T cells from a subject; (ii) contacting the T cells with an anti-CD137 antibody; (iii) determining the amount of at least one cytokine secreted by the T cells; and (iv) comparing the amount of the at least one cytokine produced by the T cells with the amount secreted by a reference T cell; In this case, the reference T cells are contacted with a control antibody, and in this case, an increase in the amount of the at least one cytokine produced by the T cells compared to the reference T cells indicates that the anti-CD137 antibody induced or enhanced T cell activation.
[0325] In some embodiments, the T cell activation assay comprises determining the level of at least one cytokine secreted by the T cell after contact with an anti-CD137 antibody described herein, wherein the at least one cytokine is selected from the group consisting of IL-2, IFNγ, TNFα, and IL-13. In some embodiments, the cytokine is IL-2. In some embodiments, the cytokine is IFNγ. In some embodiments, the cytokine is TNFα. In some embodiments, the cytokine is IL-13. In some embodiments, the T cell activation assay comprises a cytokine assay, such as an assay to determine the amount of at least one cytokine described herein. In some embodiments, the cytokine produced is IL-2. In some embodiments, the cytokine produced is TNFα. In some embodiments, the cytokine produced is IL-13. In some embodiments, the cytokine produced is IFNγ. In some embodiments, the cytokine produced is IL-2 and TNFα. In some embodiments, the cytokine produced is IL-2 and IL-13. In some embodiments, the cytokine produced is IL-2 and IFNγ. In some embodiments, the cytokines produced are TNFα and IL-13. In some embodiments, the cytokines produced are TNFα and IFNγ. In some embodiments, the cytokines produced are IL-13 and IFNγ. In some embodiments, the cytokines produced are IL-2, TNFα, and IL-13. In some embodiments, the cytokines produced are IL-2, TNFα, and IFNγ. In some embodiments, the cytokines produced are IFNγ, TNFα, and IL-13.
[0326] In some embodiments, the anti-CD137 antibodies described herein induce or enhance T cell activation as determined by a T cell activation assay, wherein the T cell activation assay comprises detecting surface expression of at least one activation marker on T cells, and wherein an increase in the expression level of the at least one activation marker indicates induction or enhancement of T cell activation. In some embodiments, "increased surface expression" refers to at least a 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% increase in surface expression compared to surface expression in the presence of a control antibody or in the absence of the antibody.
[0327] In some embodiments, the anti-CD137 antibodies described herein induce or enhance T cell activation as determined by an in vitro T cell activation assay, wherein the T cell activation assay comprises the steps of: (i) isolating T cells from a subject; (ii) contacting the T cells with an anti-CD137 antibody; and (iii) detecting surface expression of at least one activation marker on the T cells; In this case, an increase in surface expression of the at least one activation marker indicates that the anti-CD137 antibody has induced or enhanced T cell activation.
[0328] In some embodiments, the anti-CD137 antibodies described herein induce or enhance T cell activation as determined by a T cell activation assay, wherein the T cell activation assay comprises the steps of: (i) isolating T cells from a subject; (ii) contacting the T cells with an anti-CD137 antibody; (iii) determining the surface expression of at least one activation marker on the T cells; and (iv) comparing the surface expression of at least one activation marker on the T cells with the surface expression of the at least one activation marker on a reference T cell; In this case, the reference T cells have not been contacted with an anti-CD137 antibody, and in this case, an increase in surface expression of at least one activation marker on the T cells compared to the reference T cells indicates that the anti-CD137 antibody has induced or enhanced T cell activation.
[0329] In some embodiments, the anti-CD137 antibodies described herein induce or enhance T cell activation as determined by a T cell activation assay, wherein the T cell activation assay comprises the steps of: (i) isolating T cells from a subject; (ii) contacting the T cells with an anti-CD137 antibody; (iii) determining the surface expression of at least one activation marker on the T cells; (iv) comparing the surface expression of at least one activation marker on the T cells with the surface expression of the at least one activation marker on a reference T cell; In this case, the reference T cells are contacted with a control antibody, and in this case, an increase in surface expression of at least one activation marker on the T cells compared to surface expression of at least one activation marker on the reference T cells indicates that the anti-CD137 antibody induced or enhanced T cell activation.
[0330] In some embodiments, the anti-CD137 antibodies described herein induce or enhance T cell activation as determined by an in vivo T cell activation assay, wherein the T cell activation assay comprises the steps of: (i) administering an anti-CD137 antibody to a subject; (ii) isolating T cells from the subject; and (iii) detecting surface expression of at least one activation marker on the T cells; In this case, an increase in surface expression of the at least one activation marker indicates that the anti-CD137 antibody induced or enhanced CD137-mediated T cell activation.
[0331] In some embodiments, the anti-CD137 antibodies described herein induce or enhance T cell activation as determined by a T cell activation assay, wherein the T cell activation assay comprises the steps of: (i) administering an anti-CD137 antibody to a subject; (ii) isolating T cells from the subject; (iii) then determining the surface expression of at least one activation marker on the T cells; and (iv) comparing the surface expression of at least one activation marker on the T cells with the surface expression of the at least one activation marker on a reference T cell; In this case, the reference T cells are isolated from a subject that has not been administered the anti-CD137 antibody, and in this case, an increase in surface expression of at least one activation marker on the T cells compared to the reference T cells indicates that the anti-CD137 antibody has induced or enhanced T cell activation.
[0332] In some embodiments, the anti-CD137 antibodies described herein induce or enhance T cell activation as determined by a T cell activation assay, wherein the T cell activation assay comprises the steps of: (i) administering an anti-CD137 antibody to a subject; (ii) isolating T cells from the subject; (iii) determining the surface expression of at least one activation marker on the T cells; and (iv) comparing the surface expression of at least one activation marker on the T cells with the surface expression of the at least one activation marker on a reference T cell; In this case, the reference T cells are isolated from a subject contacted with a control antibody, and in this case, an increase in surface expression of at least one activation marker on the T cells compared to surface expression of at least one activation marker on the reference T cells indicates that the anti-CD137 antibody has induced or enhanced T cell activation.
[0333] In some embodiments, the anti-CD137 antibodies described herein do not induce or enhance intrahepatic T cell activation as determined by an in vivo T cell activation assay, wherein the T cell activation assay comprises the steps of: (i) administering anti-CD137 to a subject; (ii) isolating T cells from the liver of the subject; (iii) detecting surface expression of at least one activation marker on the T cells; and (iv) comparing the surface expression of at least one activation marker on the T cells with the surface expression of the at least one activation marker on a reference T cell; In this case, the reference T cells are isolated from a subject that has not been administered an anti-CD137 antibody; optionally, the reference T cells are isolated from a subject that has been administered a control antibody, and in this case, no increase in surface expression of at least one activation marker on the T cells compared to surface expression of at least one activation marker on the reference T cells indicates that the anti-CD137 antibody has induced or enhanced T cell activation.
[0334] In some embodiments, the anti-CD137 antibodies described herein do not induce or enhance intrasplenic T cell activation as determined by an in vivo T cell activation assay, wherein the T cell activation assay comprises the steps of: (i) administering anti-CD137 to a subject; (ii) isolating T cells from the subject's spleen; (iii) detecting surface expression of at least one activation marker on the T cells; and (iv) comparing the surface expression of at least one activation marker on the T cells with the surface expression of the at least one activation marker on a reference T cell; In this case, the reference T cells are isolated from a subject that has not been administered an anti-CD137 antibody; optionally, the reference T cells are isolated from a subject that has been administered a control antibody, and in this case, no increase in surface expression of at least one activation marker on the T cells compared to surface expression of at least one activation marker on the reference T cells indicates that the anti-CD137 antibody has induced or enhanced T cell activation.
[0335] In some embodiments, "does not induce or enhance" is intended to refer to the absence of, or lack of increase in, activity (e.g., T cell activation) compared to the increase caused by a reference antibody.
[0336] In some embodiments, surface expression of the T cell activation marker is equivalent to surface expression in the absence of antibody, hi some embodiments, surface expression of the T cell activation marker is lower than surface expression in the presence of a reference antibody, which induces or enhances surface expression by at least 1-fold, 5-fold, 10-fold, 50-fold, or 100-fold compared to surface expression in the absence of antibody.
[0337] In some embodiments, the at least one activation marker is selected from the group consisting of CD25, CD69, and CD40L, hi some embodiments, the one or more activation markers is CD25.
[0338] In some embodiments, the T cells are isolated from a subject having a tumor. In some embodiments, the T cells are isolated from a tumor. In some embodiments, the control antibody is an isotype control antibody.
[0339] In some embodiments, the anti-CD137 antibodies described herein induce or enhance the infiltration of one or more immune cells into the tumor microenvironment as determined by an immune cell infiltration assay. In some embodiments, the anti-CD137 antibodies described herein reduce the infiltration of one or more immune cells into the tumor microenvironment as determined by an immune cell infiltration assay.
[0340] In some embodiments, the immune cell infiltration assay determines the amount of immune cells expressing one or more immune cell markers in the tumor. In some embodiments, the one or more immune cell markers are labeled with an antibody. In some embodiments, the one or more immune cell markers are selected from the group consisting of CD45, CD25, FOXP3, CD4, CD8, F4 / 80, CD11b, TIGIT, and PD-1. In some embodiments, the amount of immune cells expressing one or more immune cell markers in the tumor is determined by flow cytometry. Methods for quantifying immune cells expressing one or more immune cell markers by flow cytometry are known in the art.
[0341] In some embodiments, the anti-CD137 antibody induces or enhances the infiltration of one or more immune cells into the tumor microenvironment compared to a reference antibody, as determined by an immune cell infiltration assay. In some embodiments, the reference antibody is an antibody that comprises the same isotype as the anti-CD137 antibody but does not specifically bind to CD137. In some embodiments, the reference antibody is an antibody that comprises the same isotype as the anti-CD137 antibody and specifically binds to CD137. In some embodiments, the reference antibody is an antibody that comprises a different isotype from the anti-CD137 antibody and does not specifically bind to CD137. In some embodiments, the reference antibody is an antibody that comprises a different isotype from the anti-CD137 antibody but specifically binds to CD137.
[0342] In some embodiments, the anti-CD137 antibodies described herein increase the infiltration of CD45-expressing immune cells into the tumor microenvironment of a subject as determined by an immune cell infiltration assay, wherein the assay comprises the steps of: (i) administering an anti-CD137 antibody to a subject having a tumor; (ii) obtaining a sample of the tumor; (iii) contacting the sample with a fluorescently labeled detection antibody that specifically binds to CD45, wherein the detection antibody fluorescently labels immune cells that express CD45; and (iv) determining the amount of fluorescently labeled immune cells expressing CD45 by flow cytometry; In this case, an increase in the amount of fluorescently labeled cells expressing CD45 in the tumor suggests that the anti-CD137 antibody has induced or enhanced infiltration of immune cells into the tumor microenvironment. In some embodiments, the increase in the amount of immune cells expressing CD45 is at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or 80% of the total cells in the tumor microenvironment.
[0343] In some embodiments, the anti-CD137 antibodies described herein reduce or inhibit the infiltration of one or more immune cells into the tumor microenvironment as determined by an immune cell infiltration assay. In some embodiments, the anti-CD137 antibodies reduce the infiltration of one or more immune cells into the tumor microenvironment compared to a reference antibody as determined by an immune cell infiltration assay. In some embodiments, the reference antibody is an antibody that comprises the same isotype as the anti-CD137 antibody but does not specifically bind to CD137. In some embodiments, the reference antibody is an antibody that comprises the same isotype as the anti-CD137 antibody and specifically binds to CD137. In some embodiments, the reference antibody is an antibody that comprises a different isotype from the anti-CD137 antibody and does not specifically bind to CD137. In some embodiments, the reference antibody is an antibody that comprises a different isotype from the anti-CD137 antibody but specifically binds to CD137. In some embodiments, the reduction in immune cells is less than 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5% of the total cells in the tumor microenvironment.
[0344] In some embodiments, the anti-CD137 antibodies described herein reduce the infiltration of tumor-associated macrophages into the tumor microenvironment of a subject as determined by an immune cell infiltration assay, wherein the assay comprises the steps of: (i) obtaining a sample of the tumor; (ii) contacting the sample with one or more antibodies that label the tumor-associated macrophages, wherein the one or more antibodies specifically bind to an immune cell marker selected from the group consisting of F4 / 80, CD11b, CD45, and combinations thereof; and (iii) determining the amount of the labeled tumor-associated macrophages by flow cytometry. In some embodiments, tumor-associated macrophages represent less than 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5% of immune cells in the tumor microenvironment. In some embodiments, tumor-associated macrophages express F4 / 80, CD11b, and CD45.
[0345] In some embodiments, the anti-CD137 antibodies described herein reduce the infiltration of T regulatory cells (Tregs) into the tumor microenvironment of a subject as determined by an immune cell infiltration assay, wherein the assay comprises the steps of: (i) obtaining a sample of the tumor; (ii) contacting the sample with one or more antibodies that label the tumor-associated macrophages, wherein the one or more antibodies specifically bind to an immune cell marker selected from the group consisting of CD25, FOXP-3, CD4, and combinations thereof; and (iii) determining the amount of labeled Treg cells by flow cytometry. In some embodiments, Treg cells represent less than 35%, 30%, 25%, 20%, 15%, 10%, or 5% of the CD4+ T cells in the tumor microenvironment. In some embodiments, Treg cells express CD4, FOXP-3, and CD25.
[0346] In some embodiments, the anti-CD137 antibodies described herein protect T cells from and / or reverse T cell exhaustion, as determined by T cell exhaustion assays. Exhausted T cells can be distinguished from other T cell dysfunctions, such as anergy and senescence, based on underlying molecular mechanisms (Crespo et al., (2013) Curr Opin Immunol 25(2):241-221). Anergy occurs during priming due to the absence of costimulatory signals, while senescence is growth arrest after extensive proliferation. Exhausted T cells, on the other hand, arise from T cells that initially acquired and provided T cell effector function but gradually exhibit a deterioration of T cell effector function due to ongoing T cell receptor (TCR) stimulation from persistent antigens and inflammatory mediators, both of which are ubiquitous in tumors (Wherry & Kurachi (2015) Nat Rev Immunol 15(8):486-99). Characteristics of T cell exhaustion include, but are not limited to, a continuous deterioration of T cell function in vivo and / or ex vivo, increased expression of multiple inhibitory receptors (IR) (e.g., PD-1, CTLA-4, LAG-3, TIM-3, CD244, CD160, TIGIT), progressive loss or reduction in secretion of effector cytokines (e.g., IL-2, interferon gamma (IFNγ), tumor necrosis factor alpha (TNFα)), loss or reduction in CC chemokine (β-chemokine) production, poor responsiveness to IL-7 and IL-15, loss or reduction in proliferative capacity, loss or reduction in cytolytic activity in vivo and / or ex vivo, altered cellular metabolism, and a distinct transcriptional profile compared to no...
Claims
1. An isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds to human CD137, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain and a light chain comprising the amino acid sequences of SEQ ID NOs: 129 and 133, respectively.
2. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 1 and a pharma- ceutically acceptable carrier.
3. 3. The pharmaceutical composition of claim 2 for use in a method of treating cancer in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition.
4. 3. The pharmaceutical composition of claim 2 for use in a method of treating cancer in a subject, the method comprising administering to the subject an amount of the pharmaceutical composition effective to induce or enhance an anti-tumor immune response, the subject having cancer cells that express major histocompatibility complex I (MHC-I).
5. 5. The pharmaceutical composition of claim 4 for use in a method for treating cancer in a subject, wherein the cancer is selected from the group consisting of melanoma, glioma, renal cancer, colon cancer, lung cancer, prostate cancer, breast cancer, blood cancer and head and neck cancer.
6. 5. The pharmaceutical composition of claim 4, for use in a method for treating cancer in a subject, wherein the monoclonal antibody or antigen-binding fragment thereof exhibits one of the following characteristics compared to a reference antibody that binds to human CD137: (a) does not induce or enhance intrahepatic T cell activation; (b) does not induce or enhance intrahepatic T cell proliferation; (c) does not induce or enhance intrasplenic T cell activation; (d) does not induce or enhance intrasplenic T cell proliferation; (e) does not induce or enhance macrophage activation; (f) does not induce or enhance macrophage differentiation; (g) does not induce or enhance alanine aminotransferase (ALT) activity; and (h) any combination of characteristics (a) to (g). and wherein said reference antibody is urelumab.
7. 5. The pharmaceutical composition of claim 4, for use in a method for treating cancer in a subject, wherein the monoclonal antibody or antigen-binding fragment thereof induces or enhances cytokine production of immune cells in the subject.
8. The pharmaceutical composition of claim 7, wherein the cytokine produced is IL-2, TNFα, IL-13, IFNγ, or a combination thereof.
9. The pharmaceutical composition of claim 7 , wherein the immune cells express CD45.
10. The pharmaceutical composition of claim 4, wherein the monoclonal antibody or antigen-binding fragment thereof reduces the amount of T regulatory (Treg) cells in the tumor microenvironment in the subject.
11. The pharmaceutical composition of claim 10, wherein the Treg cells express CD4, FOXP-3 and CD25.
12. The pharmaceutical composition of claim 4, wherein the monoclonal antibody or antigen-binding fragment thereof reduces the amount of macrophages in a tumor microenvironment in the subject.
13. The pharmaceutical composition of claim 12, wherein the macrophages express CD45 and CD11b.
14. The pharmaceutical composition of claim 4, wherein the monoclonal antibody or antigen-binding fragment thereof reduces T cell exhaustion in a tumor microenvironment in the subject.
15. The pharmaceutical composition of claim 14, wherein the reduced T cell exhaustion comprises a decrease in the expression of TIGIT, PD-1, LAG-3, or a combination thereof.
16. The pharmaceutical composition of claim 4 , wherein the monoclonal antibody or antigen-binding fragment thereof induces an anti-tumor memory immune response in the subject.
17. In cancer cells: (a) dimerization of CD137 trimers; (b) multimerization of CD137 trimers; (c) human CD137-mediated T cell activation; (d) human CD137-mediated cytotoxic T cell responses; (e) human CD137-mediated T cell proliferation; and (f) Human CD137-mediated cytokine production 5. The pharmaceutical composition of claim 4 for further use in a method comprising inducing or enhancing one or more of:
Citation Information
Patent Citations
4-1BB binding molecules
JP2013544756A
JPP7402521B
